Antimicrobial compositions

Abstract

Polycationic ingredients and organic acid chelators for use in improving the antimicrobial efficacy of known organic acid compositions at neutral to basic pH, and / or reducing the amount of organic acids needed for antimicrobial activity. Methods of boosting antimicrobial activity of organic acid compositions is achieved through adding polycationic compound(s) and organic acid chelator(s). Use of the antimicrobial compositions in products is also described.

Description

[0001] Attorney Docket No. 15939.0027-01304

[0002] ANTIMICROBIAL COMPOSITIONS FIELD OF INVENTION

[0003] [1] The field pertains to using polycationic compounds to facilitate the use of organic acids at about neutral and elevated pH for product preservation, antimicrobial applications, and / or product performance.

[0004] BACKGROUND

[0005] [2] The ingredients and composition of many personal care, cosmetic, household products, healthcare products, industrial products, pharmaceutical products, food and beverage products, and consumer products provide viable growth medium for microorganisms. If water is present in a product or process, risk of microbial contamination is greater. As such, antimicrobial ingredients are needed to inhibit the growth of microorganisms to prevent or deter growth of microorganisms and maintain the integrity of the products when used over time or in storage. For centuries, organic acids have been used as antimicrobial agents for the preservation of food and beverages. More recently, organic acids have been employed in the preservation of cosmetics and household cleaning products as regulation of traditional preservatives grows more stringent.

[0006] [3] Certain organic acids, such as benzoic acid, are popular in consumer products due to low cost, ecofriendly profile, and water solubility. However, these acids may have limited utility for preservation above certain pH ranges. For example, benzoic acid is most effective to inhibit growth of microorganisms between pH 2.5 to pH 4.0, and with certain antimicrobial boosters or anionic surfactants, can be used to effectively inhibit microbial growth up to pH 6.5; such pH values are noted as “effective pH.” The recommended use level for sodium benzoate (benzoic acid’s conjugate salt) in rinse-off personal care products is 0.1 -1.0% while the recommended use level for leave-on personal care products is 0.1-0.5%. In food and beverage, sodium benzoate is Attorney Docket No. 15939.0027-01304

[0007] typically limited to 0.1 % or less, and its use is typically limited to pH 4.0 or below. The effective pH range of sodium benzoate and permitted concentrations ranges further limit the tools available to formulators to achieve microbial control in leave on personal care products and in food and beverage. Similarly, salicylic acid is commonly used for anti-acne and anti-dandruff products but is typically only effective when the pH is less than 5.0 and more ideally in the about pH 3-4 range, which can lead to further skin and scalp irritation. Unfortunately, the narrow effective pH range of organic acids, such as benzoic acid and salicylic acid, for antimicrobial activity limits their utility in neutral pH products such as cleaning products, paints, coatings, adhesives, topical creams, and shampoo where product formulation at near neutral or basic pH is preferrable for product performance.

[0008] [4] Inexpensive antimicrobial compounds that effectively preserve neutral-pH products and processes are limited to biocides such as isothiazolinones, formaldehyde, formaldehyde releasers, and other highly sensitizing, corrosive, and / or irritating molecules. There is thus a need for safe, low cost, and effective preservatives at neutral pH.

[0009] SUMMARY

[0010] [5] Herein we disclose an antimicrobial composition comprising one or more ammonium-containing cationic polymers and one or more organic acid chelators, wherein the composition has antimicrobial activity. Such antimicrobial composition may have antimicrobial activity over a wide pH range, e.g., pH 2.5-10, in particular in neutral and basic pH ranges like pH 6.5 and above.

[0011] [6] Herein we disclose an antimicrobial composition comprising one or more ammonium-containing cationic polymers, one or more organic acid chelators, and optionally one or more additional organic acids wherein the antimicrobial activity of the composition is observed at elevated pH, e.g. pH at least 1.5 units higher than the organic acid’s pKa in water or pH 6.5 and Attorney Docket No. 15939.0027-01304

[0012] above. The present disclosure illustrates an extension of the useful pH range for those additional organic acids as preservatives. In certain embodiments, this disclosure provides use of ammonium-containing cationic polymer(s) to extend the useful pH range of organic acids, such as benzoic acid, above pH values of 6.5 for microbial control. This invention allows the organic acid to be used at a higher pH than it would normally be effective and additionally allows the organic acid to be dosed at a lower concentration when the ammonium-containing cationic polymer(s) and the organic acid chelator(s) are present relative to the same product at the same pH containing the organic acid without the ammonium-containing cationic polymer(s) and the organic acid chelator(s). The composition can be used to inhibit microbial growth in a product, especially a product of neutral to basic pH, addressing an unmet challenge in the field.

[0013] [7] We further disclose methods for preserving and extending the shelf life of a product, especially a product of neutral or basic pH, by adding an effective amount of the antimicrobial composition disclosed herein to the product. Products comprising an effective amount of the antimicrobial composition as a preservative is also disclosed. The use of ammonium-containing cationic polymer(s), organic acid chelator(s), and optionally additional organic acid(s) disclosed herein for preservation is compatible with other conventional chemical preservatives or biological based antimicrobials (e.g., peptides, proteins, and enzymes). The products include, but not limited to, (1) rinse-off personal care products, (2) leave-on personal care products, (3) household products, (4) paint, coating, adhesives, or related products, and (5) industrial and institutional cleaning, industrial, or recreational water products.

[0014] [8] In a first embodiment, an antimicrobial composition comprises (1) an ammonium-containing cationic polymer and (2) an organic acid chelator, wherein the antimicrobial Attorney Docket No. 15939.0027-01304

[0015] composition has antimicrobial activity when incorporated into a product to a concentration of about 0.001% to about 1% by weight of the organic acid chelator in the product.

[0016] [9] In a second embodiment, the antimicrobial composition of the first embodiment has antimicrobial activity from about pH 6.5 to about pH 10.0 when incorporated into the product.

[0017]

[0010] In a third embodiment, the organic acid chelator of the first or second embodiment is one or more selected from ethylenediamine-N, N’-disuccinic acid (EDDS), gluconolactone, dicarboxymethyl alaninate (MGDA), glutamate diacetate (GLDA), and phytic acid.

[0018]

[0011] In a fourth embodiment, the concentration of EDDS in the product of the third embodiment is equivalent to trisodium EDDS at about 0.005% to about 0.2% by weight.

[0019]

[0012] In a fifth embodiment, the concentration of gluconolactone in the product of the third or fourth embodiment is about 0.05% to about 0.5% by weight.

[0020]

[0013] In a sixth embodiment, the concentration of MGDA in the product of any of the third through the fifth embodiments is equivalent to trisodium MGDA at about 0.005% to about 0.2% by weight.

[0021]

[0014] In a seventh embodiment, the concentration of GLDA in the product of any of the third through the sixth embodiments is equivalent to tetrasodium GLDA at about 0.005% to about 0.2% by weight.

[0022]

[0015] In an eighth embodiment, the concentration of phytic acid in the product of any of the third through the seventh embodiments is about 0.05% to about 0.5% by weight.

[0023]

[0016] In a ninth embodiment, the ammonium -containing cationic polymer of any of the first eight embodiments has a molecular weight of about 800 g / mol to about 1,000,000 g / mol. Attorney Docket No. 15939.0027-01304

[0024]

[0017] In a tenth embodiment, the concentration of the ammonium-containing cationic polymer in the product of any of the first nine embodiments is about 0.0001% to about 0.2% by weight.

[0025]

[0018] In an eleventh embodiment, the ammonium-containing cationic polymer of any of the first ten embodiments is a primary ammonium-containing polymer, a secondary ammonium-containing polymer, a tertiary ammonium-containing polymer, a quaternary ammonium-containing polymer, and / or a copolymer thereof.

[0026]

[0019] In a twelfth embodiment, the ammonium-containing cationic polymer of any of the first eleven embodiments comprises polymerized monomers, wherein the monomers are selected from ethyleneimine, dimethylamine, epichlorohydrin, aziridine, ethylenediamine, diallyl dimethyl ammonium chloride, acrylamide, hydroxyethyl cellulose, vinylpyrrolidone and dimethylaminoethyl methacrylate, diallyldimethyl ammonium chloride, acrylic acid, and butyl methacrylate-2-methacryloyloxy ethylphosphorylcholine copolymer.

[0027]

[0020] In a thirteenth embodiment, the ammonium-containing cationic polymer of any of the first eleven embodiments is selected from a linear polyethylenimine, a branched polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquaternium-10, polyquaternium-11, polyquaternium-39, and polyquaternium-51, and the concentration of the ammonium-containing cationic polymer in the product is about 0.00015% to about 0.2% by weight.

[0028]

[0021] In a fourteenth embodiment, the antimicrobial composition of any of the first thirteen embodiments further comprises an additional organic acid, wherein the ratio by weight between the ammonium-containing cationic polymer and the organic acid is from about 1:3 to about Attorney Docket No. 15939.0027-01304

[0029] 1:2,000, and more specifically from about 1:50 to about 1:200 and the concentration of the additional organic acid in the product is about 0.02% to about 3% by weight.

[0030]

[0022] In a fifteenth embodiment, the additional organic acid of the fourteenth embodiment is sodium benzoate and / or sodium salicylate.

[0031]

[0023] In a sixteenth embodiment, the concentration of sodium benzoate in the product of the fifteenth embodiment is about 1.0% or lower by weight.

[0032]

[0024] In a seventeenth embodiment, the concentration of sodium salicylate in the product of the fifteenth or sixteenth embodiment is about 0.5% or lower by weight.

[0033]

[0025] In an eighteenth embodiment, the product of any of the first seventeen embodiments is a rinse-off personal care product at about pH 6.5 to about pH 10.0.

[0034]

[0026] In a nineteenth embodiment, the concentration of the ammonium-containing cationic polymer in the rinse-off personal care product of the eighteenth embodiment is about 0.000625% to about 0.2% by weight.

[0035]

[0027] In a twentieth embodiment, the rinse-off personal care product of any of the seventeenth through the nineteenth embodiments comprises sodium benzoate wherein the concentration of sodium benzoate in the rinse-off personal product is about 0.1% to about 1.0% by weight.

[0036]

[0028] In a twenty -first embodiment, the product of any of the first seventeenth embodiments is a leave-on personal care product at about pH 6.5 to about pH 9.0.

[0037]

[0029] In a twenty-second embodiment, the concentration of the ammonium-containing cationic polymer in the leave-on personal care product of the twenty-first embodiment is about 0.000625% to about 0.2% by weight. Attorney Docket No. 15939.0027-01304

[0038]

[0030] In a twenty-third embodiment, the leave-on personal care product of the twenty-first or the twenty-second embodiment comprises sodium benzoate wherein the concentration of sodium benzoate in the leave-on personal care product is about 0.1% to about 1% by weight.

[0039]

[0031] In a twenty-fourth embodiment, the product of any of the first seventeen embodiments is a household product at about pH 6.5 to about pH 10.0.

[0040]

[0032] In a twenty-fifth embodiment, the concentration of the ammonium-containing cationic polymer in the household product of the twenty-fourth embodiment is about 0.000625% to about 0.2% by weight.

[0041]

[0033] In a twenty-sixth embodiment, the household product of the twenty-fourth or the twenty-fifth embodiment comprises sodium benzoate wherein the concentration of sodium benzoate in the household product is about 0.1% to about 3% by weight.

[0042]

[0034] In a twenty -seventh embodiment, the product of any of the first seventeen embodiments is (1) a paint or related product or (2) a coating, adhesive, or related product wherein the product is at about pH 6.5 to about pH 10.0.

[0043]

[0035] In a twenty-eighth embodiment, the paint or related product of the twenty-seventh embodiment comprises sodium benzoate wherein the concentration of sodium benzoate in the paint or related product is about 0.1% to about 1% by weight.

[0044]

[0036] In a twenty -ninth embodiment, the coating, adhesive, or related product of the twentyseventh embodiment comprises sodium benzoate wherein the concentration of sodium benzoate in the coating, adhesive, or related product is about 0.1% to about 7% by weight.

[0045]

[0037] In a thirtieth embodiment, the concentration of the ammonium-containing cationic polymer in the paint or related product or the coating, adhesives, or related product of any of the Attorney Docket No. 15939.0027-01304

[0046] twenty-seventh through the twenty-ninth embodiments is about 0.000625% to about 0.2% by weight.

[0047]

[0038] In a thirty-first embodiment, the product of any of the first seventeen embodiments is an industrial and institutional cleaning, industrial, or recreational water product and is at about pH 6.5 to about pH 9.0.

[0048]

[0039] In a thirty-second embodiment, the concentration of the ammonium-containing cationic polymer in the industrial and institutional cleaning, industrial, or recreational water product of the thirty-first embodiment is about 0.000625% to about 0.2% by weight.

[0049]

[0040] In a thirty -third embodiment, a product comprises the antimicrobial composition of any of the first thirty-two embodiments.

[0050]

[0041] In a thirty-fourth embodiment, a method of increasing the shelf life of a product comprises incorporating an antimicrobial composition of any of the first thirty-two embodiments into the product in an amount effective to provide antimicrobial activity in comparison to an identical product that does not comprise the antimicrobial composition.

[0051]

[0042] In a thirty-fifth embodiment, a method of preserving a product comprises incorporating an antimicrobial composition of any of the first thirty-two embodiments into the product in an amount effective to provide antimicrobial activity in comparison to an identical product that does not comprise the antimicrobial composition.

[0052]

[0043] In a thirty-sixth embodiment, a composition consists essentially of an ammonium-containing cationic polymer and an organic acid chelator, wherein the composition increases the shelf life of a product when incorporated into the product such that the organic acid chelator is present in the product at a concentration of about 0.001% to about 1% by weight. Attorney Docket No. 15939.0027-01304

[0053]

[0044] In a thirty-seventh embodiment, a composition consists essentially of the ammonium-containing cationic polymer, an organic acid chelator, and an additional organic acid, wherein the composition increases the shelf life of a product when incorporated into the product such that the organic acid chelator is present in the product at a concentration of about 0.001% to about 1% by weight, and the additional organic acid is sodium benzoate and / or sodium salicylate.

[0054]

[0045] In a thirty-eighth embodiment, the product of the thirty-sixth or the thirty-seventh embodiment is at about pH 6.5 to about pH 10.0.

[0055]

[0046] In a thirty-ninth embodiment, the organic acid chelator of any of the thirty-sixth through the thirty-eighth embodiments is one or more selected from ethylenediamine-N, N’-disuccinic acid (EDDS), gluconolactone, dicarboxymethyl alaninate (MGDA), glutamate diacetate (GLDA), and phytic acid.

[0056]

[0047] In a fortieth embodiment, the concentration of EDDS in the product of the thirty -ninth embodiment is equivalent to trisodium EDDS at about 0.005% to about 0.2% by weight.

[0057]

[0048] In a forty-first embodiment, the concentration of gluconolactone in the product of the thirty -ninth or the fortieth embodiment is about 0.05% to about 0.5% by weight.

[0058]

[0049] In a forty-second embodiment, the concentration of MGDA in the product of any of the thirty-ninth through the forty-first embodiments is equivalent to trisodium MGDA at about 0.005% to about 0.2% by weight.

[0059]

[0050] In a forty-third embodiment, the concentration of GLDA in the product of any of the thirty-ninth through the forty-second embodiments is equivalent to tetrasodium GLDA at about 0.005% to about 0.2% by weight.

[0060]

[0051] In a forty-fourth embodiment, the concentration of phytic acid in the product of any of the thirty-ninth through the forty-third embodiments is about 0.05% to about 0.5% by weight. Attorney Docket No. 15939.0027-01304

[0061]

[0052] In a forty-fifth embodiment, the concentration of the ammonium-containing cationic polymer in the product of any of the thirty-ninth through the forty-fourth embodiments is at about 0.0025% by weight.

[0062]

[0053] In a forty-sixth embodiment, the ratio by weight between the ammonium-containing cationic polymer and the organic acid of any of the thirty-seventh through the forty-fourth embodiments is from about 1:50 to about 1:400, and more specifically from about 1:100 to about 1:200.

[0063]

[0054] In a forty-seventh embodiment, the concentration of sodium benzoate in the composition of the forty-sixth embodiment is about 30% by weight, and the ratio by weight between the ammonium-containing cationic polymer and sodium benzoate is about 1: 120.

[0064]

[0055] In a forty-eighth embodiment, the concentration of sodium salicylate in the composition of the forty-sixth embodiment is about 45% by weight, and the ratio by weight between the ammonium-containing cationic polymer and sodium salicylate is about 1:180.

[0065]

[0056] In a forty-ninth embodiment, the concentration of the ammonium-containing cationic polymer in the composition of any of the thirty-sixth through the forty-eighth embodiments is at about 0.25% by weight, and the concentration of the organic acid chelator in the composition of any of the thirty-sixth through the forty-eighth embodiments is about 0.1% or higher by weight to lower than 50% by weight.

[0066]

[0057] In a fiftieth embodiment, the concentration of EDDS in the composition of the fortyninth embodiment is equivalent to trisodium EDDS at about 0.5% to about 20% by weight.

[0067]

[0058] In a fifty-first embodiment, the concentration of gluconolactone in the composition of the forty-ninth embodiment is about 2.5% to about 10% by weight. Attorney Docket No. 15939.0027-01304

[0068]

[0059] In a fifty-second embodiment, the concentration of MGDA in the composition of the forty-ninth embodiment is equivalent to trisodium MGDA at about 0.5% to about 20% by weight.

[0069]

[0060] In a fifty-third embodiment, the concentration of GLDA in the composition of the fortyninth embodiment is equivalent to tetrasodium GLDA at about 0.5% to about 20% by weight.

[0070]

[0061] In a fifty-fourth embodiment, the concentration of phytic acid in the composition of the forty-ninth embodiment is about 0.5% to about 50% by weight.

[0071]

[0062] In a fifty-fifth embodiment, the composition of the thirty-sixth or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and EDDS equivalent to trisodium EDDS at about 10% by weight.

[0072]

[0063] In a fifty-sixth embodiment, the composition of the thirty-sixth or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and gluconolactone at about 10% by weight.

[0073]

[0064] In a fifty-seventh embodiment, the composition of the thirty-sixth or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and MGDA equivalent to trisodium MGDA at about 10% by weight.

[0074]

[0065] In a fifty-eighth embodiment, the composition of the thirty-sixth or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and GLDA equivalent to tetrasodium GLDA at about 10% by weight.

[0075]

[0066] In a fifty-ninth embodiment, the composition of the thirty-sixth or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and phytic acid at about 30% by weight.

[0076]

[0067] In a sixtieth embodiment, the composition of the thirty-seventh or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by Attorney Docket No. 15939.0027-01304

[0077] weight, EDDS equivalent to trisodium EDDS at about 2.5% by weight, and sodium benzoate at about 30% by weight.

[0078]

[0068] In a sixty-first embodiment, the composition of the thirty-seventh or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, gluconolactone at about 10% by weight, and sodium benzoate at about 30% by weight.

[0079]

[0069] In a sixty-second embodiment, the composition of the thirty-seventh or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, MGDA equivalent to trisodium MGDA at about 2.5% by weight, and sodium benzoate at about 30% by weight.

[0080]

[0070] In a sixty-third embodiment, the composition of the thirty-seventh or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, GLDA equivalent to tetrasodium GLDA at about 1.25% by weight, and sodium benzoate at about 30% by weight.

[0081]

[0071] In a sixty-fourth embodiment, the composition of the thirty-seventh or the thirty-eighth embodiment consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, phytic acid at about 50% by weight, and sodium benzoate at about 30% by weight.

[0082] DETAILED DESCRIPTION

[0083]

[0072] All patents, patent applications, and publications cited herein are incorporated by reference in their entireties.

[0084] Definitions

[0085]

[0073] Words using the singular include the plural, and vice versa, unless the context clearly dictates otherwise. Attorney Docket No. 15939.0027-01304

[0086]

[0074] In this disclosure, many terms and abbreviations are used. The following definitions apply unless specifically stated otherwise.

[0087]

[0075] As used herein, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof. The terms “a,” “an,” “the,” “one or more,” and “at least one,” for example, can be used interchangeably herein.

[0088]

[0076] The term “about” as used herein can allow for a degree of variability in a value or range of at most within 10%, e.g., within 5%, or within 1% of a stated value or of a stated limit of a range.

[0089]

[0077] The terms “and / or” and “or” are used interchangeably herein and refer to a specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and / or” as used in a phrase such as “A and / or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and / or” as used in a phrase such as “A, B and / or C” is intended to encompass each of the following aspects: “A, B and C”; “A, B or C”; “A or C”; “A or B”; “B or C”; “A and C”; “A and B”; “B and C”; “A” (alone); “B” (alone); and “C” (alone).

[0090]

[0078] Throughout this application, various embodiments can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the embodiments described herein. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range, such as from 1 to 6 should be considered to have subranges such as from 1 to 2, from 1 to 3, from 1 to 4 and from 1 to 5, from 2 to 3, from 2 to 4, from 2 to 5, from 2 to 6, Attorney Docket No. 15939.0027-01304

[0091] from 3 to 4, from 3 to 5, from 3 to 6, etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5 and 6. This applies regardless of the breadth of the range.

[0092]

[0079] “Optional” or “optionally” means that the subsequently described event, circumstance, or material may or may not occur or be present, and that the description includes instances where the event, circumstance, or material occurs or is present and instances where it does not occur or is not present.

[0093]

[0080] The term “antimicrobial” refers to any agent or combination of agents that kills, inactivates, or inhibits the growth of any microbes such as bacteria, archaea, protozoa, fungi, algae, amoebas, viruses and the like. Antimicrobials can be biocides, biostats, disinfectants, boosters, and preservatives. In some cases, antimicrobials can work in synergy or have additive effects which may enhance their effectiveness. Antimicrobials that demonstrate additive, potentiating, or synergistic effects are often referred to as boosters. Some antimicrobials are multifunctional agents, which may have multiple benefits including antimicrobial properties. Examples of antimicrobials include, but are not limited to, antimicrobial chemicals, antimicrobial polymers, antimicrobial proteins, antimicrobial enzymes, and antimicrobial peptides. The term “antibacterial” refers to any agent or combination of agents that kills, inactivates, or inhibits the growth of bacteria. In certain cases, an antibacterial agent can also act on non-bacterial microbes.

[0094]

[0081] The term “disinfection” used herein describes a process wherein an area, item, surface, or container is rapidly cleaned to eliminate the present microbial population to a degree that is considered acceptable according to the Environmental Protection Agency (EPA)’s standards. Effectiveness / efficiency of disinfection can be measured by one of several standardized test methods such as the AO AC 961.02 which evaluates the efficacy of liquid disinfectants on hard, Attorney Docket No. 15939.0027-01304

[0095] non-porous surfaces. The term “disinfectant” used herein describes any agent or combination agents that performs disinfection as described herein.

[0096]

[0082] The term “sanitization” used herein describes a process wherein an area, item, surface, or container is rapidly cleaned to reduce the microbial contamination or bioburden to levels considered safe according to public health codes and regulations. Effectiveness / efficiency of sanitization can be measured by one of several standardized test methods such as ASTM E1153, which evaluates non-food contact sanitizers. The term “sanitizer” used herein describes any agent or combination of agents that performs sanitization as described herein.

[0097]

[0083] The terms “acne treatment product” and “anti-acne product” refer to personal care products intended to reduce the occurrence of acne on the skin. Acne is a common skin condition that can be caused by overgrowth of Culibacterium acnes (C. acnes). Many anti-acne products use antimicrobials such as salicylic acid to control the growth of C. acnes on skin.

[0098]

[0084] The term “anti-dandruff product” refers to personal care products intended to prevent or reduce the occurrence of dandruff. Dandruff is a common condition that causes the skin on the scalp to flake, leaving small white pieces of skin to collect in the hair and fall on clothes. Nonlimiting examples of anti-dandruff personal care products include anti-dandruff shampoo and antidandruff conditioner. Some anti-dandruff personal care products contain antifungal agents, like sodium salicylate, to control the growth of Malassezia on the scalp.

[0099]

[0085] The term “topical” refers to any product intended to be used directly on the surface of the skin. Non-limiting examples include topical lotion, topical cream, and topical ointment.

[0100]

[0086] The term “household product” refers to any type of commercially available cleaning products intended for consumers to use around their homes. Non-limiting examples of household products include household cleaners, floor cleaning products, wood cleaning products, laundry Attorney Docket No. 15939.0027-01304

[0101] detergent, dish soap, laundry sanitizer, fabric softener, window cleaner, cleaning wipes, furniture polish, dishwasher detergent, bathroom cleaner, toilet cleaner, liquid cleaner concentrates, all-purpose cleaner, shower cleaner, dishwasher detergent, dishwasher rinse aid, and surface disinfectants.

[0102]

[0087] The terms “paint” and “coating” refer to any commercial or industrial product intended to cover and / or protect a substrate or surface. Coatings may additionally have decorative properties, friction modifying properties, corrosion inhibition properties, and / or wear resistance properties. Coatings typically contain binding agents and solvents, with optionally pigments, polymers, corrosion inhibitors, preservatives, and / or rheology modifiers. Some of the paints and coatings are water-based. Non-limiting examples of paints and coatings include primers, sealers, spray paints, anticorrosive coatings, anticorrosive coatings, wood stains, wood varnishes, latex coatings, food-contact surface coatings, acrylic binders, film forming chemicals, pigments, and emulsificants.

[0103]

[0088] The term “adhesive” refers to any commercial or industrial product intended to bond or glue an object, surface, or product upon itself or another object, surface, or product.

[0104]

[0089] The term “processing aid” refers to substances added during processing or to manufacturing streams which have a technical effect during processing only but are either not present at significant levels in the final product or have no functional or technical effect in the final product. Processing aids may be added in order to maintain sanitary conditions and reduce microbial load (i.e., the number and type of microorganisms present) in processing steps.

[0105]

[0090] The term “Cleaning in Place” (CIP) refers to a method used to clean and sanitize equipment and pipelines without dismantling them. The CIP process involves circulating a cleaning solution through the equipment and piping using pumps, while valves and control systems Attorney Docket No. 15939.0027-01304

[0106] regulate the flow rate and pressure. The cleaning solution is typically a mixture of water and cleaning agents, including antimicrobial agents, detergents, acids, or alkalis, depending on the type of equipment being cleaned and the type of soil to be removed. CIP is widely used in various industries, including food and beverage, pharmaceuticals, cosmetics, and biotechnology, to ensure equipment cleanliness and product quality while minimizing downtime and labor costs. Additionally, substances to maintain sanitary conditions or a reasonable microbial load during processing may be added as processing aids. These processing aids may be added directly to manufacturing streams in order to maintain sanitary conditions and reduce microbial load (i.e., the number and type of microorganisms present) in processing steps.

[0107]

[0091] The term “rinse-off personal care product” refers to personal care products which are applied to the hair, skin, oral cavity, or teeth and then rinsed off. Non-limiting examples of the rinse-off personal care product include shampoos, conditioners, facial cleansers, body washes, hand soap, bar soap, liquid soap, hair treatments, face masks, toothpastes, and mouthwashes.

[0108]

[0092] The term “leave-on personal care product” refers to person care products applied to hair, skin, oral cavity, or teeth without the need of rinsing off. Non-limiting examples of leave-on personal care products include cleansing wipes, cosmetic products, deodorant, topical lotion, topical cream, topical ointment, hair styling products, and skin toner.

[0109]

[0093] The term “industrial and institutional cleaning, industrial, or recreational water product” refers to products for cleaning and sanitization under industrial and institutional setups as well as products used for treating water for industrial or recreational use. Non-limiting examples of industrial and institutional cleaning, industrial, or recreational water products include products for cleaning and sanitizing surfaces in the clinics, surfaces in food industry, and manufacture line; products for treating swimming pool water and industrial cooling tower; products for industrial Attorney Docket No. 15939.0027-01304

[0110] disinfection and sanitization; and disinfecting and sanitizing products for oil, gas, and energy industries.

[0111]

[0094] The term “effective amount” used herein refers to an amount of a preservative composition as disclosed herein that is sufficient to prevent or inhibit microbial growth. The preservative compositions described herein may be active against Gram-positive bacteria, Gramnegative bacteria, yeast, and / or fungi (e.g., molds).

[0112]

[0095] The term “elevated pH” refers to a pH value higher than the organic acid is ideally or typically formulated at for product performance (i.e. preservation, cell penetration, or other use). The elevated pH may be at least about 1.5 units higher than the organic acid’s pKa in water.

[0113]

[0096] The term “foaming hand soap” refers to a diluted version of liquid hand soap used with specialized dispensers that infuse the solution with air to generate a frothy lather. Inherently, a foaming hand soap is not antimicrobial. The mechanical friction of rubbing the foaming hand soap and rinsing with water is responsible for decreasing the number of microbes on the surface of the skin.

[0114]

[0097] The terms “microorganism” and “microbe” are used interchangeably herein and refer to any living thing that is so small that it can be seen with a microscope, i.e., a microscopic organism. Microbes may exist in a single-celled form or in a colony of cells or in a biofilm. Microbes include eukaryotes and prokaryotes such as bacteria, archaea, protozoa, fungi, algae, amoebas, viruses and the like.

[0115]

[0098] The term “neutral pH” used herein refers to a pH value of about 7.0.

[0116]

[0099] The terms “polyamine” and “polyammonium containing polymer” are used interchangeably and refer to polymers containing primary, secondary, tertiary or quaternary amines in their charged or uncharged state. The term “ammonium-containing cationic polymer” Attorney Docket No. 15939.0027-01304

[0117] refers to polymers containing primary, secondary, tertiary or quaternary amines in their charged state.

[0118]

[0100] The terms “polycationic compounds” and “cationic polymer” and “ammonium-containing cationic polymer” are used interchangeably and refer to a polymer having more than one positive charge.

[0119]

[0101] As used herein, the term “polymer” refers to any of a class of natural or synthetic substances composed of repeating chains of molecules. The repeating molecules are multiples of simpler chemical units called monomers. Copolymer refers to two or more chemically different monomers present in the final polymer. When referring to a polymer composed of, comprising, or made from a particular monomer, it is understood that the monomer may undergo changes in chemical composition depending on the synthesis method.

[0120]

[0102] As used herein, “amines” are organic compounds derived from ammonia by replacement of one or more hydrogen atoms by organic groups. Amine compounds and polyamines can exist as primary, secondary, tertiary, and quaternary amines, which refers to the number carbon-nitrogen bonds. Primary amines arise when one of three hydrogen atoms in ammonia is replaced by an alkyl or aromatic group, leaving two hydrogens bound if in the neutral state or three hydrogens if in the protonated state or cationic state. Secondary amines have two organic substituents (alkyl, aryl or both) bound to the nitrogen together with one hydrogen in the neutral state or two hydrogens if in the protonated or cationic state. In tertiary amines, nitrogen has three organic substituents. Quaternary ammoniums have four organic substituents and exists in a cationic charged state. “Ammonium” refers to the charged state of an amine. In the present disclosure, “amine” and “ammonium” may refer to the same compound, depending on its charge state. Attorney Docket No. 15939.0027-01304

[0121]

[0103] The term “organic acid” refers to organic compounds that possess acidic properties and salts thereof. Given that these acids are organic, a carbon atom must exist in its structure. One of the most common organic acids is carboxylic acid, which has the molecular formula RCOOH.

[0122]

[0104] The term “organic acid chelator” refers to an organic acid and salts thereof which can act as a chelator. The term “chelator” refers to a compound that binds with and removes free metal ions from solutions. Non-limiting examples of organic acid chelators include EDTA, EDDS, gluconolactone, MGDA, GLDA, phytic acid, and salts thereof.

[0123]

[0105] The term “EDTA” refers to ethylenediaminetetraacetic acid and salts thereof. EDTA may be in a hydrate form, a fully protonated form, or a partially or fully deprotonated conjugate base form. The percentages by weight and ratios by weight of EDTA disclosed herein were calculated based on disodium EDTA dihydrate (e.g., CAS# 6381-92-6 or 139-33-3).

[0124]

[0106] The term “EDDS” refers to ethylenediamine-M N ’-disuccinic acid and salts thereof. EDDS may be in a hydrate form, a fully protonated form, or a partially or fully deprotonated conjugate base form. The percentages by weight and ratios by weight of EDDS disclosed herein were calculated based on trisodium EDDS (e.g., CAS# 178949-82-1).

[0125]

[0107] The term “gluconolactone” refers to glucono-delta-lactone, an oxidized derivative of glucose, and salts thereof. The terms “gluconolactone,” “D-gluconolactone,” “gluconic acid,” “gluconate,” and “sodium gluconate” are used interchangeably herein for referring to the acid and salt forms of gluconolactone. Gluconolactone may be in a hydrate form, a fully protonated form, or a partially or fully deprotonated conjugate base form. The percentages by weight and ratios by weight of gluconolactone disclosed herein were calculated based on gluconolactone (e.g., CAS# 90-80-2). Attorney Docket No. 15939.0027-01304

[0126]

[0108] The term “MGDA” refers to dicarboxymethyl alaninate and salts thereof. MGDA may be in a hydrate form, a fully protonated form, or a partially or fully deprotonated conjugate base form. The percentages by weight and ratios by weight of MGDA disclosed herein were calculated based on trisodium MGDA (e.g., CAS# 164462-16-2).

[0127]

[0109] The term “GLDA” refers to glutamate diacetate and salts thereof. GLDA may be in a hydrate form, a fully protonated form, or a partially or fully deprotonated conjugate base form. The percentages by weight and ratios by weight of GLDA disclosed herein were calculated based on tetrasodium GLDA (e.g., CAS# 51981-21-6).

[0128] [HO] The term “phytic acid” refers to (2,3,4,5,6-pentaphosphonooxycyclohexyl) dihydrogen phosphate. The terms “phytic acid,” “phytate,” “sodium phytate,” and “inositol hexaphosphate” are used interchangeably herein for referring to the acid and salt forms of phytic acid. Phytic acid may be in a hydrate form, a fully protonated form, or a partially or fully deprotonated conjugate base form. The percentages by weight and ratios by weight of phytic acid disclosed herein were calculated based on the acid form (e.g., CAS# 83-86-3).

[0129] [Hl] The term “ionic solids level” refers to the content of non-water charged ions dissolved in an aqueous solution. Non-limiting examples of ionic solids include disassociated inorganic salt ions such as sodium ions or chloride ions, charged organic ions such as citrate ions, and charged surfactant ions such as sodium dodecyl sulfate ions.

[0130]

[0112] The term “preservative” refers to a substance or agent that is added to a product to prevent decomposition or contamination by microbial growth or by undesirable chemical changes. As used herein, preservatives include antimicrobial ingredients added to product formulations to maintain the microbiological safety of the products by inhibiting the growth of and reducing the amount of microbial contaminants. US Pharmacopeia (USP) and the Personal Care Products Attorney Docket No. 15939.0027-01304

[0131] Counsel (PCPC) have published protocols for acceptable microbial survival for preservatives in cosmetics and personal care products, such as USP <51> (Antimicrobial Effectiveness Test) as well as PCPC M-3 (also available are PCPC M-l, PCPC M-2, PCPC M-4, PCPC M-5, PCPC M-6, and PCPC M-7).

[0132]

[0113] The term “shelf life” refers to the length of time for which an item (e.g., a product as described herein) remains usable, saleable, or fit for consumption.

[0133] Compositions

[0134]

[0114] Disclosed herein are antimicrobial compositions comprising one or more ammonium-containing cationic polymers, one or more organic acid chelators, and optionally one or more additional organic acids, wherein the compositions have biocidal, preservative, antimicrobial, antibacterial, and / or antiviral (virucidal) activities at an elevated pH and / or at a pH lower than the elevated pH. In some embodiments, the antimicrobial composition is effective at a pH at least about 1.5 units higher than the pKa of the additional organic acid in water. The composition may have an antimicrobial effect above pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, or higher. The composition may have an effective pH range of about 2.5 to about 6.0, and in particular the effective pH is about 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0. Such an antimicrobial composition may be included in or with (e.g., within or associated with) products to be preserved, e.g., for microbial control. Preservative effectiveness may be evaluated according to USP <51> and PCPC M-3 guidelines, among other standardized testing protocols. Additional testing protocols for antimicrobial efficacy for disinfection, sanitization, acne, and dandruff are described herein. These guidelines provide culture and testing criteria for a variety of microorganisms including bacteria, mold, and yeast, including for example S. enterica (ATCC# 10708), S. aureus (ATCC# 6538), P. aeruginosa (ATCC# 9027), E. coli (ATCC# 8739), C. albicans (ATCC# 10231), A. brasiliensis Attorney Docket No. 15939.0027-01304

[0135] (ATCC# 16404), C. acnes (ATCC# MB-0170P), M. pachydermatis (ATCC# 14522), and K. pneumoniae (ATCC# 4352). P. aeruginosa (ATCC# 9027) was renamed P. paraeruginosa in June 2023. Both “aeruginosa” and “par aeruginosa” are used interchangeably herein and refer to ATCC# 9027. The compositions disclosed herein may be used in products for personal care, household, industrial, industrial and institutional cleaning, industrial and recreational water, cooling water, food, beverage, pharmaceutical, cosmetic, healthcare, marine, paint, coating, oil, gas, plastic, packaging, textile, agricultural, latex, pulp, and paper products. The compositions disclosed herein may be added to those products at an amount effective for preserving the product and increasing the shelf life of the product. The product supplemented with the compositions disclosed herein is also referred to as the “final product.”

[0136]

[0115] In some embodiments, the antimicrobial composition disclosed herein has an enhanced antimicrobial / preservative efficacy compared to a composition comprising the same components except for the ammonium-containing cationic polymer(s). In some embodiments, the antimicrobial composition disclosed herein has an enhanced antimicrobial / preservative efficacy compared to a composition comprising the same components except for the organic acid chelator(s). In some embodiments, the antimicrobial composition disclosed herein has a similar or enhanced antimicrobial / preservative efficacy compared to a composition comprising the additional organic acid(s) at a higher concentration s) and all the other components in the antimicrobial composition disclosed herein except for the ammonium-containing cationic polymer(s) and / or the organic acid chelator(s), wherein the concentration(s) of the additional organic acid(s) is higher than the composition disclosed herein.

[0137]

[0116] In some embodiments, the composition includes one or more ammonium-containing cationic polymers, one or more organic acid chelators, and optionally one or more additional Attorney Docket No. 15939.0027-01304

[0138] organic acids, wherein each of the polymer(s), chelator(s), and optionally the additional organic acid(s) are in an amount effective to act as an antimicrobial composition, at an elevated pH. In some embodiments, the antimicrobial composition inhibits microbial (e.g., bacterial) growth, resulting in inhibition of up to at least 80%, 85%, 90%, 95%, 98%, 99%, 99.9%, 99.99%, or 99.999% of microbial growth at an elevated pH and / or at a pH lower than the elevated pH. In some embodiments, the elevated pH is at least about 1.5 units higher than the additional organic acid’s pKa in water. In additional embodiments, the elevated pH is higher than about 5.5, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.5, 9.0, 9.5, or 10. In certain embodiments, the elevated pH is up to about 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.5, 9.0, 9.5, or 10. In certain embodiments, the elevated pH is between 6.0 and 10.0, between 6.0 and 9.0, between 6.0 and 8.5, between 6.0 and 8.0, between 6.5 and 10.0, between 6.5 and 9.0, between 6.5 and 8.5, or between 6.5 and 8.0. In some embodiments, the antimicrobial composition disclosed herein has an effective pH range of about 2.5 to about 6.0, and in particular the effective pH is about 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0.

[0139]

[0117] In some embodiments, the ammonium-containing cationic polymer(s) disclosed herein is a quaternary, tertiary, or secondary polyamine, or a copolymer thereof. In some embodiments, the ammonium-containing cationic polymer is a copolymer of quaternary and tertiary amines. In additional embodiments, the ammonium-containing cationic polymer(s) is one or more selected from a linear polyethylenimine, a branched polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquaternium-10, polyquaternium-11, polyquaternium-39, and polyquaternium-51. Attorney Docket No. 15939.0027-01304

[0140]

[0118] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and one or more organic acid chelators, wherein the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically is about 0.0025% by weight in a final product and the organic acid chelator(s) is about 0.001% to about 1% by weight, about 0.002% to about 0.8% by weight, about 0.003% to about 0.6% by weight, about 0.004% to about 0.4% by weight, or about 0.005% to about 0.2% by weight in the final product. In some embodiments, the concentration of the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically is about 0.0025% by weight in the final product and the organic acid chelator(s) is about 0.001% to about 1% by weight, about 0.002% to about 0.9% by weight, about 0.005% to about 0.8% by weight, about 0.01% to about 0.7% by weight, about 0.02% to about 0.6% by weight, or at about 0.05% to about 0.5% by weight in the final product. In some embodiments, the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically is about 0.0025% by weight in the final product and the organic acid chelator(s) is about 0.005% to about 0.2% by weight or about 0.05% to about 0.5% by weight in the final product. In some embodiments, the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically is about 0.0025% by weight in the final product and the organic acid chelator(s) is no more than 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight in the final product. In some embodiments, the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight in the final product or more specifically is about 0.0025% by weight and the organic acid chelator(s) is about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight in the final product. In some embodiments, the ammonium-containing cationic polymer(s) is about 0.0025% by weight in the final product. In Attorney Docket No. 15939.0027-01304

[0141] some embodiments, the organic acid chelator(s) is about 0.025% by weight in the final product and the ammonium-containing cationic polymer(s) is about 0.0025% by weight in the final product. In some embodiments, the organic acid chelator(s) is about 0.025% by weight in the final product. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and one or more organic acid chelators selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the organic acid chelator is EDTA. In some embodiments, the organic acid chelator is EDDS. In some embodiments, the organic acid chelator is gluconolactone. In some embodiments, the organic acid chelator is MGDA. In some embodiments, the organic acid chelator is GLDA. In some embodiments, the organic acid chelator is phytic acid.

[0142]

[0119] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and EDTA, wherein the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight in the final product and EDTA is equivalent to disodium EDTA dihydrate at about 0.022% to about 0.5% by weight or more specifically equivalent to disodium EDTA dihydrate at about 0.05% by weight in the final product. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and EDDS, wherein the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight in the final product and EDDS is equivalent to trisodium EDDS at about 0.005% to about 0.2% by weight or more specifically equivalent to trisodium EDDS at about 0.1% by weight in the final product. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and gluconolactone, wherein the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically 0.0025% by Attorney Docket No. 15939.0027-01304

[0143] weight in the final product and gluconolactone is about 0.05% to about 0.5% by weight or more specifically about 0.3% by weight in the final product. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and MGDA, wherein the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight in the final product and MGDA is equivalent to trisodium MGDA at about 0.005% to about 0.2% by weight or more specifically about 0.1% by weight in the final product. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and GLDA, wherein the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight in the final product and GLDA is equivalent to tetrasodium GLDA at about 0.005% to about 0.2% by weight or more specifically about 0.1% by weight in the final product. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and phytic acid, wherein the ammonium-containing cationic polymer(s) is about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight in the final product and phytic acid is about 0.05% to about 0.5% by weight or more specifically about 0.3% by weight in the final product.

[0144]

[0120] In some embodiments, the antimicrobial composition further comprises one or more additional organic acids selected from sodium benzoate, sodium salicylate, and citric acid. In some embodiments, the additional organic acid is sodium benzoate. In some embodiments, the additional organic acid is sodium salicylate. In some embodiments, the additional organic acid is citric acid. In some embodiments, the concentration of the additional one or more organic acid in a final product is about 0.02% to about 3% by weight or about 0.1% to about 7% by weight. Attorney Docket No. 15939.0027-01304

[0145]

[0121] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers, one or more organic acid chelators, and one or more additional organic acids, wherein the one or more ammonium-containing cationic polymers and the one or more additional organic acids or salt thereof are at a ratio by weight between 1: 1 and 1:6,000, between 1:1 and 1:10, between 1:10 and 1:50, between 1:50 and 1:100, between 1:100 and 1:200, between 1:200 and 1:300, between 1:300 and 1:400, between 1:400 and 1:500, between 1:500 and 1:600, between 1:600 and 1:700, between 1:700 and 1:800, between 1:800 and 1:900, between 1:900 and 1:1,000, between 1:1,000 and 1:1,100, between 1:1,100 and 1:1,200, between 1:1,200 and 1:1,300, between 1:1,300 and 1:1,400, between 1:1,400 and 1:1,500, between 1:1,500 and 1:1,600, between 1:1,600 and 1:1,700, between 1:1,700 and 1:1,800, between 1:1,800 and 1:1,900, between 1:1,900 and 1:2,000, between 1:1,900 and 1:2,000, between 1:1,900 and 1:2,000, between 1:1,900 and 1:2,000, between 1:1,900 and 1:2,000, between 1:2,000 and 1:2,200, between 1:2,200 and 1:2,400, between 1:2,400 and 1:2,600, between 1:2,600 and 1:2,800, between 1:2,800 and 1:3,000, between 1:3,000 and 1:3,500, between 1:3,500 and 1:4,000, between 1:4,000 and 1:4,500, between 1:4,500 and 1:5,000, between 1:5,000 and 1:5,500, or between 1:5,500 and 1:6,000. In some embodiments, the ammonium-containing cationic polymer and an organic acid or salt thereof are incorporated at a ratio by weight of 1:400 to 1: 1,700. In some embodiments, the ammonium-containing cationic polymer and the organic acid or salt thereof are incorporated at a ratio by weight of 1:100 to 1:200. In some embodiments, the ammonium-containing cationic polymer and an organic acid or salt thereof are incorporated at a ratio by weight of 1:3,000 to 1:6,000. In some embodiments, the ammonium-containing cationic polymer and an organic acid or salt thereof are incorporated at a ratio by weight of 1:4 to 1:200. In some embodiments, the ammonium-containing cationic polymer and an organic acid or salt thereof are incorporated at a Attorney Docket No. 15939.0027-01304

[0146] ratio by weight of 1: 120, 1:140, 1:180, 1:200, 1:400, 1:800, or 1:1,600. In some embodiments, the ammonium-containing cationic polymer and an organic acid or salt thereof are incorporated at a ratio by weight of 1:3 to 1:2,000, 1:50 to 1:200, 1:50 to 1:400, or 1:100 to 1:200.

[0147]

[0122] In some embodiments, the concentrations of sodium benzoate and the ammonium-containing cationic polymer(s) are about 1% by weight and about 0.0025% by weight, respectively, or about 0.5% by weight and about 0.0025% by weight in the final product, respectively. In some embodiments, the sodium benzoate is no more than 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% by weight in the final product. In some embodiments, the antimicrobial composition comprising sodium benzoate disclosed herein has an effective pH range of about 2.5 to about 6.0, and in particular the effective pH is about 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5 or 6.0. In some embodiments, the antimicrobial composition comprising sodium benzoate disclosed herein has an effective pH range of at least 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10. More particularly, the effective pH range is between 6.0 and 10.0, between 6.0 and 9.0, between 6.0 and 8.5, between 6.0 and 8.0, between 6.5 and 10.0, between 6.5 and 9.0, between 6.5 and 8.5, or between 6.5 and 8.0.

[0148]

[0123] In some embodiments, the concentrations of sodium salicylate and the ammonium-containing cationic polymer(s) in the final product are about 0.5% or lower by weight and about 0.0001% to about 0.2% by weight, respectively. In some embodiments, the sodium salicylate is lower than about 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.4%, 0.5%, or 1% by weight in the final product. In some embodiments, the antimicrobial composition comprising sodium salicylate disclosed herein has an effective pH range of at least 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10. More particularly, the effective pH range is between 6.0 and 10.0, between 6.0 and 9.0, between Attorney Docket No. 15939.0027-01304

[0149] 6.0 and 8.5, between 6.0 and 8.0, between 6.5 and 10.0, between 6.5 and 9.0, between 6.5 and 8.5, or between 6.5 and 8.0.

[0150]

[0124] In some embodiments, the concentrations of sodium salicylate and one or more the ammonium-containing cationic polymers in the final product are about 0.5% to about 3% by weight and about 0.0001% to about 0.2% by weight. In some embodiments, the sodium salicylate is lower than about 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, or 4% by weight in the final product. In some embodiments, the antimicrobial composition comprising sodium salicylate disclosed herein has an effective pH range of at least 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10. More particularly, the effective pH range is between 5.0 and 10.0, between 5.0 and 9.5, between 5.0 and 9.0, between 5.0 and 8.5, between 5.0 and 8.0, between 6.5 and 10.0, between 6.5 and 9.0, between 6.5 and 8.5, or between 6.5 and 8.0.

[0151]

[0125] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers, EDTA, and sodium benzoate, wherein the concentrations of the ammonium-containing cationic polymer(s), EDTA, and sodium benzoate in a final product are about 0.0025% by weight, equivalent to disodium EDTA dihydrate at about 0.025% by weight, and about 0.3% by weight, respectively. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers, EDDS, and sodium benzoate, wherein the concentrations of the ammonium-containing cationic polymer(s), EDDS, and sodium benzoate in a final product are about 0.0025% by weight, equivalent to trisodium EDDS at about 0.025% by weight, and about 0.3% by weight, respectively. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers, gluconolactone, and sodium benzoate, wherein the concentrations of the ammonium-containing cationic polymer(s), gluconolactone, and sodium benzoate in a final Attorney Docket No. 15939.0027-01304

[0152] product are about 0.005% by weight, about 0.3% by weight, and about 0.6% by weight, respectively. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers, gluconolactone, and sodium benzoate, wherein the concentrations of the ammonium-containing cationic polymer(s), gluconolactone, and sodium benzoate in a final product are about 0.025% by weight, about 0.5% by weight, and about 0.3% by weight, respectively. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers, MGDA, and sodium benzoate, wherein the concentrations of the ammonium-containing cationic polymer(s), MGDA, and sodium benzoate in a final product are about 0.0025% by weight, equivalent to trisodium MGDA at about 0.025% by weight, and about 0.3% by weight, respectively. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers, GLDA, and sodium benzoate, wherein the concentrations of the ammonium-containing cationic polymer(s), GLDA, and sodium benzoate in a final product are about 0.0025% by weight, equivalent to tetrasodium GLDA at about 0.0125% by weight, and about 0.3% by weight, respectively. In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers, phytic acid, and sodium benzoate, wherein the concentrations of the ammonium-containing cationic polymer(s), phytic acid, and sodium benzoate in a final product are about 0.0025% by weight, about 0.5% by weight, and about 0.3% by weight, respectively.

[0153]

[0126] In some embodiments, the antimicrobial composition further comprises one or more antimicrobial enzymes, one or more antimicrobial peptides, one or more antimicrobial proteins, and / or one or more antimicrobial chemicals.

[0154]

[0127] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers at about 0.01% to about 20% by weight and one or more Attorney Docket No. 15939.0027-01304

[0155] organic acid chelators at about 0.1% by weight to lower than 50% by weight. In some embodiments, the organic acid chelator is EDTA equivalent to disodium EDTA dihydrate about 2.2% to about 50% by weight or more specifically equivalent to disodium EDTA dihydrate at about 0.05% by weight in the antimicrobial composition. In some embodiments, the organic acid chelator is EDDS equivalent to trisodium EDDS at about 0.5% to about 20% by weight or more specifically equivalent to trisodium EDDS at about 10% by weight in the antimicrobial composition. In some embodiments, the organic acid chelator is gluconolactone is about 2.5% to about 10% by weight or more specifically about 10% by weight in the antimicrobial composition. In some embodiments, the organic acid chelator is MGDA is equivalent to trisodium MGDA at about 0.5% to about 20% by weight or more specifically about 10% by weight in the antimicrobial composition. In some embodiments, the organic acid chelator is GLDA equivalent to tetrasodium GLDA at about 0.5% to about 20% by weight or more specifically about 10% by weight in the antimicrobial composition. In some embodiments, the organic acid chelator is phytic acid at about 5% to about 50% by weight or more specifically about 30% by weight in the antimicrobial composition.

[0156]

[0128] In some embodiments, the antimicrobial composition comprises sodium benzoate at about 30% by weight and one or more ammonium-containing cationic polymers at about 0.25% by weight. In some embodiments, the antimicrobial composition comprises sodium salicylate at about 45% by weight and one or more ammonium-containing cationic polymers at about 0.25% by weight. In some embodiments, the ratio by weight between the ammonium-containing cationic polymer and the organic acid is from 1:50 to 1:400, and more specifically from 1:100 to 1:200. In some embodiments, the ratio by weight between the ammonium-containing cationic polymer and sodium benzoate is from 1:120. In some embodiments, the ratio by weight between the Attorney Docket No. 15939.0027-01304

[0157] ammonium-containing cationic polymer and sodium salicylate is from 1:180. In some embodiments, the antimicrobial composition further comprises EDTA equivalent to disodium EDTA dihydrate at about 2.5% by weight. In some embodiments, the antimicrobial composition further comprises EDDS equivalent to trisodium EDDS at about 2.5% by weight. In some embodiments, the antimicrobial composition further comprises gluconolactone at about 10% by weight. In some embodiments, the antimicrobial composition further comprises MGDA equivalent to trisodium MGDA at about 2.5% by weight. In some embodiments, the antimicrobial composition further comprises GLDA equivalent to tetrasodium GLDA at about 1.25% by weight. In some embodiments, the antimicrobial composition further comprises phytic acid at about 50% by weight.

[0158] A. Ammonium-containing cationic polymers

[0159]

[0129] As used herein, the term “cationic polymer” references to a specific cationic polymer. In some embodiments, the cationic polymer disclosed herein is an ammonium-containing cationic polymer. In some embodiments, the ammonium-containing cationic polymer is a quaternary ammonium-containing polymer, a tertiary ammonium-containing polymer, secondary ammonium-containing polymer, or a primary ammonium-containing polymer, or a combination thereof. In some embodiments, the cationic ammonium-containing polymer is a co-polymer of quaternary ammonium-, a tertiary ammonium-, secondary ammonium-, or a primary ammonium-containing polymer, or a combination thereof.

[0160]

[0130] In some embodiments, the ammonium-containing cationic polymer is a polyquaternium. Non-limiting examples of the polyquaternium include Polyquaternium Crosspolymer-2, Polyquaternium Crosspolymer-3, Polyquaternium-1, Polyquaternium- 10, Polyquaternium- 10 / Phosphorylcholine Glycol Acrylate Copolymer, Polyquaternium- 100, Attorney Docket No. 15939.0027-01304

[0161] Polyquaternium-102, Polyquaternium-103, Polyquaternium-104, Polyquaternium-105 Poly quaternium- 106, Poly quaternium- 107, Polyquaternium-109, Polyquaternium-11. Polyquaternium-110, Polyquaternium-111, Polyquaternium-112, Polyquaternium-113 Polyquaternium-114, Polyquaternium-115, Polyquaternium-116, Poly quaternium- 12 Poly quaternium- 13, Poly quaternium- 14, Poly quaternium- 16, Polyquaternium-17 Polyquaternium-18, Polyquatemium-19, Polyquatemium-2, Polyquaternium-20, Poly quaternium- 22, Polyquaternium-24, Polyquaternium-27, Polyquaternium-28, Polyquaternium-29, Poly quaternium -30, Polyquaternium-31, Polyquaternium-32, Polyquaternium-33. Poly quaternium -34, Poly quaterni um-35, Polyquaternium-36, Polyquaternium-37 Polyquaternium-39, Polyquatemium-4, Poly quatemium-4 / Hydroxy propyl Starch Copolymer, Polyquaternium-42, Poly quaternium -43, Polyquaternium-44, Polyquaternium-45, Polyquaternium-46, Polyquaternium-47, Polyquaternium-48, Polyquaternium-49, Poly quaterni um-5, Polyquatemium-50, Polyquaternium-51, Polyquaternium-52, Polyquatemium-53, Polyquaternium-54, Polyquaternium-55, Polyquaternium-56, Polyquaternium-57, Polyquaternium-58, Polyquatemium-59, Polyquatemium-6, Polyquaternium-60, Polyquaternium-61, Polyquaternium-62, Polyquaternium-63, Polyquaternium-64, Polyquatemium-65, Polyquaternium-66, Polyquaternium-67, Polyquaternium-68, Polyquaternium-69, Polyquaternium-7, Polyquatemium-70, Polyquaternium-71, Polyquaternium-72, Polyquatemium-73, Polyquaternium-74, Polyquaternium-75, Polyquaternium-76, Polyquaternium-77, Polyquaternium-78, Polyquatemium-79, Polyquatemium-8, Polyquaternium-80, Polyquaternium-81, Polyquaternium-82, Polyquaternium-83, Polyquaternium-84, Polyquaternium-85, Polyquaternium-86, Polyquaternium-87, Polyquaternium-88, Polyquaternium-89, Poly quaternium -9, Polyquaternium-90, Polyquaternium-91, Poly quaternium -92, Poly quaternium - Attorney Docket No. 15939.0027-01304

[0162] 94, Polyquatemium-95, Polyquatemium-96, Polyquaternium-98, Polyquaternium-99, and Sodium Polyquaternium Crosspolymer- 1

[0163]

[0131] In certain circumstances, the ammonium-containing cationic polymer is prepared from monomers resulting in polyammonium containing polymers with quaternary, tertiary, secondary, or primary ammonium ions or any co-polymer of functionalized amine. Nonlimiting examples of such monomers include diallyl dimethyl ammonium chloride, dimethylamine, ethylenimine, diethylamine, dipropylamine, methanamine, 4-(2-nitrobutyl)morpholine, N-(3 -ami nopropyl )-N-dodecylpropane- 1,3 -diamine, glucoprotamine, triethanolamine, lysine, aziridine, acrylamide, vinylpyrrolidone, dimethylamine ethylmethacrylate, acrylic acid, N-butyl methacrylate, dimethylaminopropyl methacrylate, methacryloyl-aminopropyl-lauryldimonium chloride, 2-methacryloyloxyethyl phosphorylcholine, and the like. In some cases, the ammonium-containing cationic polymer may be comprised of copolymers of dimethylamine-epichlorohydrin, diethylenetriamine, dimethylaminohydroxypropyl-diethylenetriamine, and the like. Examples of ammonium-containing cationic polymers can also be found in WO 2013 / 124784 Al, EP 0431739 Al, Sun et al. (1981), US 10,563,042 B2, and US 3,975,347 A, which are incorporated by reference in their entirety.

[0164]

[0132] The ammonium-containing cationic polymers disclosed herein are capable of extending the pH range at which organic acids have antimicrobial effects (“antimicrobial pH range”). In certain circumstances, the ammonium-containing cationic polymer extends the antimicrobial pH range of an organic acid with a pKa lower than 5 (in water) to have antimicrobial effects at an elevated pH. In some embodiments, the organic acid has a pKa of about 2.9 to about 4.9 in water. In some embodiments, the ammonium-containing cationic polymer extends the antimicrobial pH range of the organic acid to at least about 1.5 units higher than the organic acid’ s Attorney Docket No. 15939.0027-01304

[0165] pKa in water. Depending on the organic acid used, the extended antimicrobial pH range may be above about pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10. In some embodiments, the ammonium-containing cationic polymer is a quaternary, tertiary, or secondary polyamine, or a copolymer thereof. In some embodiments, the ammonium-containing cationic polymer is a copolymer of quaternary and tertiary amines. In additional embodiments, the ammonium-containing cationic polymer is selected from a linear polyethylenimine, a branched poly ethyl enimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, or polyquaternium-7. In additional embodiments, the ammonium-containing cationic polymer is selected from a linear polyethylenimine, a branched polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamineepi chlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquatemium-10, polyquaternium-11, polyquaternium-39, or polyquaternium-51 and the organic acid is benzoic acid.

[0166]

[0133] In some embodiments, the average molecular weight of the ammonium-containing cationic polymer as measured by gel permeation chromatography may range from about 200 g / mol to about 1,000,000 g / mol. In some embodiments, the average molecular weight of the ammonium-containing cationic polymer may be from about 500 g / mol to about 100,000 g / mol, from about 500 g / mol to about 50,000 g / mol, from about 500 g / mol to about 40,000 g / mol, from about 500 g / mol to about 30,000 g / mol, from about 5,000 g / mol to about 30,000 g / mol, from about 10,000 g / mol to about 30,000 g / mol, from about 500 g / mol to about 20,000 g / mol, from about 500 g / mol to about 10,000 g / mol, from about 50,000 g / mol to 120,000 g / mol, from about 75,000 g / mol to about 110,000 g / mol, or from about 500 gm / mol to about 5,000 g / mol. In some embodiments, the Attorney Docket No. 15939.0027-01304

[0167] average molecular weight of the ammonium-containing cationic polymer may be about 100,000 g / mol.

[0168]

[0134] In some embodiments, the antimicrobial composition disclosed herein comprises one or more ammonium-containing cationic polymers and one or more organic acids in an effective amount to prevent or decrease growth of one or more microbes in comparison to the identical composition that does not comprise the one or more ammonium-containing cationic polymer at an elevated pH. In some embodiments, the elevated pH is at least about 1.5 units higher than the organic acid’s pKa in water. In some embodiments, the composition may comprise no more than 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, 0.005%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.12%, 0.14%, 0.16%, 0.18%, 0.20%, 0.30%, 0.40%, or 0.50% by weight of the ammonium-containing cationic polymer in a final product.

[0169] B. Organic acid chelators

[0170]

[0135] As used herein, the term “organic acid” or reference to a specific organic acid includes salt forms of such organic acid and includes mixtures of ionized and salt forms. For example, “benzoic acid” shall include the acid form and any conjugate salt form, such as sodium benzoate. Specific salt forms shall include acid forms or salts containing other counter ions. For example, “sodium benzoate” shall include “benzoic acid” and also “potassium benzoate” and other salt forms. Equivalent concentrations of different forms of the organic acid can be derived from the concentrations of the form of the corresponding organic acid disclosed herein. Unless stated otherwise, the percentages by weight of the organic acids disclosed herein were calculated based on an anhydrous sodium salt of the organic acid. Attorney Docket No. 15939.0027-01304

[0171]

[0136] As used herein, the term “organic acid chelator” refers to an organic acid and salts thereof which can act as a chelator. Non-limiting examples of organic acid chelators include EDTA, EDDS, gluconolactone, MGDA, GLDA, phytic acid, and salts thereof.

[0172]

[0137] In the case of EDTA, the percentages by weight were calculated based on disodium EDTA dihydrate (e.g., CAS# 6381-92-6 or 139-33-3). In the case of EDDS, the percentages by weight were calculated based on trisodium EDDS (e.g., CAS# 178949-82-1). In the case of gluconolactone, the percentages by weight were calculated based on gluconolactone (e.g., CAS# 90-80-2). In the case of MGDA, the percentages by weight were calculated based on a trisodium MGDA (e.g., CAS# 164462-16-2). In the case of GLDA, the percentages by weight were calculated based on tetrasodium GLDA (e.g., CAS# 51981-21-6). In the case of phytic acid, the percentages by weight were calculated based on phytic acid (e.g., CAS# 83-86-3).

[0173]

[0138] In some embodiments, the antimicrobial composition disclosed herein comprises one or more ammonium-containing cationic polymers and one or more organic acid chelators. In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the organic acid chelator is EDTA. In some embodiments, the organic acid chelator is EDDS. In some embodiments, the organic acid chelator is gluconolactone. In some embodiments, the organic acid chelator is MGDA. In some embodiments, the organic acid chelator is GLDA. In some embodiments, the organic acid chelator is phytic acid.

[0174]

[0139] In some embodiments, the antimicrobial composition disclosed herein comprises one or more organic acid chelators at an effective amount to prevent or decrease growth of one or more microbes in comparison to the identical composition that does not comprise the organic acid chelator(s) at pH 6.0 or higher (e.g., at pH 6.0, 6.5. 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, or higher) and / or Attorney Docket No. 15939.0027-01304

[0175] at pH 2.5-6.0 (e.g., at pH 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0). In some embodiments, the antimicrobial composition is added to a product to produce a final product comprising an effective amount of the organic acid chelator(s) to prevent or decrease growth of one or more microbes in comparison to the identical product that does not comprise the organic acid chelator(s) at pH 6.0 or higher (e.g., at pH 6.0, 6.5. 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, or higher) and / or at pH 2.5-6.0 (e.g., at pH 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0).

[0176]

[0140] In some embodiments, the concentration of the organic acid chelator(s) in the final product is about 0.001% to about 1% by weight, about 0.002% to about 0.8% by weight, about 0.003% to about 0.6% by weight, about 0.004% to about 0.4% by weight, or about 0.005% to about 0.2% by weight. In some embodiments, the concentration of the organic acid chelator(s) in the final product is about 0.001% to about 1% by weight, about 0.002% to about 0.9% by weight, about 0.005% to about 0.8% by weight, about 0.01% to about 0.7% by weight, about 0.02% to about 0.6% by weight, or at about 0.05% to about 0.5% by weight. In some embodiments, the concentration of the organic acid chelator(s) in the final product is about 0.005% to about 0.2% by weight or about 0.05% to about 0.5% by weight. In some embodiments, the concentration of the one or more organic acid chelators in the final product is no more than 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight. In some embodiments, the concentration of the one or more organic acid chelators in the final product is about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight.

[0177]

[0141] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and EDTA, wherein the concentration of the one or more ammonium-containing cationic polymers in a final product is about 0.0001% to about 0.2% by weight or more specifically about 0.0025% by weight; and wherein the concentration of EDTA in Attorney Docket No. 15939.0027-01304

[0178] the final product is equivalent to disodium EDTA dihydrate at about 0.001% to about 1% by weight, about 0.002% to about 0.9% by weight, about 0.005% to about 0.8% by weight, about 0.01% to about 0.7% by weight, about 0.02% to about 0.6% by weight, or at about 0.022% to about 0.5% by weight. In some embodiments, the concentration of EDTA in the final product is equivalent to disodium EDTA dihydrate at no more than 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%. 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of EDTA in the final product is equivalent to disodium EDTA dihydrate at about 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%. 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of EDTA in the final product is equivalent to disodium EDTA dihydrate at about 0.022% to about 0.5% by weight or more specifically equivalent to disodium EDTA dihydrate at about 0.025% by weight or at about 0.05% by weight.

[0179]

[0142] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and EDDS, wherein the concentration of the one or more ammonium-containing cationic polymers in a final product is about 0.0001% to about 0.2% by weight or more specifically about 0.0025% by weight; and wherein the concentration of EDDS in the final product is equivalent to trisodium EDDS at about 0.001% to about 1% by weight, about 0.002% to about 0.8% by weight, about 0.003% to about 0.6% by weight, about 0.004% to about 0.4% by weight, or about 0.005% to about 0.2% by weight. In some embodiments, the concentration of EDDS in the final product is equivalent to trisodium EDDS at no more than 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%.

[0180] 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the Attorney Docket No. 15939.0027-01304

[0181] concentration of EDDS in the final product is equivalent to trisodium EDDS at about 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%. 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of EDDS in the final product is equivalent to trisodium EDDS at about 0.005% to about 0.2% by weight or more specifically equivalent to trisodium EDDS at about 0.025% or about 0.1% by weight.

[0182]

[0143] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and gluconolactone, wherein the concentration of the one or more ammonium-containing cationic polymers in a final product is about 0.0001% to about 0.2% by weight or more specifically about 0.0025% by weight; and wherein the concentration of gluconolactone in the final product is about 0.001% to about 1% by weight, about 0.002% to about 0.9% by weight, about 0.005% to about 0.8% by weight, about 0.01% to about 0.7% by weight, about 0.02% to about 0.6% by weight, or at about 0.05% to about 0.5% by weight. In some embodiments, the concentration of gluconolactone in the final product is no more than 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%. 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of gluconolactone in the final product is about 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%. 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of gluconolactone in the final product is about 0.05% to about 0.5% by weight or more specifically about 0.3% or about 0.5% by weight.

[0183]

[0144] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and MGDA, wherein the concentration of the one or more ammonium-containing cationic polymers in a final product is about 0.0001% to about 0.2% Attorney Docket No. 15939.0027-01304

[0184] by weight or more specifically about 0.0025% by weight; and wherein the concentration of MGDA in the final product is equivalent to trisodium MGDA at about 0.001% to about 1% by weight, about 0.002% to about 0.8% by weight, about 0.003% to about 0.6% by weight, about 0.004% to about 0.4% by weight, or about 0.005% to about 0.2% by weight. In some embodiments, the concentration of MGDA in the final product is equivalent to trisodium MGDA at no more than 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%.

[0185] 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of MGDA in the final product is equivalent to trisodium MGDA at about 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%. 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of MGDA in the final product is equivalent to trisodium MGDA at about 0.005% to about 0.2% by weight or more specifically equivalent to trisodium MGDA at about 0.025% or about 0.1% by weight.

[0186]

[0145] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and GLDA, wherein the concentration of the one or more ammonium-containing cationic polymers in a final product is about 0.0001% to about 0.2% by weight or more specifically about 0.0025% by weight; and wherein the concentration of GLDA in the final product is equivalent to tetrasodium GLDA at about 0.001% to about 1% by weight, about 0.002% to about 0.8% by weight, about 0.003% to about 0.6% by weight, about 0.004% to about 0.4% by weight, or about 0.005% to about 0.2% by weight. In some embodiments, the concentration of MGDA in the final product is equivalent to tetrasodium GLDA at no more than 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%.

[0187] 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the Attorney Docket No. 15939.0027-01304

[0188] concentration of MGDA in the final product is equivalent to tetrasodium GLDA at about 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%. 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of GLDA in the final product is equivalent to tetrasodium GLDA at about 0.005% to about 0.2% by weight or more specifically equivalent to tetrasodium GLDA at about 0.0125% or about 0.1% by weight.

[0189]

[0146] In some embodiments, the antimicrobial composition comprises one or more ammonium-containing cationic polymers and phytic acid, wherein the concentration of the one or more ammonium-containing cationic polymers in a final product is about 0.0001% to about 0.2% by weight or more specifically about 0.0025% by weight; and wherein the concentration of phytic acid in the final product is about 0.001% to about 1% by weight, about 0.002% to about 0.9% by weight, about 0.005% to about 0.8% by weight, about 0.01% to about 0.7% by weight, about 0.02% to about 0.6% by weight, or at about 0.05% to about 0.5% by weight. In some embodiments, the concentration of phytic acid in the final product is no more than 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.1%, 0.1%, 0.2%. 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% by weight. In some embodiments, the concentration of phytic acid in the final product is about 0.05% to about 0.5% by weight or more specifically about 0.3% or about 0.5% by weight.

[0190] C. Additional organic acids

[0191]

[0147] In some embodiments, the antimicrobial composition disclosed herein comprises one or more ammonium-containing cationic polymers, one or more organic acid chelators, and optionally one or more additional organic acids. In some embodiments, the antimicrobial Attorney Docket No. 15939.0027-01304

[0192] composition disclosed herein comprises one or more ammonium-containing cationic polymers, one or more organic acid chelators, and one or more additional organic acids.

[0193]

[0148] In some embodiments, the organic acid in the antimicrobial composition disclosed herein has a pKa lower than 5 in water. In some embodiments, the organic acid has a pKa of about 2.9 to about 4.9 in water. In some embodiments, the organic acid alone has antimicrobial activity at a pH lower than the organic acid’s pKa in water and has no or very weak antimicrobial activity at a pH more than 1 unit higher than the organic acid’s pKa in water.

[0194]

[0149] Nonlimiting examples of the additional organic acids in the antimicrobial composition disclosed herein include benzoic acid, lactic acid, propionic acid, citric acid, salicylic acid, azelaic acid, tannic acid, boric acid, sorbic acid, acetic acid, levulinic acid, ascorbic acid, and caprylic acid and similar fatty acids or derivatives thereof as well as salts of the aforementioned organic acids. In some embodiments, two or more such organic acids can be used in combination, for example benzoic acid and citric acid or salicylic acid and citric acid. In some embodiments, the additional organic acid is benzoic acid. In some embodiments, the salt of the organic acid is sodium benzoate. In some embodiments, the organic acid is salicylic acid. In some embodiments, the salt of the organic acid is sodium salicylate.

[0195]

[0150] In some embodiments, the additional organic acid is optionally incorporated in the antimicrobial composition disclosed herein in an effective amount to prevent or decrease growth of one or more microbes in comparison to the identical composition that does not comprise the organic acid at a pH higher than 6.0, 6.5. 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10. In some embodiments, the antimicrobial composition is added to a product to produce a final product comprising an effective amount of the additional organic acid(s) to prevent or decrease growth of one or more microbes in comparison to the identical product that does not comprise the organic acid chelator(s) Attorney Docket No. 15939.0027-01304

[0196] at pH 6.0 or higher (e.g., at pH 6.0, 6.5. 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, or higher) and / or at pH 2.5-6.0 (e.g., at pH 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0). In some embodiments, the final product may comprise no more than 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2.5%, 3%, 3.5%, 4%, 4%, 4.5%, or 5% by weight of the additional organic acid(s).

[0197]

[0151] In particular embodiments, benzoic acid or a salt thereof is incorporated into an antimicrobial composition that prevents or decreases growth of one or more microbes at a pH higher than 6.0, 6.5. 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10, and wherein the composition comprises no more than 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% by weight of the organic acid in a final product. In particular embodiments, salicylic acid or a salt thereof is incorporated into an antimicrobial composition that prevents or decreases growth of one or more microbes at a pH higher than 6.0, 6.5. 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10, and wherein the composition comprises no more than 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.4%, 0.5%, or 1% by weight of the organic acid in a final product. In particular embodiments, EDTA or a salt thereof is incorporated into an antimicrobial composition that prevents or decreases growth of one or more microbes at a pH higher than 6.0, 6.5. 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10, and wherein the composition comprises no more than 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.05%, 0.1%, 0.15%, or 0.2% by weight of the organic acid in a final product.

[0198]

[0152] In particular embodiments, salicylic acid or a salt thereof is incorporated into an antimicrobial composition that prevents or decreases growth of one or more microbes at a pH higher than 5.0, 5.5, 6.0, 6.5. 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10, and wherein the composition comprises no more than 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.4%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, or 4% by weight of the organic acid in a final product. Attorney Docket No. 15939.0027-01304

[0199]

[0153] In some embodiments, the additional organic acid or salt thereof performs a function other than preservation, such as in cosmetic or drug products with anti-inflammation, anti-acne, or anti-dandruff applications, wherein the active ingredient is an organic acid formulated at low pH to maximize absorption into cells or skin. Ascorbic acid, azelaic acid, and other organic acids require formulation at low pH to absorb into skin and deliver the desired effects. Use of these organic acids range from antimicrobial needs such as anti-acne and anti-dandruff to aesthetic needs reducing inflammation or treating hyperpigmentation of the skin, or antioxidant properties. In some products, organic acids are used as corrosion inhibitors wherein higher pH would be ideal for product performance.

[0200] D. Other additional components

[0201]

[0154] In some embodiments, the antimicrobial composition disclosed herein further comprises one or more antimicrobial enzymes, peptides, and / or proteins, such as a crosslinking enzyme, an oxidase, a nuclease, a hydrolase, a protease, and / or a lytic enzyme. In some embodiments, the composition further comprises one or more additional antimicrobial chemicals, such as, but not limited to, phenoxyethanol, coco betaine, and glycols (e.g. caprylyl glycol, hexanediol, propane diol, ethylhexylglycerin, etc.). In some embodiments, the composition includes both one or more antimicrobial peptides, enzymes and / or proteins and one or more additional antimicrobial chemicals. Nonlimiting examples of known antimicrobial proteins, enzymes, and peptides are shown in Table 1. Nonlimiting examples of antimicrobial chemicals are shown in Table 2. Other miscellaneous antimicrobial chemicals include: iodopropynyl butyl carbamate (IPBC), polyhexamethylene biguanide (PHMB), l,2-dibromo-2,4-dicyanobutane (DBDCB), and Styrene acrylates. Attorney Docket No. 15939.0027-01304

[0202] Table 1. Enzymes, Peptides, and Proteins with Known Antimicrobial Properties Mechanism Enzyme Description Citation Lytic Lysozyme Produced by animals as Ibrahim et al. (2001)

[0203] part of the innate immune FEBS Letters 506(1 ):27- system. Hydrolyzes the 32; Malaczewska et al. peptidoglycan subunits in (2019) BMC Vet. Res. the bacterial cell wall. 15:318

[0204] Chitinase Secreted by soil bacteria Martinez-Zavala et al including Bacillus (2020) Front. Microbiol. thuringiensis to combat 10:3032

[0205] insects and fungi

[0206] Lipase Hydrolyzes extracellular Prabhawathi et al. (2014) lipids and polymers. PloS One 9(5)

[0207] Lysin Utilized by bacteriophages Hoops et al. (2008) Appl. to hydrolyze the glycan Environ. Microbiol. 75:5, component of bacterial 1388-1394

[0208] cell wall

[0209] Lysostaphin Metalloendopeptidase Kokai-Kun et al. (2003) which cleaves the Antimicrob Agents pentaglycine bridges Chemother 47(5): 1589- found in cell wall 1597

[0210] peptidoglycan.

[0211]

[0212] Attorney Docket No. 15939.0027-01304

[0213] Mechanism Enzyme Description Citation Glucanase Secreted by soil bacteria Shafi et al. (2017)

[0214] including Bacillus species Biotechnology & to degrade the fungal cell Biotechnological wall. Has also been Equipment 31:3 446-459 utilized as an algicide and

[0215] for biofilm control.

[0216] Nuclease DNase Hydrolyzes extracellular Kaplan et al. (2012) J.

[0217] nucleic acids and viral Antibiot. (Tokyo) genomic DNA. 65(2):73-77

[0218] RNase Hydrolyzes viral RNA. Wirth (1992)

[0219] WO 1994000016A1

[0220] Lactoferrin Sequesters essential iron Niaz et al. (2019)

[0221] ions to prevent microbial International Journal of growth. Also possesses Food Properties 22: 1 nuclease activity and 1626-1641 hydrolyzes biofilm

[0222] polymers.

[0223] Oxidoreductase Glucose Oxidase Oxidizes glucose to D- Wong et al. (2008) Appl glucono-5-lactone and Microbiol Biotechnol. hydrogen peroxide. 78(6):927-938 Peroxidase Oxidizes inert substrates Ihalin et al. (2006) Arch.

[0224] to form antimicrobial Biochem. Biophys. 445, actives. 261-268 Lactoperoxidase Oxidizes inert substrates White et al. (1983)

[0225] to form antimicrobial Antimicrob Agents actives. Chemother 32(2): 267-272

[0226]

[0227] Attorney Docket No. 15939.0027-01304

[0228] Mechanism Enzyme Description Citation Quorum Lactonase Hydrolyzes quorum Schwab et al. (2019) Quenching sensing lactones, Front Microbiol. 10:611 preventing activation of

[0229] biofilm- and pathogenesispromoting pathways.

[0230] Acylase Hydrolyzes quorum Vogel et al. (2020) Front.

[0231] sensing lactones, Chem. 8:54 preventing activation of

[0232] biofilm- and pathogenesispromoting pathways.

[0233] Hydrolase Dispersin B Hydrolyzes biofilm Izano et al. (2007) J Dent polymers Acs 86(7):618-622 a- Amylase Hydrolyzes extracellular Craigen et al. (2011) Open polysaccharides. Microbiol J. 5: 21 -31 Cellulase Hydrolyzes the cellulose Loiselle et al. (2003)

[0234] component of biofilms Biofouling 19(2):77-85 and algal cell walls.

[0235] Cross-Linking Transglutaminase, US 2022 / 0117236 A1 Enzymes tyrosinase, and

[0236] lysyl oxidase

[0237] Antimicrobial Nisin Increases permeability of Li et al. (2018) Appl Peptides the microbial cell Environ Microbiol 18(12) membrane.

[0238] Bacteriocin Modes of action include Meade et al. (2020)

[0239] inhibition of cell wall Antibiotics 9( 1 ): 32 synthesis and increasing

[0240] cell membrane

[0241] permeability.

[0242]

[0243] Attorney Docket No. 15939.0027-01304

[0244] Mechanism Enzyme Description Citation Siderophore Binds to and sequesters Raaska et al. (1999) J iron ions Indust Microbiol Biotechnol 22, 27-32 Polymyxin Increases permeability of Poirel et al. (2017) Clin the microbial cell Microbiol Rev 30:577-596 membrane.

[0245] Defensin Increases permeability of Ganz (2003) Nat Rev the microbial cell Immunol 3, 710-720 membrane.

[0246]

[0247] Table 2. Examples of Antimicrobial Chemicals

[0248] Classification Chemical

[0249] Polymers Chitosan

[0250] N, N, N-trimethyl chitosan

[0251] s-poly-lysine

[0252] Polyvinylbenzyl-dimethylbutyl ammonium chloride Polyvinylbenzyl trimethyl ammonium chloride Quaternary ammonium polyethylenimine

[0253] Quaternary phosphonium modified epoxidized

[0254] natural rubber

[0255] Arginine-tryptophan-rich peptide

[0256] Guanylated polymethacrylate

[0257] Ammonium ethyl methacrylate homopolymers Metallo-terpyridine carboxymethyl cellulose

[0258] Poly(n-vinylimidazole) modified silicone rubber Quaternary Ammonium Cocamidopropyl Betaine

[0259] Myristamidopropyl-pg-dimonium Cl Phosphate Benzalkonium Chloride (BZK)

[0260] Quatemium-6

[0261] Lauryl Betaine

[0262] Coco Betaine

[0263] Detergents Sodium Lauryl Sulfate

[0264] Dodecylbenzenesulfonic Acid

[0265] Chaotropic Agent Polyamidopropyl biguanide

[0266] Guanidinium chloride

[0267] Phenols, Alcohols, & Ethanol

[0268]

[0269] Polyols Isopropanol Attorney Docket No. 15939.0027-01304

[0270] Classification Chemical

[0271] Dichlorobenzyl Alcohol

[0272] Glycerol

[0273] Caprylyl Glycol

[0274] Ethylhexylglycerin

[0275] 1,3 -Propanediol

[0276] 1,2-Hexanediol and 1,6-Hexanediol

[0277] 1,2-Pentanediol

[0278] 1,10-Decanediol

[0279] 2,3 -Butanediol

[0280] Phenylpropanol

[0281] Caprylyl glyceryl ether

[0282] Gluconolactone

[0283] Hydroxyacetophenone

[0284] Benzyl Alcohol

[0285] Phenethyl alcohol

[0286] p-Anisic acid

[0287] 2-Phenoxyethanol

[0288] Aldehydes & Aldehyde Glutaraldehyde

[0289] Releasers Formaldehyde and Formaldehyde releasers

[0290] Sodium Hydroxymethylglycerate

[0291] DMDM Hydantoin

[0292] Base Sodium Hydroxide

[0293] Oxidizers Hydrogen Peroxide and Peracids (peracetic acid) Parabens Methyl Paraben

[0294] Ethyl Paraben

[0295] Propyl Paraben

[0296] Miscellaneous Natamycin

[0297] Benzisothiazolinone (BIT)

[0298] Bronopol

[0299] Sorbitan Caprylate

[0300] Ethyl Lauroyl Arginate

[0301] Methylisothiazolinone (MIT)

[0302] Cetylpyridinium Chloride

[0303] Chlorphenesin

[0304] Zinc Omadine

[0305] Sodium Omadine

[0306] N-(3-aminopropyl)-N-dodecylpropane- 1,3 -diamine Methylchloroisothiazolinone

[0307] 2,2-dibromo-3-nitrilopropionamide

[0308] 1-Octadecanaminium, N,N-dimethyl-N-[3-(trimethoxysilyl)propyl]-, chloride

[0309] Saponin

[0310] Ethyl lauroyl arginate

[0311]

[0312] Capryl hydroxamic acid (CHA) Attorney Docket No. 15939.0027-01304

[0313] Products and Uses

[0314]

[0155] The compositions described herein can be used to inhibit microbial growth in many types of products. In some cases, the antimicrobial compositions can act as a preservative or extend the shelf life of such products. In some embodiments the compositions described herein can function as corrosion inhibitors, oxidation inhibitors, chelators, or skin and cell penetration of acids for hyperpigmentation. In some embodiments, the antimicrobial composition disclosed herein is a product. In some embodiments, the antimicrobial composition disclosed herein can be added to a product. In some embodiments, the products disclosed herein include an effective amount of an antimicrobial composition as described herein, to act as an antimicrobial agent, e.g., preservative, in the product. In some embodiments, the products disclosed herein include personal care products, including rinse-off personal care products or leave-on personal care products, household products, industrial, industrial and institutional cleaning, industrial and recreational water, cooling water, food, beverages, pharmaceutical, cosmetic, healthcare, marine, paints, coatings, adhesives, oil, gas, plastic, packaging, textiles, agricultural, latex, pulp, or paper products. In such products containing an antimicrobial composition, microbial growth is decreased, the product is preserved, and / or shelf life of the product is increased in comparison to an identical product that does not contain the antimicrobial composition.

[0315] A. Viscosity and ionic solids level

[0316]

[0156] Commercial and industrial products with total ionic solids level about 10% by weight or greater may require a higher level of organic acid and preservation boosters than commercial and industrial products with total ionic solids levels about 10% by weight or less. Similarly commercial or industrial products of higher viscosity of about 50 centipoise (cP) or greater may Attorney Docket No. 15939.0027-01304

[0317] require a higher level of organic acid and preservation boosters than commercial and industrial products with lower viscosity of about 50 cP or lower. A non-limiting example of a personal care product or a household product comprising ionic surfactant solids at above about 10% by weight may require sodium benzoate at about 0.5% to 1.0% for preservation whereas a personal care product or a household product comprising ionic surfactant solids below about 10% may require sodium benzoate at about 0.1% to 0.5% for preservation.

[0318] B. Products

[0319]

[0157] In some embodiments, the product comprising the antimicrobial composition disclosed herein has a pH value of about 5.0, 5.5, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.5, 9.0, 9.5, or 10. In some embodiments, the products has a pH value of at least 5.0, 5.5, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.5, 9.0, 9.5, or 10. In some embodiments, the products has a pH value between 5.0 and 10, between 5.0 and 9.0, between 5.0 and 8.5, between 5.0 and 8.0, between 5.5 and 10, between 5.5 and 9.0, between 5.5 and 8.5, between 5.5 and 8.0. between 6.0 and 10, between 6.0 and 9.0, between 6.0 and 8.5, between 6.0 and 8.0, between 6.5 and 10, between 6.5 and 9.0, between 6.5 and 8.5, or between 6.5 and 8.0.

[0320]

[0158] In some embodiments, the product comprising the antimicrobial composition disclosed herein, wherein antimicrobial composition comprises one or more ammonium-containing cationic polymers, one or more organic acid chelators, and optionally one or more additional organic acids. In some embodiments, the ammonium-containing cationic polymer is a quaternary, tertiary, or secondary polyamine, or a copolymer thereof. In some embodiments, the ammonium-containing cationic polymer is a copolymer of quaternary and tertiary amines. In additional embodiments, the ammonium-containing cationic polymer is selected from a linear polyethylenimine, a branched Attorney Docket No. 15939.0027-01304

[0321] polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, or polyquaternium-7. In additional embodiments, the ammonium-containing cationic polymer is selected from a linear polyethylenimine, a branched polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquatemium-10, polyquaternium-11, polyquaternium-39, or polyquaternium-51. In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the organic acid chelator is EDTA. In some embodiments, the organic acid chelator is EDDS. In some embodiments, the organic acid chelator is gluconolactone. In some embodiments, the organic acid chelator is MGDA. In some embodiments, the organic acid chelator is GLDA. In some embodiments, the organic acid chelator is phytic acid. In some embodiments, the additional organic acid(s) is selected from sodium benzoate and sodium salicylate. In some embodiments, the additional organic acid is sodium benzoate. In some embodiments, the additional organic acid is sodium salicylate.

[0322]

[0159] In some embodiments, the product may comprise at least 0.00005%, 0.0001%, 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, or 0.005% by weight of the ammonium-containing cationic polymer(s) and about 0.001% to about 1% by weight, about 0.002% to about 0.8% by weight, about 0.003% to about 0.6% by weight, about 0.004% to about 0.4% by weight, or about 0.005% to about 0.2% by weight of the organic acid chelator(s). In some embodiments, the product may comprise about 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, or 0.005% by weight of the ammonium-containing cationic polymer(s) and about 0.001% to about 1% by weight, about 0.002% to about 0.8% by weight, Attorney Docket No. 15939.0027-01304

[0323] about 0.003% to about 0.6% by weight, about 0.004% to about 0.4% by weight, or about 0.005% to about 0.2% by weight of the organic acid chelator(s).

[0324]

[0160] In some embodiments, the product may comprise at least 0.00005%, 0.0001%, 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, or 0.005% by weight of the ammonium-containing cationic polymer(s) and about 0.005% to about 0.2% by weight or about 0.05% to about 0.5% by weight of the organic acid chelator(s). In some embodiments, the product may comprise about 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, or 0.005% by weight of the ammonium-containing cationic polymer(s) and about 0.005% to about 0.2% by weight or about 0.05% to about 0.5% by weight of the organic acid chelator(s).

[0325]

[0161] In some embodiments, the product may comprise at least 0.00005%, 0.0001%, 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, or 0.005% by weight of the ammonium-containing cationic polymer(s) and no more than 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s). In some embodiments, the product may comprise about 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, or 0.005% by weight of the ammonium-containing cationic polymer(s) and no more than 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s).

[0326]

[0162] In some embodiments, the product may comprise at least 0.00005%, 0.0001%, 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, or 0.005% by weight of the ammonium-containing cationic polymer(s) and about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s). In some embodiments, the product may comprise about 0.00015%, 0.00025%, 0.0005%, 0.0075%, 0.001%, 0.00125%, 0.0025%, or 0.005% by weight of the ammonium-containing cationic Attorney Docket No. 15939.0027-01304

[0327] polymer(s) and about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s).

[0328]

[0163] In some embodiments, the product may comprise the ammonium-containing cationic polymer(s) in at about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight and EDTA equivalent to disodium EDTA dihydrate at about 0.022% to about 0.5% by weight or more specifically equivalent to disodium EDTA dihydrate at about 0.05% by weight. In some embodiments, the product may comprise the ammonium-containing cationic polymer(s) in at about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight and EDDS equivalent to trisodium EDDS at about 0.005% to about 0.2% by weight or more specifically equivalent to trisodium EDDS at about 0.1% by weight. In some embodiments, the product may comprise the ammonium-containing cationic polymer(s) at about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight and gluconolactone at about 0.05% to about 0.5% by weight or more specifically at about 0.3% by weight. In some embodiments, the product may comprise the ammonium-containing cationic polymer(s) at about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight and MGDA equivalent to trisodium MGDA at about 0.005% to about 0.2% by weight or more specifically about 0.1% by weight. In some embodiments, the product may comprise the ammonium-containing cationic polymer(s) at about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight and GLDA equivalent to tetrasodium GLDA at about 0.005% to about 0.2% by weight or more specifically at about 0.1% by weight. In some embodiments, the product may comprise the ammonium-containing cationic polymer(s) at about 0.0001% to about 0.2% by weight or more specifically 0.0025% by weight and phytic acid at about 0.05% to about 0.5% by weight or more specifically at about 0.3% by weight. Attorney Docket No. 15939.0027-01304

[0329]

[0164] In some embodiments, the product may further comprise no more than 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% by weight or about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, or 7% by weight of the additional organic acid(s). In some embodiments, the product may further comprise about 0.02% to about 3% by weight or about 0.1% to about 7% by weight of the additional organic acid(s). In some embodiments, the product may further comprise about 0.3% by weight or about 0.6% by weight of the additional organic acid(s). In some embodiments, the additional organic acid(s) may be sodium benzoate and / or sodium salicylate.

[0330]

[0165] In some embodiments, the product may comprise an ammonium-containing cationic polymer at about 0.0025% by weight, EDTA equivalent to disodium EDTA at about 0.025% by weight, and sodium benzoate at about 0.3% by weight. In some embodiments, the product may comprise an ammonium-containing cationic polymer at about 0.0025% by weight, EDDS equivalent to trisodium EDDS at about 0.025% by weight, and sodium benzoate at about 0.3% by weight. In some embodiments the product may comprise an ammonium-containing cationic polymer at about 0.005% by weight, gluconolactone at about 0.3% by weight, and sodium benzoate at about 0.6% by weight. In some embodiments the product may comprise an ammonium-containing cationic polymer at about 0.0025% by weight, gluconolactone at about 0.5% by weight, and sodium benzoate at about 0.3% by weight. In some embodiments, the product may comprise an ammonium-containing cationic polymer at about 0.0025% by weight, MGDA equivalent to trisodium MGDA at about 0.025% by weight, and sodium benzoate at about 0.3% by weight. In some embodiments, the product may comprise an ammonium-containing cationic polymer at about 0.0025% by weight, GLDA equivalent to tetrasodium GLDA at about 0.0125% by weight, and sodium benzoate at about 0.3% by weight. In some embodiments, the product may Attorney Docket No. 15939.0027-01304

[0331] comprise an ammonium-containing cationic polymer at about 0.005% by weight, phytic acid at about 0.5% by weight, and sodium benzoate at about 0.3% by weight.

[0332]

[0166] In some embodiments, products comprising an effective amount of an antimicrobial composition disclosed herein have a prolonged shelf life compared to identical products comprising all components of the antimicrobial composition disclosed herein except for the ammonium-containing cationic polymer(s) and / or the organic acid chelator(s). In some embodiments, products comprising an effective amount of an antimicrobial composition disclosed herein have reduced microbial growth compared to identical products that do not contain any ammonium-containing cationic polymer and / or any organic acid chelator as disclosed herein. In some embodiments, products comprising an effective amount of an antimicrobial composition disclosed herein have improved ability to withstand microbial challenges compared to identical products that do not contain any ammonium-containing cationic polymer and / or organic acid chelator as disclosed herein. In some embodiments, the products comprising an effective amount of the antimicrobial composition disclosed herein has a similar or prolonged shelf life compared to identical products comprising the organic acid(s) at a higher concentration(s) and all the other components of the antimicrobial composition disclosed herein except for the ammonium-containing cationic polymer(s) and / or the organic acid chelator(s).

[0333]

[0167] Exemplary products having reduced microbial growth, increased shelf-life, or increased ability to withstand microbial challenge are summarized in Table 3. Attorney Docket No. 15939.0027-01304

[0334] Table 3. Products

[0335] Industrial

[0336] and

[0337] Rinse-Off Leave-On Paint, Institutional Anti-Acne Products Personal Personal Household Coating, Cleaning or and AntiCare Care Products and Industrial or Dandruff Products Products Adhesive Recreational Products Water

[0338] Products

[0339] pH 6.5-10.0 6.5-9.0 65-10.0 6.5-10.0 6.5-9.0 5.0-90 Water Ammonium-Containing Lreatment:

[0340] 0.000625- 0.000625- 0.000625- 0.000625- 0.000625- 0001

[0341] Cationic Polymer (%) 0.2 0.2 0.2 0.2 0.2 Others:

[0342] 0.0001-0.2

[0343] EDTA 0022-05

[0344] Organic EDDS 0.005-0.2

[0345] Acid Gluconolactone 0.05-0.5

[0346] Chelator MGDA 0.005-0.2

[0347] (%) GLDA 0.005-0.2

[0348] Phytic Acid 0.05-0.5

[0349] Low

[0350] Solids: 0.1- Low Solids:

[0351] Paint: 0.1-1

[0352] Sodium 0.5 0.1-0.5

[0353] Benzoate 0.1-1 Others: 0.1- 0.1-6.7 - High High Solids:

[0354] Additional Solids: 0.5- 0.5-3 7

[0355] Organic 1

[0356] Acid

[0357] Anti- Acne:

[0358] (%)

[0359] Sodium 0.5-2 Salicylate < 0.5 <05 - - Varies Anti- Dandruff:

[0360]

[0361] 1.8-3

[0362] a. Personal care products

[0363]

[0168] In some embodiments, an antimicrobial composition is included in a personal care product, such as, but not limited to, bar soap, liquid or hand soap, hand sanitizer (including rinse off and leave-on alcohol based and aqueous-based hand disinfectants), preoperative skin disinfectant, cleansing wipes, disinfecting wipes, body wash, acne treatment products, diaper rash cream, skin cream, shampoo, anti-dandruff shampoo, conditioner, cosmetics (including but not limited to liquid or powder foundation, liquid or solid eyeliner, mascara, cream eye shadow, tinted powder, “pancake” type powder to be used dry or moistened, make up removal products, etc.), Attorney Docket No. 15939.0027-01304

[0364] deodorant, antimicrobial creams, body lotion, hand cream, topical cream, aftershave lotion, skin toner, mouth wash, toothpaste, sunscreen lotion, and baby products such as, but not limited to, cleansing wipes, baby shampoo, baby soap, and diaper cream. In some embodiments, the antimicrobial composition is included in a wound care item, such as, but not limited to, wound healing ointments, creams, and lotions, wound coverings, bum wound cream, bandages, tape, and steri-strips. In some embodiments, the antimicrobial composition is included in an oral care product, such as mouth rinse, toothpaste, or dental floss coating, a veterinary or pet care product, a preservative composition, or a surface disinfectant, such as a disinfectant solution, spray, or wipe.

[0365]

[0169] In some embodiments, products disclosed herein include rinse-off personal care products such as bar soap, liquid soap, body wash, face cleanser, rinse-off anti-acne products, antidandruff products, shampoo and conditioner, toothpaste, and mouthwash. In some embodiments, the product may comprise about 0.00015%, 0.00025%, 0.0005%, 0.000625%, 0.001%, 0.00125%, 0.0025%, 0.005%, 0.01%, 0.05%, 0.1%, or 0.2% by weight of the ammonium-containing cationic polymer(s), about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s), and optionally about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.3%, 0.5%, 0.6%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% by weight of the additional organic acid(s) and. In some embodiments, the ammonium-containing cationic polymer is a linear polyethylenimine, a branched polyethylenimine, a dimethylamineepichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquaternium-10, polyquaternium-11, polyquaternium-39, or polyquaternium-51. The rinse-off personal care products disclosed herein may have a pH of 6.5-9.0. In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the additional organic Attorney Docket No. 15939.0027-01304

[0366] acid(s) is sodium benzoate and / sodium salicylate. In some cases, such as mouthwash or toothpaste, the rinse-off personal care product may have a pH of 6.5-10.0. In other cases, such as anti-dandruff or anti-acne products, the product may have a pH of 5.0-9.0.

[0367]

[0170] In some embodiments, products disclosed herein include leave-in personal care products such as cleansing wipes, cosmetic products, deodorant, topical lotion, topical cream, topical ointment, anti -acne products, anti-dandruff products, hair styling products, and skin toner. In some embodiments, the product may comprise about 0.00015% w / w, 0.00025%, 0.0005%, 0.000625%, 0.001%, 0.00125%, 0.0025%, 0.005%, 0.01%, 0.05%, 0.1%, or 0.2% by weight of the ammonium-containing cationic polymer(s), about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s), and optionally about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.3%, 0.5%, 0.6%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% by weight of the additional organic acid(s). In some embodiments, the ammonium-containing cationic polymer is a linear poly ethyl enimine, a branched poly ethyl enimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquatemium-10, polyquaternium-11, polyquaternium-39, or polyquaternium-51. In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the additional organic acid is sodium benzoate and / or sodium salicylate. The leave-in personal care products disclosed herein may have a pH of 6.5-9.0. The leave-in anti -acne and the leave-in anti-dandruff products may have a pH of 5.0-9.0.

[0368]

[0171] In some embodiments, products disclosed herein include anti -acne products and antidandruff products. In some embodiments, the anti-acne products and anti-dandruff products are at about pH 5.0 to about pH 9.0. In some embodiments, the anti-acne products comprise sodium Attorney Docket No. 15939.0027-01304

[0369] salicylate at about 0.5% to about 2% by weight and one or more of the ammonium-containing cationic polymers disclosed herein at about 0.0005% to about 0.2% by weight. In some embodiments, the anti-dandruff products comprise sodium salicylate at about 1.8% to about 3% by weight and one or more of the ammonium-containing cationic polymers disclosed herein at about 0.0005% to about 0.2% by weight. In some embodiments, the product may further comprise about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s). In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the anti-acne products and anti-dandruff products may further comprise disodium EDTA dihydrate at about 0.01% to about 0.05% by weight. In some embodiments, the anti -acne products may be anti-acne face wash, anti-acne body wash, anti-acne lotion, anti-acne scrubs, antiacne toner, anti-acne masks, etc. In some embodiments, the anti-dandruff products may be antidandruff shampoos, anti -dandruff hair conditioners, anti -dandruff scalp treatment, etc.

[0370] b. Household products

[0371]

[0172] In some embodiments, products disclosed herein include household products such as all-purpose cleaner, laundry detergent, dish soap, laundry sanitizer, fabric softener, window cleaner, cleaning wipes, furniture polish, concentrated liquid cleaner, toilet cleaner, floor cleaner, shower cleaner, wood cleaner, dishwasher detergent, dishwasher rinse aid. In some embodiments, the product may comprise 0.00015%, 0.00025%, 0.0005%, 0.000625%, 0.001%, 0.00125%, 0.0025%, 0.005%, 0.01%, 0.05%, 0.1%, or 0.2% by weight of the ammonium-containing cationic polymer(s), about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.025%, 0.5%, or 1% by weight of the organic acid chelator(s), and optionally about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.3%, 0.5%, 0.6%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% of the Attorney Docket No. 15939.0027-01304

[0372] additional organic acid(s).. In some embodiments, the ammonium-containing cationic polymer is a linear polyethylenimine, a branched polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquaternium-10, polyquaternium-11, polyquaternium-39, or polyquaternium-51. In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the additional organic acid(s) is sodium benzoate and / or sodium salicylate. The household products disclosed herein may have a pH of 6.5-10.0.

[0373] c. Paint and coating

[0374]

[0173] In some embodiments, products disclosed herein include paints, coatings, adhesives, and related products. Non-limiting examples of such products include primers, sealers, spray paints, anticorrosive coatings, anticorrosive coatings, wood stains, wood varnishes, latex coatings, food-contact surface coatings, acrylic binders, film forming chemicals, pigments, and emulsificants. In some embodiments, the product may comprise about 0.00015%, 0.00025%, 0.0005%, 0.000625%, 0.001%, 0.00125%, 0.0025%, 0.005%, 0.01%, 0.05%, 0.1%, or 0.2% by weight of the ammonium-containing cationic polymer(s), about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s), and optionally about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.3%, 0.5%, 0.6%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% by weight or more specifically about 0.1% to about 7% by weight of the additional organic acid(s). In some embodiments, the product is a paint. In some embodiments, the product is a water-based paint. In some embodiments, the product is a paint comprising about 0.00015%, 0.00025%, 0.0005%, 0.000625%, 0.001%, 0.00125%, 0.0025%, 0.005%, 0.01%, 0.05%, 0.1%, or 0.2% by weight of Attorney Docket No. 15939.0027-01304

[0375] the ammonium-containing cationic polymer(s), about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s), and optionally about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.3%, 0.5%, 0.6%, 1%, 1.5%, or 2% by weight or more specifically about 0.1% to about 1% by weight of the additional organic acid(s). In some embodiments, the ammonium-containing cationic polymer is a linear polyethylenimine, a branched polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquatemium-10, polyquaternium-11, polyquaternium-39, or polyquaternium-51. In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the additional organic acid(s) is sodium benzoate and / or sodium salicylate. The paint, coating, adhesive products disclosed herein may have a pH of 6.5-8.0, 6.5-9.0, or 6.5-10.0.

[0376] d. Industrial and institutional cleaning, industrial, or recreational water product

[0174] In some embodiments, products disclosed herein include industrial and institutional cleaning, industrial, or recreational water products for cleaning and sanitization under industrial and institutional setups as well as products used for treating water for industrial or recreational use. Non-limiting examples of industrial and institutional cleaning, industrial, or recreational water products include products for cleaning and sanitizing surfaces in the clinics, surfaces in food industry, and manufacture line; products for treating swimming pool water and industrial cooling tower; products for industrial disinfection and sanitization; and disinfecting and sanitizing products for oil, gas, and energy industries. In some embodiments, the product may comprise about 0.00015%, 0.00025%, 0.0005%, 0.000625%, 0.001%, 0.00125%, 0.0025%, 0.005%, 0.01%, 0.05%, 0.1%, or 0.2% by weight of the ammonium-containing cationic polymer(s), about 0.001%, Attorney Docket No. 15939.0027-01304

[0377] 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s), and optionally about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.3%, 0.5%, 0.6%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% by weight of the additional organic acid(s). In some embodiments, the ammonium-containing cationic polymer is a linear polyethylenimine, a branched polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine-epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquaternium-10, polyquaternium-11, polyquaternium-39, or polyquaternium-51. In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the additional organic acid(s) is sodium benzoate and / or sodium salicylate. The industrial and institutional cleaning, industrial, or recreational water products disclosed herein may have a pH of 6.5-8.0, 6.5-9.0, or 6.5-10.0.

[0378] e. Food and Beverage

[0379]

[0175] In some embodiments, the product disclosed herein is a food and beverage product having a pH of about 7.0, 6.5, 6.0, 5.5, 5.0, 4.5, 4.0, or lower and comprises the antimicrobial composition in an amount of about 0.00015%, 0.00025%, 0.0005%, 0.0075%, or 0.001% by weight of the ammonium-containing cationic polymer(s), about 0.001%, 0.002%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.2%, 0.5%, or 1% by weight of the organic acid chelator(s), and optionally about 0.001%, 0.005%, 0.01%, 0.05%, or 0.1% by weight of the organic acid(s). In some embodiments, the product has a pH of about 7.0 or lower, comprises the antimicrobial composition in an amount of about 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% by weight or less of the organic acid(s), and has improved preservative or antimicrobial activity compared to an identical product that does not contain the ammonium-containing cationic polymer. Non-limiting examples of products having a pH of about 7.0 or less include food or beverage products such as fruit juice, Attorney Docket No. 15939.0027-01304

[0380] carbonated soft drink beverage, jams, sauces, or personal care products. In some embodiments, the ammonium-containing cationic polymer is a quaternary, tertiary, or secondary polyamine, or a copolymer thereof. In some embodiments, the ammonium-containing cationic polymer is a copolymer of quaternary and tertiary amines. In additional embodiments, the ammonium-containing cationic polymer is selected from polylysine, a dimethylamine-epichlorohydrin copolymer or a dimethylamine-epichlorohydrin-ethylenediamine copolymer. In some embodiments, the organic acid chelator(s) is one or more selected from EDTA, EDDS, gluconolactone, MGDA, GLDA, and phytic acid. In some embodiments, the additional organic acid is sodium benzoate.

[0381] C. Uses

[0382]

[0176] In some embodiments, a method for increasing the shelf life, integrity, or microbial free (e.g., bacterial and / or fungal free) status of a product composition, or preserving a product composition, such as a personal care, household or industrial product is provided, wherein the method includes incorporating an effective amount of an antimicrobial composition as disclosed herein into the product. In some embodiments, the effective amount may be an amount, referred to as the MIC (minimum inhibitory concentration), which results in reduction of microbial growth by approximately 80 - 100%, or any of at least about 80%, 85%, 90%, 95%, 98%, 99%, 99.9%, 99.99%, or 99.999% reduction of microbial growth as described herein.

[0383]

[0177] In some embodiments, the method involves extending the effective pH range of a preservative in a product, comprising incorporation of a composition comprising one or more ammonium-containing cationic polymers and one or more organic acid chelators disclosed herein. In some embodiments, the product is at about pH 6.5 to about pH 10.0. Attorney Docket No. 15939.0027-01304

[0384]

[0178] In some embodiments, the method comprises incorporation of a composition comprising one or more ammonium-containing cationic polymers and one or more organic acid chelators disclosed herein into a product comprising a preservative, whereby the shelf life of the product is extended or maintained compared to the same product comprising a higher concentration of the preservative and no such composition. In some embodiments, the product is at about pH 6.5 to about pH 10.0.

[0385]

[0179] In certain embodiments, the method includes adding a concentrated form of an antimicrobial composition (e.g., a mixture of an ammonium-containing polymer, an organic acid chelator, and an additional organic acid) to a product, resulting in a product having increased shelf life, reduced microbial growth, or increased ability to withstand microbial challenge compared to a product not including the antimicrobial composition. In some embodiments, the product is at about pH 6.5 to about pH 10.0. Such concentrated forms of antimicrobial compositions disclosed herein include compositions containing between about 0.01% to about 20% by weight of one or more ammonium-containing cationic polymers, about 0.1% by weight to lower than 50% by weight of one or more organic acid chelators, and optionally between about 10% to about 50% by weight of one or more additional organic acids (e.g., sodium benzoate) as described herein. In certain embodiments, the concentrated antimicrobial composition comprises about 30% sodium benzoate or about 45% sodium salicylate. In certain embodiments the concentrated antimicrobial composition may contain more than one organic acid.

[0386]

[0180] In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight and EDTA equivalent to disodium EDTA dihydrate at about 2.2% to about 50% by weight or more specifically equivalent to trisodium EDTA at about 5% by Attorney Docket No. 15939.0027-01304

[0387] weight. In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight, EDTA equivalent to disodium EDTA dihydrate at about 2.2% to about 50% by weight or more specifically equivalent to disodium EDTA dihydrate at about 2.5% by weight, and sodium benzoate at 30% by weight.

[0388]

[0181] In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight and EDDS equivalent to trisodium EDDS at about 0.5% to about 20% by weight or more specifically equivalent to trisodium EDDS at about 10% by weight. In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight, EDDS equivalent to trisodium EDDS at about 0.5% to about 20% by weight or more specifically equivalent to trisodium EDDS at about 2.5% by weight, and sodium benzoate at 30% by weight.

[0389]

[0182] In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight and gluconolactone at about 5% to about 50% by weight or more specifically at about 30% by weight. In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically about 0.25% by weight, gluconolactone at about 2.5% to about 10% by weight or more specifically at about 10% by weight, and sodium benzoate at 30% by weight. Attorney Docket No. 15939.0027-01304

[0390]

[0183] In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight and MGDA equivalent to trisodium MGDA at about 0.5% to about 20% by weight or more specifically equivalent to trisodium MGDA at about 10% by weight. In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight, MGDA equivalent to trisodium MGDA at about 0.5% to about 20% by weight or more specifically equivalent to trisodium MGDA at about 2.5% by weight, and sodium benzoate at 30% by weight.

[0391]

[0184] In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight and GLDA equivalent to tetrasodium GLDA at about 0.5% to about 20% by weight or more specifically equivalent to tetrasodium GLDA at about 10% by weight. In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight, GLDA equivalent to tetrasodium GLDA at about 0.5% to about 20% by weight or more specifically equivalent to tetrasodium GLDA at about 1.25% by weight, and sodium benzoate at 30% by weight.

[0392]

[0185] In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about 20% by weight or more specifically at about 0.25% by weight and phytic acid at about 5% to about 50% by weight or more specifically at about 30% by weight. In certain embodiments, the concentrated antimicrobial composition comprises the ammonium-containing cationic polymer(s) at about 0.01% to about Attorney Docket No. 15939.0027-01304

[0393] 20% by weight or more specifically at about 0.25% by weight, phytic acid at about 5% to about 50% by weight or more specifically at about 50% by weight, and sodium benzoate at 30% by weight.

[0394]

[0186] In certain embodiments, the methods include using a reduced amount of organic acid as a preservative or antimicrobial agent when used with one or more ammonium-containing cationic polymer(s) and one or more organic acid chelator(s) at pH below 6.5, compared to the amount of organic acid needed to achieve the same level of preservative or antimicrobial properties without the ammonium-containing cationic polymer(s) and the organic acid chelator(s).

[0395]

[0187] In additional embodiments, the methods include use of a pre-mixed antimicrobial cocktail in the manufacture of a product to achieve a product with reduced microbial growth, increased shelflife, or increase ability to withstand microbial challenge. In certain embodiments, such cocktail can include one or more ammonium-containing cationic polymers, one or more organic acid chelators, and optionally one or more additional organic acids as described herein.

[0396] EXAMPLES

[0397]

[0188] The following examples are intended to illustrate, but not limit, the invention. Accordingly, from the above discussion and the Examples, one skilled in the art can ascertain essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt to various uses and conditions.

[0398]

[0189] Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0399]

[0190] Microbial strains used in the examples disclosed herein and their corresponding ATCC nos. are as follows: E. coli (ATCC# 8739), S. aureus (ATCC# 6538), P. aeruginosa (ATCC# 9027, Attorney Docket No. 15939.0027-01304

[0400] 10145, and 15442), S. enterica (ATCC# 10708), C. albicans (ATCC# 10231), A. brasiliensis (ATCC# 16404), C. acnes (ATCC# MB-0170P), M. pachydermatis (ATCC# 14522), and K. pneumoniae (ATCC# 4352). Sodium benzoate (USP grade) was obtained from AD Distribution. Butterfield’s phosphate dilution buffer (BPDB) was acquired from Remel (Lenexa, KS). Tryptic soy agar plus polysorbate 80 plus lecithin petri dishes, and Sabouraud dextrose agar petri dishes were obtained from Smith River Biologicals (Ferrum, VA) and Northeast Laboratories (Westbrook, ME).

[0401]

[0191] Sodium benzoate (USP grade) was obtained from AD Distribution. Benzalkonium chloride, betaine, choline chloride, sodium propionate, sodium caprylate, sodium salicylate, and sodium hydroxide were obtained from Sigma-Aldrich Inc. (St. Louis, MO). Tetramethylammonium hydroxide pentahydrate was obtained from Thermo Fisher Scientific Chemicals, Inc. (Ward Hill, MA). BTMS-50 MB (cetyl alcohol and behentrimonium methosulfate) was obtained from Simply Ingredients (Dallas, TX). Disodium ethylenediaminetetraacetic acid dihydrate (EDTA) and sodium L-lactate was obtained from Fischer Scientific Company (Fair Lawn, NJ). Anhydrous citric acid was obtained from MakingCosmetics (Redmond, WA). Trisodium dicarboxymethyl alaninate (MGDA) was obtained from BASF (Florham Park, NJ). Tetrasodium glutamate diacetate (GLDA) was obtained from Coast Southwest (Irving, TX). Trisodium ethylenediamine-N,N′-disuccinate (EDDS) was obtained from Sigma-Aldrich Inc. (St. Louis, MO), D-Gluconolactone was obtained from Thermo Fisher Scientific Chemicals, Inc. (Ward Hill, MA), Phytic acid was obtained from TCI America (Portland, OR).

[0402]

[0192] The ammonium-containing cationic polymers are summarized in Table 3A. Polyquaternium-7 (8.5-9.5% solids in water), linear polyethylenimine (linear PEI; 50% solids in water), branched polyethylenimine (branched PEI; neat, viscous liquid, <1% water) and s- Attorney Docket No. 15939.0027-01304

[0403] polylysine (solid) were sourced from Tri-K, MP Biomedicals, Sigma-Aldrich, and MarkNature, respectively. Polyammonium containing polymers that are copolymers of dimethylamine and epichlororhydrin and polyammonium containing polymers that are copolymers of dimethylamine, epichlororhydrin, and ethylenediamine were sourced from Alfa Chemical, Kemira, Buckman, BOC Sciences, Shanghai Sunwise Chemical Co., and Parchem as 48-52% solids in water and performed similarly in testing.

[0404]

[0193] The concentration of each ammonium-containing cationic polymer is reported as the percent active (solids or polymer) in solution by weight. For example, a sample containing 0.0025% polymer no. 1 contains 0.0025% polymer by weight. The concentration (percentage by weight) of each organic acid is reported based on the sodium salt thereof, with the exception of EDTA which is reported based on disodium EDTA dihydrate.

[0405] Table 4A. Ammonium-containing cationic polymers

[0406] Polymer Common or Trade Monomers Molecular CAS# No. Name Weight

[0407] 1 Superfloc® C-569 Medium

[0408] 2 DimethylamineDimethylamineLow 25988-97-0 epichlorohydrin epichlorohydrin copolymer

[0409] copolymer

[0410] 3 Dimethylamine / Eth DimethylamineLow 42751-79-1 ylenediamine / Epich epichlorohydrinlorohydrin ethylenediamine copolymer

[0411] Copolymer

[0412] 4 Dimethylamine / Eth DimethylamineMedium 42751-79-1 ylenediamine / Epich epichlorohydrin(-100,000

[0413] lorohydrin ethylenediamine copolymer g / mol)

[0414] Copolymer

[0415] 5 Dimethylamine / Eth DimethylamineHigh 42751-79-1 ylenediamine / Epich epichlorohydrinlorohydrin ethylenediamine copolymer

[0416] Copolymer

[0417] 6 Linear Substituted aziridine or 2- low 9002-98-6 Polyethylenimine oxazolines

[0418] 7 Branched Aziridine low 9002-98-6

[0419]

[0420] Polyethylenimine Attorney Docket No. 15939.0027-01304 Polymer Common or Trade Monomers Molecular CAS# No. Name Weight

[0421] 8 Polyquaternium-7 Acrylamide, diallyl low 26590-05-6 dimethylammonium chloride

[0422] 9 s-Polylysine Lysine low 28211-04-3 10 Polyquaternium- 10 Hydroxyethyl cellulose Low 68610-92-4 ammonium salt

[0423] 11 Polyquaternium-11 Vinylpyrrolidone and High 53633-54-8 dimethylaminoethyl

[0424] methacrylate

[0425] 12 Poly quaternium-39 Diallyldimethyl ammonium Low 25136-75-8 chloride, acrylic acid and

[0426] acrylamide

[0427] 13 Polyquaternium-51 Butyl methacrylate-2- Low 125275-25-4 methacryloyloxy ethylphosph

[0428]

[0429] orylcholine copolymer

[0430] Table 4B. Preservative cocktails

[0431] Preservative

[0432] Contents*

[0433] Cocktail No.

[0434] 1 30% Sodium Benzoate

[0435] 2 30% Sodium Benzoate, 0.25% Ammonium-Containing Cationic Polymer

[0436]

[0437] 3 45% Sodium Salicylate, 0.25% Ammonium-Containing Cationic Polymer *To aid in dissolution of organic acids, sodium hydroxide (<2%) and / or a chelator (<3%) was used. Up to 2% citric acid was used to adjust all cocktails to pH 8.0-9.5.

[0438] Table 4C. Surfactants

[0439] INCI* Trade Name CAS# Supplier Location MakingCosmetics Redmond, Cocamidopropyl Betaine 6189-40-0

[0440] Inc. WA Crafter’s Choice Moberly, Lauramidopropyl Betaine 4292-10-8

[0441] Brands, LLC MO Cocamidopropyl MakingCosmetics Redmond,

[0442] 68139-30-0

[0443] Hydroxysultaine Inc. WA Miranol®

[0444] Sodium Princeton,

[0445] Ultra L-32 68608-66-2 Solvay USA Inc.

[0446] Lauroamphoacetate NJ

[0447] MB

[0448] Plantaren® Crafter’s Choice Moberly, Coco Glucoside 110615-47-9

[0449]

[0450] 818 UP Brands, LLC MO Attorney Docket No. 15939.0027-01304

[0451] INCI* Trade Name CAS# Supplier Location Endinol®

[0452] Coast Southwest,

[0453] Decyl Glucoside MILD DG- 68515-73-1 Irving, TX Inc.

[0454] 1050

[0455] Glucopon® 110615-47-9, BASF Florham Alkyl Polyglucosides

[0456] 420UP 68515-73-1 Corporation Park, NJ South Functionalized Alkyl Suga®Boost Colonial

[0457] Pittsburg, Polyglucosides 050 Chemical, Inc.

[0458] TN

[0459] MakingCosmetics Redmond, Sodium Lauryl Sulfate 151-21-3

[0460] Inc. WA Sodium Lauryl Ether

[0461] SLES 70 9004-82-4 Chemboys LLC Liberty, TX Sulfate

[0462] Sodium Methyl 2- Alpha-Step® 149458-07-1, Northbrook, Sulfolaurate and Stepan Company

[0463] PC-48 68937-84-8 IL

[0464] Di sodium 2-Sulfolaurate

[0465] Sodium Methyl Cocoyl MakingCosmetics Redmond,

[0466] 61790-42-2

[0467]

[0468] Taurate Inc. WA ’’‘International Nomenclature of Cosmetic Ingredients.

[0469] Table 4D. Small cationic molecules

[0470] Small Cationic Molecule Trade Name CAS# Benzalkonium Chloride 63449-41-2 Betaine 107-43-7 Choline Chloride 67-48-1 Tetramethylammonium Hydroxide Pentahydrate 10424-65-4 Cetyl Alcohol and Behentrimonium 67762-27-0, BTMS-50 MB

[0471]

[0472] Methosulfate 81646-13-1

[0473] Formulation Examples

[0474] Table 5A. Foaming hand soap No. 1

[0475] Ingredient % composition (w / w) Purpose

[0476] Water Q. S. to 100% Carrier Suga®Boost 050 15% Surfactant Polysorbate 20 0.2% Nonionic Surfactant D, L-Panthenol (50% liquid) 0.3% Humectant Glycerin 2% Humectant Sodium Hydroxide Q. S. pH Adjuster

[0477] Citric Acid Q. S. pH Adjuster

[0478]

[0479] Preservative Varies Preservative Attorney Docket No. 15939.0027-01304

[0480] Table 5B. Foaming hand soap No. 2

[0481] Ingredient % composition (w / w) Purpose

[0482] Water Q. S. to 100% Carrier SugaOBoost 050 15% Surfactant Polysorbate 20 0.2% Nonionic Surfactant D, L-Panthenol (50% liquid) 0.3% Humectant Glycerin 2% Humectant EDTA 0.025% Chelator Citric Acid Q. S. pH Adjuster Sodium Hydroxide Q. S. pH Adjuster

[0483]

[0484] Preservative Varies Preservative

[0485] Table 5C. Lotion

[0486] Ingredient % composition (w / w) Purpose

[0487] Water Q. S. to 100% Carrier

[0488] Glycerin 2% Humectant BP-Triluronic® Acid (Water,

[0489] 2% Humectant

[0490] Sodium Hyaluronate)

[0491] Xanthan Gum 0.2% Thickener Niacinamide 2% Humectant Montanov™ L MB (Cl 4-22

[0492] Alcohols, C 12-20 Alkyl 3% Emulsifier Glucoside)

[0493] Cetearyl Alcohol 3% Emulsifier

[0494] Cetiol® RLF (Caprylyl

[0495] 4% Emollient Caprylate / Caprate)

[0496] Sodium Hydroxide Q. S. pH Adjuster

[0497] Citric Acid Q. S. pH Adjuster

[0498]

[0499] Preservative Varies Preservative

[0500] Table 5D. Laundry Detergent

[0501] % composition

[0502] Ingredient Purpose

[0503] (w / w)

[0504] Water Q. S. to 100% Carrier Sodium Hydroxide 1% Neutralizer

[0505] Sodium Lauryl Ether Sulfate (SLES) 12% Primary Surfactant

[0506]

[0507] Alpha Olefin Sulfonate 4.5% Primary Surfactant Attorney Docket No. 15939.0027-01304

[0508] % composition

[0509] Ingredient Purpose

[0510] (w / w)

[0511] Lauramine Oxide 3% Secondary Surfactant Sodium Citrate 1% Builder

[0512] Amylase 0.56% Enzyme

[0513] Cellulase 0.04% Enzyme

[0514] Anti-Redeposition Rapithix™ A- 100 1%

[0515] Agent

[0516] Citric Acid Q. S. pH Adjuster Sodium Hydroxide Q. S. pH Adjuster

[0517]

[0518] Preservative Varies Preservative

[0519] Table 5E. Paint

[0520] Ingredient % composition (w / w) Vinavil Crilat 4830

[0521] 69.15% (46% solids, water-based acrylic dispersion)

[0522] RUCOLAC B-541 Defoamer

[0523] 0.04% (96% active polysiloxane and silica in polyglycol)

[0524] BYK Aquacer 539 Paraffin Wax Emulsion 2.31% RUCOLAC B-323 Wetting Aid

[0525] 0.12% (90% active polyether-modified polysiloxane blend)

[0526] EPS® 9147

[0527] 1.50% (Dipropylene glycol n-butyl ether)

[0528] Ammonium Hydroxide 28-30% 0.12% RUCOLAC B-541 Defoamer

[0529] 0.06% (96% active polysiloxane and silica in polyglycol)

[0530] Tylose HS 6000 YP2 HEC Thickener

[0531] 0.46% (hydroxyethyl cellulose)

[0532] Munzing Tafigel® PUR 80

[0533] 0.12% (20% Non-ionic polyurethane in water)

[0534] Munzing Tafigel® PUR 41

[0535] 0.02% (20% Non-ionic polyurethane)

[0536] Water 26.1% Sodium Hydroxide Q. S.

[0537]

[0538] Citric Acid Q. S. Attorney Docket No. 15939.0027-01304

[0539] Example 1. Preparation of foaming hand soap, lotion, laundry detergent, paint, and preservative cocktails

[0540] A. Foaming Hand Soap No. 1

[0541]

[0194] A foaming hand soap was prepared according to the formulation listed in Table 5A as follows. A vessel was filled with deionized water, placed under an overhead stirrer set to a moderate mixing speed, and heated to 65-75 °C. Suga®Boost 050 (functionalized alkyl polyglucosides), polysorbate 20, D, L-panthenol (50% liquid), and glycerin were sequentially added to a final concentration of 15%, 0.2%, 0.3%, and 2%, respectively. The batch of foaming hand soap was split into portions and allowed to cool. pH was measured and adjusted to 7.0 using citric acid or sodium hydroxide as needed. Each portion of the batch was sterilized by filtering with a 0.22-μm filter.

[0542] B. Foaming Hand Soap No. 2

[0543]

[0195] A foaming hand soap was prepared according to the formulation listed in Table 5B as follows. A vessel was filled with deionized water, placed under an overhead stirrer set to a moderate mixing speed, and heated to 65-75 °C. Suga®Boost 050 (functionalized alkyl polyglucosides), polysorbate 20, D, L-panthenol (50% liquid), glycerin, and EDTA were sequentially added to a final concentration of 15%, 0.2%, 0.3%, 2%, and 0.025%, respectively. The batch of foaming hand soap was split into portions and allowed to cool. pH was measured and adjusted to 7.0 using citric acid or sodium hydroxide as needed. Each portion of the batch was sterilized by filtering with a 0.22-μm filter.

[0544] C. Lotion

[0545]

[0196] A lotion was prepared according to the formulation listed in Table 5C as follows. A vessel was filled with deionized water and placed under an overhead stirrer set to a moderate Attorney Docket No. 15939.0027-01304

[0546] mixing speed. Glycerin and BP-Triluronic® Acid (water and sodium hyaluronate) were added sequentially to a final concentration of 2% each while the vessel was heated to 75-80 °C. Xanthan gum was added to a final concentration of 0.2%. Once the batch was viscous and clear, niacinamide was added to a final concentration of 2%. Once the batch was heated to 75-80 °C, Montanov™ L MB (C14-22 alcohols and C12-20 alkyl glucoside), cetearyl alcohol, and Cetiol® RLF (caprylyl caprylate / caprate) were added sequentially to a final concentration of 3%, 3%, and 4%, respectively. The batch was homogenized with a Silverson homogenizer using the standard emulsion screen. The batch was then slowly stirred, and the pH was adjusted to 6.5-7.0 at 40 °C with sodium hydroxide and citric acid as needed. Once cooled to room temperature, the batch of lotion was portioned into sterile containers and stored at 4 °C. The lotion was warmed to room temperature before any testing. The lotion was tested for contamination in the following manner before used for antimicrobial challenging testing. Under sterile conditions, a sterile inoculating loop was used to take a sample of the lotion and spread across a Tryptic Soy Agar (TSA) plate. The inoculated plate was incubated for 24 to 72 hours at 31.5 ± 1 °C and then visually inspected for microbial growth. If there was no growth present, the lotion was used for testing.

[0547] D. Laundry detergent

[0548]

[0197] A laundry detergent was prepared according to the formulation listed in Table 5D as follows. A vessel was filled with deionized water, placed under an overhead stirrer set to a slow mixing speed, and heated to 50-60 °C. Sodium hydroxide, sodium lauryl ether sulfate, and alpha olefin sulfonate were sequentially added to a final concentration of 1%, 12%, and 4.5%, respectively. After being thoroughly mixed, the pH was measured and adjusted to be between pH 7.0 and pH 9.0 using citric acid and sodium hydroxide. Lauramine oxide and sodium citrate were added sequentially to a final concentration of 3% and 1%, respectively. The batch was allowed to Attorney Docket No. 15939.0027-01304

[0549] cool to room temperature with continuous slow mixing. Amylase and cellulase were added sequentially to a final concentration of 0.56% and 0.04%, respectively. Rapithix™ A-100 (sodium polyacrylate) was added to a final concentration of 1%. Once homogenous and cooled to room temperature, the batch was portioned into sterile containers and stored at 4 °C. Before any testing, the portions were allowed to come to room temperature. The batch was tested for contamination in the following manner. Under sterile conditions, a sterile inoculating loop was used to take a sample of the laundry detergent and spread across a TSA plate. The inoculated plate was incubated for 24 to 72 hours at 31.5 ± 1 °C and visually inspected for microbial growth. If there was no growth present, the laundry detergent was used for challenge testing.

[0550] E. Paint

[0551]

[0198] An unpreserved paint formulation was made according to the ingredients listed in Table 5E as follows. A vessel was placed under an overhead stirrer set to slow mixing and filled with Vinavil Crilat 4830 and RUCOLAC B-541 Defoamer. BYK Aquacer 539 Paraffin Wax Emulsion, water, and RUCOLAC B-323 Wetting Aid were added slowly and sequentially. The stirring was increased to a moderate speed, and EPS® 9147 was added. The stirring was increased to a high speed. Water and Tylose HS 6000 YP2 HEC Thickener were mixed in a container before being added to the vessel. Munzing Tafigel® PUR 80 and Munzing Tafigel® PUR 41 were added to the vessel. Water was used to rinse and flush the pre-mix container before being added into the vessel. Once a homogenous formulation was obtained, the pH was adjusted to 8.7 using citric acid and sodium hydroxide as needed. The batch of paint was portioned into sterile containers.

[0552]

[0199] For the challenge testing, different potions of the foaming hand soap (nos. 1 and 2), lotion, laundry detergent, and paint were either untreated (unpreserved) or treated with the compositions under test as disclosed herein. Attorney Docket No. 15939.0027-01304

[0553] Example 2. Antimicrobial challenge testing procedures

[0554]

[0200] The antimicrobial challenge testing disclosed herein includes antimicrobial challenge testing, antifungal challenge testing, and confirmatory antimicrobial challenge testing.

[0555] A. Antibacterial challenge testing- 1

[0556]

[0201] For antibacterial challenge testing- 1, one vial each of E. coli, S. aureus, and P. aeruginosa was rehydrated in 1 mL peptone buffer. The concentrations of the cell suspensions were determined based on the Certificates of Analysis accompanying each bacteria vial, and the suspensions were combined and diluted in BPDB to make a 3x 108CFU / mL bacterial pool composed of 1 x 108CFU / mL of each of E. coli, S. aureus, and P. aeruginosa (ATCC# 9027) at a final volume of 1 mL.

[0557]

[0202] The enumeration of the microbial population in antibacterial and antifungal challenge testing was performed in the following manner. At day 0, a 3-mL sample was collected from each of the prepared formulations and inoculated with 0.03 mL of the bacterial pool to obtain a final inoculum of 3 x 106CFU / mL. The inoculated samples were maintained under the same conditions from day 0 to day 7. At each analysis timepoint, the inoculated samples were subjected to 10-fold serial dilutions in BPDB to obtain diluted samples such that 25-250 colonies were estimated to be yielded from 0.1 mL of the diluted sample plated on a tryptic soy agar petri dish containing Polysorbate 80 and Lecithin. The petri dishes were incubated at 31.5 ± 1 °C for 24 to 48 hours. The petri dishes were then removed from the incubator and the colonies were counted and multiplied by their corresponding dilution factors to determine the bacterial concentrations (in CFU / mL) of the samples. At day 2 and day 7 post-inoculation, the serial dilutions, plating, and colony counting were repeated to monitor the changes in bacterial population. The antimicrobial Attorney Docket No. 15939.0027-01304

[0558] efficacies of each treatment were calculated as log reductions in CFU / mL at different timepoints (e.g., day 2 and day 7) compared to day 0 respectively.

[0559] B. Confirmatory antimicrobial challenge testing-1

[0560]

[0203] Confirmatory antimicrobial challenge testing was performed by an external certified testing facility using a modified version of PCPC M-3 with variable timepoints. E. coli, S. aureus, and P. aeruginosa (ATCC# 9027) were grown separately in tryptic soy broth for 18-24 hours. A. brasiliensis was grown on Sabouraud dextrose agar for 7-10 days. C. albicans was grown on potato dextrose agar for 48 ± 4 hours. The target inoculum for E. coli, S. aureus, and P. aeruginosa was greater than 1×106CFU / mL. The target inoculum for both A. brasiliensis and C. albicans was between 1×105CFU / mL and 1×106CFU / mL.

[0561]

[0204] A modified version of PCPC M-3 with variable timepoints to enumerate the microbial population was performed in the following manner. At day 0, 10 mL samples were collected from each of the treated formulation samples and inoculated with 0.05 mL of each organism, respectively (E. coli, S. aureus, P. aeruginosa, A. brasiliensis, and C. albicans) to obtain a final inoculum of greater than 1×106CFU / mL for bacteria and between 1×105CFU / mL and 1×106CFU / mL for fungi. At each analysis time point, 0.01 mL of the samples inoculated with bacteria were plated on a tryptic soy agar and nutrient agar petri dish, while the samples inoculated with fungi were plated on potato dextrose agar. The inoculated samples derived from all portions were maintained under the same condition for every timepoint. The petri dishes with bacteria were incubated at 36.0 ± 1 °C for 24 to 48 hours. The petri dishes with fungi were incubated at 30.0 ± 2 °C. The petri dishes were removed from the incubator and the colonies were counted and multiplied by their corresponding dilution factors to determine the microbial concentrations (in CFU / mL) of the samples. The antimicrobial efficacies of each treatment were calculated as log Attorney Docket No. 15939.0027-01304

[0562] reductions in CFU / mL at different timepoints (e.g., day 2, day 7, day 14, and day 28) compared to day 0 respectively.

[0563] C. Antibacterial challenge testing- 2

[0564]

[0205] One vial each of E. coli, S. enterica, and P. aeruginosa (ATCC# 9027) was rehydrated in 1 mL peptone buffer. The concentrations of the cell suspensions were determined based on the Certificates of Analysis accompanying each bacteria vial, and the suspensions were combined and diluted in BPDB to make a 3 x 108CFU / mL bacterial pool composed of 1 x 108CFU / mL of each of E. coli, S. enterica, and P. aeruginosa at a final volume of 1 mL. The enumeration of the microbial population in antibacterial challenge testing was performed according to Example 2A.

[0565] D. Confirmatory antimicrobial challenge testing-2

[0566]

[0206] Antimicrobial challenge testing was performed by an external certified testing facility using a standard test method for resistance of emulsion paints in the container to contamination by microorganisms in accordance with ASTM D2574. P. aeruginosa (ATCC# 10145), K. aerogenes, and B. subtilis were grown separately on tryptic soy agar slants and stored under refrigeration. Each strain was scraped off the agar slant, inoculated in a separate broth tube with 10 mL of sterile tryptic soy broth (TSB), and incubated at 30 ±2 °C overnight. The overnight cultures were used to reinoculated fresh TSB-containing tubes using a sterile inoculating loop. The cultures were then incubated to their log phase of growth and used to inoculate another round of cultures for P. aeruginosa and K. aerogenes. Then, the final round of cultures of these microorganisms were used to prepare three inocula at 109CFU / mL for inoculating paint formulations.

[0567]

[0207] The enumeration of the microbial population was performed in the following manner. At day 0, a 100 g sample was collected of each treated or untreated portion of the paint. The samples were inspected for contamination and streaked on agar. All portions were inoculated with Attorney Docket No. 15939.0027-01304

[0568] 0.1 mL of each bacterial inoculum at about 106CFU / g of paint. This first inoculation is termed Cycle 1. The inoculated paint portions were incubated at 30 ± 2 °C for one week and checked for microbial growth after 1, 2, 5, and 7 days or after 1, 3, 5, and 7 days. At day 7, each of the inoculated paint portions were inoculated again with 1 mL of each bacterial inoculum at about 109CFU / mL. This second inoculation is termed Cycle 2 and microbial growth was checked 1, 2, 5, and 7 days or 1, 3, 5, and 7 days after inoculation. At each timepoint, the samples were inspected by sight and smell for microbial growth. Microbial growth was checked by soaking a sterile cotton swab in the paint sample to collect about 200 mg of paint. The swab was spread over a TSA plate to deposit 50 mg of the paint on the surface of the plate. The agar plates were incubated at 30 ± 2 °C for one week and colonies were counted.

[0569] E. Confirmatory antimicrobial challenge testing-3

[0570]

[0208] Antimicrobial challenge testing was performed by an external certified testing facility using a modified version of PCPC M-3 with variable timepoints. C. acnes was grown anaerobically on TSA supplemented with sheep blood at 36.0 ± 1 °C for 3 days. M. pachydermatis was grown on Sabouraud dextrose agar at 20-25 °C for 5 days. The target inoculum of C. acnes was greater than 1 x 106CFU / mL. The target inoculum of M. pachydermatis was 1×105–1×106CFU / mL.

[0571]

[0209] A modified version of PCPC M-3 with variable timepoints to enumerate the microbial population was performed in the following manner. At day 0, 10-mL samples were collected from each of the treated formulation portions and separately inoculated with 0.05 mL of C. acnes and M. pachydermatis to obtain a final inoculum of greater than 1×106CFU / mL for C. acnes and 1×103CFU / mL and 1×106CFU / mL for M. pachydermatis. At each analysis time point, 0.01 mL of the samples inoculated with bacteria was plated on a tryptic soy agar and nutrient agar petri dish, while the samples inoculated with fungi were plated on potato dextrose agar. The inoculated samples Attorney Docket No. 15939.0027-01304

[0572] derived from all portions were maintained under the same conditions for every timepoint. The petri dishes with bacteria were incubated at 36.0 ± 1 °C for 24 to 48 hours. The petri dishes with fungi were incubated at 30.0 ± 2 °C. The petri dishes were removed from the incubator and the colonies were counted and multiplied by their corresponding dilution factors to determine the microbial growth (in CFU / mL) of the inoculated portion.

[0573] Example 3. Antibacterial challenge testing of foaming hand soap

[0574]

[0210] Using the method described in Example 2A, antibacterial challenge testing was performed with untreated foaming hand soap no. 1 portions adjusted to pH values of 6.5, 7.0, 7.5, or 8.0. Antibacterial challenge testing results of unpreserved foaming hand soap at different pH values are shown in Table 6. No reduction in viable bacterial cell counts was observed in unpreserved foaming hand soap at any of the pH values tested.

[0575] Table 6. Antibacterial challenge testing of unpreserved foaming hand soap against bacteria at pH 6.5, 7.0, 7.5 or 8.0

[0576] Sample PH Day 2* Day 7*

[0577] Unpreserved 6.5 -1.72 -1.71

[0578] Unpreserved 7.0 -1.77 -1.87

[0579] Unpreserved 7.5 -1.68 -1.74

[0580]

[0581] Unpreserved 8.0 -1.31 -1.69

[0582] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0583] Example 4. Antibacterial challenge testing of foaming hand soap treated with sodium benzoate

[0584]

[0211] Using the method described in Example 2A, antibacterial challenge testing was performed with foaming hand soap no. 1 portions adjusted to pH values of 6.5, 7.0, 7.5, or 8.0 and treated with sodium benzoate. The preservative efficacy of sodium benzoate at each pH value is shown in Table 7. Modest reductions in CFU / mL were observed in sodium benzoate-treated Attorney Docket No. 15939.0027-01304

[0585] foaming hand soap at pH 6.5 and pH 7.0 by day 2. By day 7, no reduction in CFU / mL was observed in any of the sodium benzoate-treated foaming hand soap no. 1 portions tested.

[0586] Table 7. Antibacterial challenge testing of sodium benzoate against bacteria in foaming hand soap at pH 6.5, 7.0, 7.5, or 8.0

[0587] Sample (dosage) pH Day 2* Day 7*

[0588] Sodium Benzoate (0.5%) 6.5 0.84 -1.25

[0589] Sodium Benzoate (1%) 7.0 0.88 -1.39

[0590] Sodium Benzoate (1%) 7.5 -0.62 -1.23

[0591]

[0592] Sodium Benzoate (1%) 8.0 -0.90 -0.91

[0593] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0594] Example 5. Antimicrobial challenge testing of foaming hand soap treated with ammonium-containing cationic polymers

[0595] A. Antimicrobial Challenge testing o f foaming hand soap at pH 7.

[0596]

[0212] Using the method described in Example 2A, antibacterial challenge testing was performed with foaming hand soap no. 1 portions (pH 7.0) treated with one of polymer nos. 1-9 at a final concentration ranging from 0.000625% to 0.09% w / w.

[0597]

[0213] The preservative efficacies of polymer nos. 1-5 at 0.0025% are shown in Table 8. No reduction in bacterial CFU / mL was observed in any of the foaming hand soap portions treated with polymer nos. 1-5 at pH 7.

[0598] Table 8. Preservative efficacy of polymer nos. 1-5 against bacteria in foaming hand soap at pH 7.0

[0599] Sample (dosage) Day 2* Day 7*

[0600] Polymer No. 1 (0.0025%) -1.13 -1.16

[0601] Polymer No. 2 (0.0025%) -1.15 -0.90

[0602] Polymer No. 3 (0.0025%) -1.08 -1.08

[0603] Polymer No. 4 (0.0025%) -1.70 -1.54

[0604]

[0605] Polymer No. 5 (0.0025%) -1.16 -1.16 Attorney Docket No. 15939.0027-01304

[0606] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0607]

[0214] Using the method described in Example 2B, antimicrobial challenge testing was performed with foaming hand soap no. 1 (pH 7.0) treated with one of polymer nos. 6-9 at a final concentration of 0.005% or 0.09% w / w. The preservative efficacies of polymer nos. 6-9 are shown in Tables 9A-E. Of the polymers tested, only polymer no. 9 achieved about a 7-log reduction in CFU / mL for all bacterial strains. Both polymer no. 6 and polymer no. 7 achieved about a 7-log reduction in CFU / mL for. aureus, while polymer no. 8 achieved a more modest reduction of about 4-log in CFU / mL by Day 7 for S. aureus.

[0608] Tables 9A-E. Preservative efficacies of polymer nos. 6-9 against 5 challenge microorganisms in foaming hand soap at pH 7.0

[0609] Table 9A, E. coli

[0610] Sample (dosage) Day 2* Day 7*

[0611] Polymer No. 6 (0.005%) 0.60 0.77

[0612] Polymer No. 7 (0.005%) 0.02 0.05

[0613] Polymer No. 8 (0.09%) -0.23 -0.29

[0614]

[0615] Polymer No. 9 (0.005%) 6.84 6.84

[0616] Table 9B. P. aeruginosa

[0617] Sample (dosage) Day 2* Day 7*

[0618] Polymer No. 6 (0.005%) -0.04 -0.15

[0619] Polymer No. 7 (0.005%) -0.20 0.33

[0620] Polymer No. 8 (0.09%) -0.14 -0.19

[0621]

[0622] Polymer No. 9 (0.005%) 6.95 6.95

[0623] Table 9C. S. aureus

[0624] Sample (dosage) Day 2* Day 7*

[0625] Polymer No. 6 (0.005%) 6.78 6.78

[0626]

[0627] Polymer No. 7 (0.005%) 6.94 6.94 Attorney Docket No. 15939.0027-01304

[0628] Sample (dosage) Day 2* Day 7*

[0629] Polymer No. 8 (0.09%) 2.89 4.46

[0630]

[0631] Polymer No. 9 (0.005%) 6.94 6.94

[0632] Table 9D, A. brasiliensis

[0633] Sample (dosage) Day 2* Day 7*

[0634] Polymer No. 6 (0.005%) 1.71 0.29

[0635] Polymer No. 7 (0.005%) 0.06 0.00

[0636] Polymer No. 8 (0.09%) 0.01 0.13

[0637]

[0638] Polymer No. 9 (0.005%) 0.16 0.46

[0639] Table 9E, C. albicans

[0640] Sample (dosage) Day 2* Day 7*

[0641] Polymer No. 6 (0.005%) -0.04 2.90

[0642] Polymer No. 7 (0.005%) 2.90 4.13

[0643] Polymer No. 8 (0.09%) 0.31 0.58

[0644]

[0645] Polymer No. 9 (0.005%) 0.62 4.13

[0646] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0647] B. Antibacterial Challenge testing of foaming hand soap at pH 6.5, 7.0, or 7.5

[0215] Using the method described in Example 2A, antibacterial challenge testing was performed with foaming hand soap portions adjusted to pH 6.5, 7.0, or 7.5 and treated with at least one of the ammonium -containing cationic polymers from polymer nos. 1-9. The preservative efficacy of polymer no. 4 is shown in Table 10. Polymer no. 4 caused no reduction in CFU / mL at each pH value tested at day 7.

[0648] Table 10. Preservative efficacy of polymer no. 4 alone against bacteria in foaming hand soap at pH 6.5, 7.0, or 7.5

[0649] Sample (dosage) PH Day 2* Day 7* Polymer No. 4 (0.0025%) 6.5 2.11 -0.67

[0650]

[0651] Polymer No. 4 (0.0025%) 7.0 -1.70 -1.54 Attorney Docket No. 15939.0027-01304

[0652] Sample (dosage) PH Day 2* Day 7*

[0653]

[0654] Polymer No. 4 (0.0025%) 7.5 -1.53 -1.30 *Log reduction in CFU / mL compared to Day 0, a negative number indicates log growth (i.e., cell growth).

[0655] Example 6. Antimicrobial challenge testing of foaming hand soap treated with sodium benzoate and ammonium-containing cationic polymers

[0656] A. Antimicrobial Challenge testing of foaming hand soap at pH 7.0

[0657]

[0216] Using the methods described in Example 2A and Example 2B, antimicrobial challenge testing was performed with foaming hand soap no. 1 portions (pH 7.0) treated with a combination of sodium benzoate at a final concentration ranging from 0.1% to 1% and at least one of the ammonium-containing cationic polymers selected from polymer nos. 1-9 at a final concentration ranging from 0.000625% to 0.09%. The final concentrations of sodium benzoate and polymer nos.

[0658] 1-9 in the different portions are indicated in Tables 11A-E and 12A-E.

[0659]

[0217] The preservative efficacies of polymer nos. 1-5 together with sodium benzoate are shown in Tables 11 A-E. For all bacterial strains tested, an approximate 7-1 og reduction in CFU / mL was observed by day 7 for all combinations tested. When challenged with A. brasiliensis, only a negligible change in CFU / mL was observed for all combinations tested. When challenged with C. albicans, a reduction of about 5-log in CFU / mL was observed by day 28 for all combinations tested.

[0660] Tables 11A-E. Preservative efficacies of polymer nos. 1-5 in combination with sodium benzoate against 5 challenge microorganisms in foaming hand soap at pH 7.0 Table 11A. E. coli

[0661] Sample (dosage) Day 2* Day 7* Day 14* Day 28* Polymer No. 1 (0.0025%) + Sodium Benzoate (1%) 6.98 6.98 6.98 6.98 Polymer No. 2 (0.0025%) + Sodium Benzoate (1%) 6.98 6.98 6.98 6.98

[0662]

[0663] Polymer No. 3 (0.0025%) + Sodium Benzoate (1%) 6.98 6.98 6.98 6.98 Attorney Docket No. 15939.0027-01304

[0664] Sample (dosage) Day 2* Day 7* Day 14* Day 28* Polymer No. 4 (0.0025%) + Sodium Benzoate (1%) 6.98 6.98 6.98 6.98

[0665]

[0666] Polymer No. 5 (0.0025%) + Sodium Benzoate (1%) 6.98 6.98 6.98 6.98

[0667] Table 11B,. aeruginosa

[0668] Sample (dosage) Day 2* Day 7* Day 14* Day 28* Polymer No. 1 (0.0025%) + Sodium Benzoate (1%) 1.95 6.99 6.99 6.99 Polymer No. 2 (0.0025%) + Sodium Benzoate (1%) 4.18 6.99 6.99 6.99 Polymer No. 3 (0.0025%) + Sodium Benzoate (1%) 3.69 6.99 6.99 6.99 Polymer No. 4 (0.0025%) + Sodium Benzoate (1%) 3.85 6.99 6.99 6.99

[0669]

[0670] Polymer No. 5 (0.0025%) + Sodium Benzoate (1%) 3.91 6.99 6.99 6.99

[0671] Table 11C.. aureus

[0672] Sample (dosage) Day 2* Day 7* Day 14* Day 28* Polymer No. 1 (0.0025%) + Sodium Benzoate (1%) 6.99 6.99 6.99 6.99 Polymer No. 2 (0.0025%) + Sodium Benzoate (1%) 6.99 6.99 6.99 6.99 Polymer No. 3 (0.0025%) + Sodium Benzoate (1%) 6.99 6.99 6.99 6.99 Polymer No. 4 (0.0025%) + Sodium Benzoate (1%) 6.99 6.99 6.99 6.99

[0673]

[0674] Polymer No. 5 (0.0025%) + Sodium Benzoate (1%) 6.99 6.99 6.99 6.99

[0675] Table IIP, A brasiliensis

[0676] Sample (dosage) Day 2* Day 7* Day 14* Day 28* Polymer No. 1 (0.0025%) + Sodium Benzoate (1%) 0.04 0.33 0.29 0.36 Polymer No. 2 (0.0025%) + Sodium Benzoate (1%) 0.08 0.22 0.21 0.26 Polymer No. 3 (0.0025%) + Sodium Benzoate (1%) 0.07 0.13 0.20 0.30 Polymer No. 4 (0.0025%) + Sodium Benzoate (1%) 0.09 0.24 0.29 0.37

[0677]

[0678] Polymer No. 5 (0.0025%) + Sodium Benzoate (1%) 0.09 0.36 0.22 0.46

[0679] Table HE, C. albicans

[0680] Sample (dosage) Day 2* Day 7* Day 14* Day 28* Polymer No. 1 (0.0025%) + Sodium Benzoate (1%) 0.50 1.45 5.64 5.64 Polymer No. 2 (0.0025%) + Sodium Benzoate (1%) 0.47 1.52 5.64 5.64 Polymer No. 3 (0.0025%) + Sodium Benzoate (1%) 0.53 1.57 5.64 5.64 Polymer No. 4 (0.0025%) + Sodium Benzoate (1%) 0.50 1.52 3.47 5.64

[0681]

[0682] Polymer No. 5 (0.0025%) + Sodium Benzoate (1%) 0.49 1.36 3.64 5.64 Attorney Docket No. 15939.0027-01304

[0683] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0684]

[0218] The preservative efficacies of polymer nos. 6-9 and sodium benzoate are shown in Tables 12A-E. When challenged by E. coli, each polymer-sodium benzoate combination achieved a greater log reduction in CFU / mL than the corresponding polymer alone (see results in Example 5), with the exception of polymer no. 9 which demonstrated similar preservative efficacy with and without the presence of sodium benzoate (Tables 11A and 12A). When challenged by S. aureus, all the polymers achieved similar preservative efficacy, whether alone or in combination with sodium benzoate, except for polymer no. 8, which was slightly less effective alone (Tables 11C and 12C). When challenged by A. brasiliensis, none of the polymers and polymer-sodium benzoate combinations resulted in any significant reduction in CFU / mL (Tables HD and 12D). When challenged by C. albicans, about 2-log to 4-log reductions in CFU / mL were observed for all polymers and polymer-sodium benzoate combinations by day 7, with the exception of polymer no.

[0685] 8, which had a negligible effect on C. albicans viable cell count, but achieved a 3.5-log reduction in CFU / mL by day 7 in the presence of sodium benzoate (Tables 1 IE and 12E).

[0686] Tables 12A-E. Preservative efficacy of polymer nos.6-9 in combination with sodium benzoate against 5 challenge microorganisms in foaming hand soap at pH 7.0 Table 12 A, E. coli

[0687] Sample (dosage) Day 2* Day 7* Polymer No. 6 (0.005%) + Sodium Benzoate (1%) 2.57 6.75 Polymer No. 7 (0.005%) + Sodium Benzoate (1%) 3.48 6.84 Polymer No. 8 (0.09%) + Sodium Benzoate (1%) 0.66 1.02

[0688]

[0689] Polymer No. 9 (0.005%) + Sodium Benzoate (1%) 6.84 6.84

[0690] Table 12B, P. aeruginosa Attorney Docket No. 15939.0027-01304

[0691] Sample (dosage) Day 2* Day 7* Polymer No. 6 (0.005%) + Sodium Benzoate (1%) 1.81 3.07 Polymer No. 7 (0.005%) + Sodium Benzoate (1%) 3.70 4.41 Polymer No. 8 (0.09%) + Sodium Benzoate (1%) 2.10 2.08

[0692]

[0693] Polymer No. 9 (0.005%) + Sodium Benzoate (1%) 6.95 6.95

[0694] Table 12C.. aureus

[0695] Sample (dosage) Day 2* Day 7* Polymer No. 6 (0.005%) + Sodium Benzoate (1%) 6.78 6.78 Polymer No. 7 (0.005%) + Sodium Benzoate (1%) 6.94 6.94 Polymer No. 8 (0.09%) + Sodium Benzoate (1%) 6.94 6.94

[0696]

[0697] Polymer No. 9 (0.005%) + Sodium Benzoate (1%) 6.94 6.94

[0698] Table 12D, A. brasiliensis

[0699] Sample (dosage) Day 2* Day 7* Polymer No. 6 (0.005%) + Sodium Benzoate (1%) 0.85 0.24 Polymer No. 7 (0.005%) + Sodium Benzoate (1%) 0.08 0.09 Polymer No. 8 (0.09%) + Sodium Benzoate (1%) 0.08 0.09

[0700]

[0701] Polymer No. 9 (0.005%) + Sodium Benzoate (1%) 0.06 0.17

[0702] Table 12E, C. albicans

[0703] Sample (dosage) Day 2* Day 7* Polymer No. 6 (0.005%) + Sodium Benzoate (1%) -0.15 3.27 Polymer No. 7 (0.005%) + Sodium Benzoate (1%) 1.16 3.53 Polymer No. 8 (0.09%) + Sodium Benzoate (1%) 1.16 3.53

[0704]

[0705] Polymer No. 9 (0.005%) + Sodium Benzoate (1%) 2.02 4.13

[0706] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0707]

[0219] Using the method described in Example 2A, antibacterial challenge testing was performed with foaming hand soap no. 1 portions (pH 7.0) treated with a combination of sodium benzoate at a final concentration ranging from 0.1% to 0.6% and each of polymer nos. 1-9, with varying degrees of efficacy. The preservative efficacies of various levels of sodium benzoate in combination with polymer no. 4 are shown in Table 13. Reductions in CFU / mL were observed in Attorney Docket No. 15939.0027-01304

[0708] foaming hand soap portions containing 0.6% sodium benzoate and 0.0025% polymer no. 4 by day 2; and no countable colonies could be observed in those portions by day 7. The combination of 0.4 % sodium benzoate and 0.0025% polymer no. 4 resulted in a reduction in CFU / mL by day 2 and an even further reduction by day 7. This was also true for the portions containing 0.2% sodium benzoate and 0.0025% polymer no. 4 and, but reductions in those portions were not as remarkable at neither day 2 nor day 7. In portions containing 0.1% sodium benzoate and 0.0025% polymer no.

[0709] 4, a modest reduction in CFU / mL was observed at day 2, but an increase in bacterial growth was observed by day 7 compared to day 0.

[0710] Table 13. Preservative efficacies of polymer no. 4 in combination with low levels of sodium benzoate (< 1%) against bacteria in foaming hand soap at pH value of 7.0

[0711] Sample (dosage) Day 2* Day 7* Polymer No. 4 (0.0025%) + Sodium Benzoate (0.6%) 4.21 6.47 Polymer No. 4 (0.0025%) + Sodium Benzoate (0.4%) 3.23 5.47 Polymer No. 4 (0.0025%) + Sodium Benzoate (0.2%) 2.21 2.82

[0712]

[0713] Polymer No. 4 (0.0025%) + Sodium Benzoate (0.1%) 1.05 -0.53

[0714] *Log reduction in CFU / mL compared to day 0, negative number indicates log growth (i.e., cell growth).

[0715] B. Antimicrobial Challenge testing of foaming hand soap at pH 6.5, 7.0, 7.5, 8.0, or 8.5

[0716]

[0220] Using the method described in Example 2A, antibacterial challenge testing was performed with foaming hand soap no. 1 portions adjusted to pH values of 6.5, 7.0, or 7.5 and treated with a combination of polymer no. 4 and sodium benzoate. The final concentrations of polymer no. 4 and sodium benzoate in the different portions are indicated in Table 14. The preservative efficacies of the combination of polymer no. 4 and sodium benzoate are shown in Table 14. The combination of polymer no. 4 and sodium benzoate achieved about a 6-log reduction Attorney Docket No. 15939.0027-01304

[0717] in CFU / mL by day 7 at all pH values tested (Table 14). In contrast, polymer no. 4 alone led to no reduction in CFU / mL by day 7 at any of the pH values tested (Table 14).

[0718] Table 14. Preservative efficacies of polymer no. 4 in combination with sodium benzoate against bacteria in foaming hand soap at pH 6.5, 7.0, or 7.5

[0719] Sample (dosage) pH Day 2* Day 7* Polymer No. 4 (0.0025%) + Sodium Benzoate (0.5%) 6.5 6.11 6.11 Polymer No. 4 (0.0025%) + Sodium Benzoate (1%) 7.0 6.07 6.07

[0720]

[0721] Polymer No. 4 (0.0025%) + Sodium Benzoate (1%) 7.5 3.93 6.14 *Log reduction in CFU / mL compared to Day 0, a negative number indicates log growth (i.e., cell growth).

[0722]

[0221] Using the method described in Example 2B, confirmatory antimicrobial challenge testing was performed with foaming hand soap no. 1 portions adjusted to pH values of pH 6.5, 7.0, 7.5, 8.0, or 8.5 and treated with polymer no. 4 and sodium benzoate. The final concentrations of polymer no. 4 and sodium benzoate in the different portions and their preservative efficacies are indicated in Tables 15A-E. For each of the bacterial strains tested, all combinations achieved about a 7-log reduction in CFU / mL by day 7. Negligible change in CFU / mL was observed in portions challenged by A. brasiliensis. When challenged by C. albicans, about 5 -log reductions in CFU / mL were observed by day 18 for all combinations tested, except for the combinations tested at pH 7.5, which had a more modest reduction of about a 3-log reduction in CFU / mL.

[0723] Tables 15A-E. Preservative efficacies of polymer no. 4 and sodium benzoate against 5 challenge microorganisms in foaming hand soap at pH 6.57.0, 7.5, 8.0, or 8.5 Table 15 A, E. coli

[0724] Sample (dosage) PH Day 2* Day 7* Day 18* Polymer No. 4 (0.000625%) + Sodium Benzoate (0.5%) 6.5 6.80 6.80 6.80 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.0 6.80 6.80 6.80 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.5 6.80 6.80 6.80

[0725]

[0726] Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.0 6.75 6.75 6.75 Attorney Docket No. 15939.0027-01304

[0727] Sample (dosage) PH Day 2* Day 7* Day 18*

[0728]

[0729] Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.5 6.75 6.75 6.75

[0730] Table 15B, P. aeruginosa

[0731] Sample (dosage) pH Day 2* Day 7* Day 18* Polymer No. 4 (0.000625%) + Sodium Benzoate (0.5%) 6.5 6.85 6.85 6.85 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.0 3.94 6.85 6.85 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.5 6.85 6.85 6.85 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.0 2.81 6.87 6.87

[0732]

[0733] Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.5 2.67 6.87 6.87

[0734] Table 15C.. aureus

[0735] Sample (dosage) PH Day 2* Day 7* Day 18* Polymer No. 4 (0.000625%) + Sodium Benzoate (0.5%) 6.5 6.82 6.82 6.82 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.0 6.82 6.82 6.82 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.5 6.82 6.82 6.82 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.0 6.78 6.78 6.78

[0736]

[0737] Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.5 6.78 6.78 6.78

[0738] Table 15D. A brasiliensis

[0739] Sample (dosage) PH Day 2* Day 7* Day 18* Polymer No. 4 (0.000625%) + Sodium Benzoate (0.5%) 6.5 0.19 0.18 0.26 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.0 0.01 0.19 0.29 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.5 0.01 0.02 0.13 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.0 -0.09 -0.01 0.04

[0740]

[0741] Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.5 -0.06 0.08 0.01

[0742] Table 15E, C. albicans

[0743] Sample (dosage) pH Day 2* Day 7* Day 18* Polymer No. 4 (0.000625%) + Sodium Benzoate (0.5%) 6.5 0.19 1.57 5.39 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.0 0.28 1.73 5.39 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 7.5 0.21 0.46 2.85 Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.0 1.00 0.70 5.45

[0744]

[0745] Polymer No. 4 (0.000625%) + Sodium Benzoate (1%) 8.5 0.21 0.61 5.45 *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth). Attorney Docket No. 15939.0027-01304

[0746] Example 7. Antimicrobial challenge testing of foaming hand soap treated with sodium benzoate, an ammonium-containing cationic polymer, and an antimicrobial chemical at pH 7J)

[0747]

[0222] Using the method described in Example 2B, confirmatory antimicrobial challenge testing was performed with foaming hand soap no. 1 portions (pH 7.0) containing 0.0025% polymer no. 4, 1% sodium benzoate, and 1% caprylyl glycol. The preservative efficacies are reported in Table 16. For each of the fungal strains, there was about a 5-log reduction in CFU / mL by day 14.

[0748] Table 16. Preservative efficacies of polymer no. 4 in combination with sodium benzoate and caprylyl glycol against yeast and mold in foaming hand soap at pH 7.0

[0749] Sample (dosage) Microorganism Day 2* Day 7* Day 14* Polymer No. 4 (0.0025%) +

[0750] A. brasiliensis 2.24 3.37 5.67 Sodium Benzoate (1%) +

[0751] Caprylyl glycol (1%)

[0752] C. albicans 3.35 5.75 5.75

[0753]

[0754] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0755] Example 8. Antimicrobial challenge testing of foaming hand soap treated a high concentration of an ammonium-containing cationic polymer and a reduced concentration of sodium benzoate

[0756]

[0223] A foaming hand soap (Foaming Hand Soap no. 1) was prepared as described in Example 1A. Different portions of the foaming hand soap were treated with 0.1% polymer no. 4 and a combination of 0.1% polymer no. 4 and 0.3% sodium benzoate and adjusted to pH 7.0 using sodium hydroxide and citric acid. The antimicrobial challenge testing was performed as described in Example 2B. The preservative efficacies are reported in Tables 17A-E as log reduction in Attorney Docket No. 15939.0027-01304

[0757] CFU / mL at day 2 and day 7 compared to day 0. The combination of polymer no. 4 and sodium benzoate achieved a 6-log reduction or higher in CFU / mL for all bacteria tested. In contrast, polymer no. 4 alone resulted in a reduction of less than 2-log in CFU / mL for each bacterial strain tested. Similar results were observed in testing against yeast or mold.

[0758] Tables 17A-E. Preservative efficacies of a high concentration of polymer no. 4 with and without a reduced concentration of sodium benzoate against 5 challenge microbes in a foaming hand soap at pH 7.0

[0759] Table 17A, E. coli

[0760] Sample Day 7* Day 14* Day 28* Polymer No. 4 (0.1%) 0.77 1.14 1.19

[0761]

[0762] Polymer No. 4 (0.1%) + Sodium Benzoate (0.3%) 6.72 6.72 6.72

[0763] Table 17B, P. aeruginosa

[0764] Sample Day 7* Day 14* Day 28* Polymer No. 4 (0.1%) 1.75 1.37 1.53

[0765]

[0766] Polymer No. 4 (0.1%) + Sodium Benzoate (0.3%) 6.93 6.93 6.93

[0767] Table 17C. S. aureus

[0768] Sample Day 7* Day 14* Day 28* Polymer No. 4 (0.1%) 1.17 1.33 1.41

[0769]

[0770] Polymer No. 4 (0.1%) + Sodium Benzoate (0.3%) 6.90 6.90 6.90

[0771] Table 17D. A. brasiliensis

[0772] Sample Day 7* Day 14* Day 28* Polymer No. 4 (0.1%) 0.60 0.76 1.76

[0773]

[0774] Polymer No. 4 (0.1%) + Sodium Benzoate (0.3%) 0.26 0.97 1.34

[0775] Table 17E, C. albicans (ATCC# 10231) Attorney Docket No. 15939.0027-01304

[0776] Sample Day 7* Day 14* Day 28* Polymer No. 4 (0.1%) 1.32 2.59 5.89

[0777]

[0778] Polymer No. 4 (0.1%) + Sodium Benzoate (0.3%) 1.91 5.89 5.89 *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0779] Example 9. Antibacterial challenge testing of foaming hand soap treated with an ammonium-containing cationic polymer and in combination with sodium benzoate

[0224] A foaming hand soap (Foaming Hand Soap No. 1) was prepared as described in Example 1 A. Different portions of the foaming hand soap were treated with one of the ammonium- containing cationic polymers listed in Table 18 alone or together with 1% sodium benzoate and then adjusted to pH 7.0 using sodium hydroxide and citric acid. The antibacterial challenge testing was performed as described in Example 2C. The preservative efficacies are reported in Table 18 as log reduction in CFU / mL at day 7 compared to day 0. Bacterial growths were observed in portions treated with any of the four polymers alone while all four polymers resulted in greater than a 3-log reduction in CFU / mL at day 7 when combined with sodium benzoate.

[0780] Table 18. Preservative efficacies of a cationic polymer alone or in combination with sodium benzoate against a bacterial pool in a foaming hand soap at pH 7.0

[0781] Sample Polymer* Polymer + 1% Sodium Benzoate* Polymer No. 10 (0.2%) -1.53 3.45

[0782] Polymer No. 11 (0.02%) -2.61 3.43

[0783] Polymer No. 12 (0.1%) -3.07 3.43

[0784]

[0785] Polymer No. 13 (0.02%) -3.07 3.70

[0786] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0787] Example 10. Antibacterial challenge testing of a foaming hand soap treated with cationic small molecules and sodium benzoate

[0788]

[0225] A foaming hand soap (Foaming Hand Soap No. 1) was prepared as described in Example 1A. Different portions of the foaming hand soap were treated with 1% sodium benzoate Attorney Docket No. 15939.0027-01304

[0789] and 0.0025% of one of the five cationic small molecules from Table 19 and then adjusted to pH 7.0 using sodium hydroxide and citric acid. The antibacterial challenge testing was performed as described in Example 2A. The preservative efficacies are reported in Table 19 as log reduction in CFU / mL at day 2 and day 7 compared to day 0. None of the 5 treatments resulted in greater than a 1-log reduction in CFU / mL at day 7.

[0790] Table 19. Preservative efficacies of cationic small molecules with sodium benzoate against a bacterial pool in a foaming hand soap at pH 7.0

[0791] Sample Day 2* Day 7* Benzalkonium Chloride (0.0025%) + Sodium Benzoate (1%) 1.22 -0.05 Betaine (0.0025%) + Sodium Benzoate (1%) 1.04 -0.13 Choline (0.0025%) + Sodium Benzoate (1%) 1.12 -0.19 Tetramethyl ammonium Hydroxide (0.0025%) + Sodium Benzoate (1%) 1.24 0.73 BTMS-50 (Behentrimonium Methosulfate and Cetyl Alcohol) (0.0025%) +

[0792] 1.16 -0.25

[0793]

[0794] Sodium Benzoate (1%)

[0795] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0796] Example 11. Antimicrobial challenge testing of a foaming hand soap treated with sodium salicylate, EDTA, or sodium propionate, alone or in combination with an ammonium- containing cationic polymer

[0797]

[0226] A foaming hand soap (Foaming Hand Soap No. 1) was prepared as described in Example 1A. Different portions of the foaming hand soap were treated with 0.5% sodium salicylate, 0.05% EDTA, or 0.3% sodium propionate and optionally 0.0025% of an ammonium- containing cationic polymer from Table 20 and then adjusted to pH 7.0 using sodium hydroxide and citric acid. The antimicrobial challenge testing was performed as described in Example 2A. The preservative efficacies are reported as log changes in bacterial growths between day 7 and day 0 in Table 20. Attorney Docket No. 15939.0027-01304

[0798]

[0227] A less than 1-log reduction in CFU / mL was observed in the portions treated with sodium salicylate alone or with sodium salicylate combined with one of polymer nos. 8, and 10- 13 at day 7. A 3-log or greater reduction in CFU / mL was observed in the portions treated with sodium salicylate in combination with one of polymer nos. 1-7 at day 7.

[0799]

[0228] A less than 1-log reduction in CFU / mL was observed in the portions treated with EDTA alone or with EDTA combined with one of polymer nos. 2, 3, 8, and 10-13 at day 7. A 3-log of greater reduction in CFU / mL was observed in of the portions treated with EDTA and either of polymers no. 4 or 5 at day 7.

[0800]

[0229] A less than 3-log reduction in CFU / mL was observed in the portions treated with sodium propionate alone and sodium propionate combined with any of the ammonium-containing cationic polymers tested at day 7.

[0801] Table 20. Preservative efficacies of sodium salicylate, EDTA, and sodium propionate alone or in combination with a cationic polymer against a bacterial pool in a foaming hand soap at pH 7.0

[0802] 0.3% Sodium Polymer 0.5% Sodium Salicylate* 0.05% EDTA*

[0803] Propionate* No Polymer - - - Polymer No. 1 (0.0025%) +++ + + Polymer No. 2 (0.0025%) +++ - - Polymer No. 3 (0.0025%) +++ - - Polymer No. 4 (0.0025%) +++ +++ - Polymer No. 5 (0.0025%) +++ +++ ++ Polymer No. 6 (0.0025%) +++ +

[0804] Polymer No. 7 (0.0025%) +++ +

[0805] Polymer No. 8 (0.0025%) - - Polymer No. 10 (0.0025%) - - Polymer No. 11 (0.0025%) - - Polymer No. 12 (0.0025%) - -

[0806]

[0807] Polymer No. 13 (0.0025%) - - * -: less than 1-log reduction in CFU / mL;

[0808] +: between 1 and 2-log reduction in CFU / mL; Attorney Docket No. 15939.0027-01304

[0809] ++: between 2 and 3-log reduction in CFU / mL;

[0810] +++: 3-log or greater reduction in CFU / mL.

[0811] Example 12. Antimicrobial challenge testing of a foaming hand soap treated with different preservative cocktails

[0812]

[0230] A foaming hand soap (Foaming Hand Soap No. 2) was prepared as described in Example IB. Different portions of the foaming hand soap were left untreated or treated with 1% sodium benzoate, 1% preservative cocktail no. 1, or 1% preservative cocktail no. 2 and adjusted to pH 7.0 using sodium hydroxide and citric acid. The antimicrobial challenge testing was performed as described in Example 2A. The preservative efficacies are reported in Table 21 as log reduction in CFU / mL at day 2 and day 7 compared to day 0, respectively. Preservative cocktail no. 2 achieved more than a 4-log reduction in CFU / mL at day 7. Sodium benzoate and the other preservative cocktails achieved less than a 2-log reduction in CFU / mL.

[0813] Table 21. Preservative efficacies of different preservative cocktails against a bacterial pool in a foaming hand soap at pH 7.0

[0814] Sample Day 2* Day 7*

[0815] Untreated -1.10 -1.94

[0816] Sodium Benzoate (1%) 0.63 1.51

[0817] Preservative Cocktail No. 1 (1%) -1.02 -1.17

[0818]

[0819] Preservative Cocktail No. 2 (1%) 2.82 4.59

[0820] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0821] Example 13. Antimicrobial challenge testing of a lotion treated with different preservative cocktails

[0822]

[0231] A lotion was prepared as described in Example 1C. Different portions of the lotion were left untreated or treated with 0.45% sodium salicylate, 1% preservative cocktail no. 2, or 1% preservative cocktail no. 3 and adjusted to pH 7.0 using sodium hydroxide and citric acid without Attorney Docket No. 15939.0027-01304

[0823] altering the desired concentration of the treatment. The antimicrobial challenge testing was performed as described in Example 2B.

[0824]

[0232] The preservative efficacies of days 7, 14, and 28 compared to day 0 are reported in Tables 22A-E. Microbial growth was observed in all untreated portions at day 7. The portions treated with 0.45% sodium salicylate did not achieve a 3 -log reduction of any microorganism in 7 days. The portions treated with 1% preservative cocktail no. 2 or 1% preservative cocktail no. 3 experienced a high knockdown of bacterial growth and at least a 1-log reduction in CFU / mL of C. albicans at day 7. No treatment was effective in reducing the population of A. brasiliensis.

[0825] Tables 22A-E. Preservative efficacy of preservative cocktails in a lotion against 5 challenge organisms at pH 7

[0826] Table 22A, E. coli (ATCC# 8739)

[0827] Sample Day 7* Day 14* Day 28* Untreated - +

[0828] Sodium Salicylate (0.45%) - +

[0829] Preservative Cocktail No. 2 (1%) +++ +++

[0830]

[0831] Preservative Cocktail No. 3 (1%) +++ +++

[0832] Table 22B, P. aeruginosa

[0833] Sample Day 7* Day 14* Day 28* Untreated - - Sodium Salicylate (0.45%) + ++

[0834] Preservative Cocktail No. 2 (1%) +++ +++

[0835]

[0836] Preservative Cocktail No. 3 (1%) +++ +++

[0837] Table 22C. S. aureus

[0838] Sample Day 7* Day 14* Day 28* Untreated - - Sodium Salicylate (0.45%) - +

[0839] Preservative Cocktail No. 2 (1%) +++ +++

[0840]

[0841] Preservative Cocktail No. 3 (1%) +++ +++ Attorney Docket No. 15939.0027-01304

[0842] Table 22D, A. brasiliensis

[0843] Sample Day 7* Day 14* Day 28* Untreated - - Sodium Salicylate (0.45%) - - Preservative Cocktail No. 2 (1%) - -

[0844]

[0845] Preservative Cocktail No. 3 (1%) - -

[0846] Table 22E. C. albicans (ATCC# 10231)

[0847] Sample Day 7* Day 14* Day 28* Untreated - - Sodium Salicylate (0.45%) - - Preservative Cocktail No. 2 (1%) ++ +++

[0848]

[0849] Preservative Cocktail No. 3 (1%) + +++

[0850] * less than 1-log reduction in CFU / mL;

[0851] +: between 1 and 2-log reduction in CFU / mL;

[0852] ++: between 2 and 3 -log reduction in CFU / mL;

[0853] +++: 3-log or greater reduction in CFU / mL

[0854] Example 14. Antimicrobial challenge testing of a laundry detergent treated with preservative cocktail no.2 at different concentrations

[0855]

[0233] Laundry detergent was prepared as described in Example ID. Different portions of the laundry detergent were left untreated or treated with 1% or 2% preservative cocktail no. 2. The antimicrobial challenge testing was performed as described in Example 2A. The preservative efficacies of day 14 compared to day 0 are reported in Table 23. The untreated portion showed a high level of increase in CFU / mL at day 14. The portions treated with 1% or 2% preservative cocktail no. 2 showed a moderate and high levels of reduction in CFU / mL at day 14, respectively.

[0856] Table 23. Preservative efficacies of preservative cocktail 2 at different concentrations against a bacterial pool in a laundry detergent

[0857] Sample Day 14*

[0858]

[0859] Untreated — Attorney Docket No. 15939.0027-01304

[0860] Sample Day 14*

[0861] Preservative Cocktail No. 2 (1%) +

[0862]

[0863] Preservative Cocktail No. 2 (2%) ++

[0864] —: an increase in CFU / mL;

[0865] +: between 1 and 2-log reduction in CFU / mL;

[0866] ++: 2-log or greater reduction in CFU / mL.

[0867] Example 15. Antimicrobial challenge testing of unpreserved and sodium benzoate treated personal care surfactants

[0868]

[0234] Surfactants in Table 24 were prepared as 3% w / w solids solutions in deionized water based on the available information of their innate solids content from the suppliers and adjusted to pH 7.0 using citric acid and sodium hydroxide. A portion of each surfactant solution was tested unpreserved. Additional portions of each surfactant solution were treated with 0.3% sodium benzoate and re-adjusted to pH 7.0 with citric acid and sodium hydroxide if necessary. The antimicrobial challenge testing was performed as described in Example 2A. The preservative efficacies of day 7 compared to day 0 are reported in Table 24. All the unpreserved surfactant solutions achieved a less than 1-log reduction in CFU / mL at day 7 with the exception of sodium lauroamphoacetate, which achieved a log reduction in CFU / mL between 2 and 3. Meanwhile, sodium benzoate achieved a less than 1 -log reduction in CFU / mL at day 7 in all surfactant solutions tested with the exception of sodium lauroamphoacetate solution, wherein sodium benzoate achieved a log reduction in CFU / mL between 2 and 3.

[0869] Table 24. Preservative efficacy of unpreserved and sodium benzoate treated surfactant solutions at pH 7.0 against a bacterial pool

[0870] 0.3% Unpreserved Sodium Surfactant Solution (3% solids)

[0871] Day 7* Benzoate Day 7* Cocamidopropyl Betaine - - Lauramidopropyl Betaine - -

[0872]

[0873] Cocamidopropyl Hydroxysultaine - - Attorney Docket No. 15939.0027-01304

[0874] 0.3% Unpreserved Sodium Surfactant Solution (3% solids)

[0875] Day 7* Benzoate Day 7* Sodium Lauroamphoacetate ++ ++ Coco Glucoside - Decyl Glucoside - Alkyl Polyglucosides - Suga®Boost 050 (Functionalized Alkyl Polyglucosides) NT Sodium Lauryl Sulfate - Sodium Lauryl Ether Sulfate - Alpha-Step® PC-48 (Sodium Methyl 2-Sulfolaurate and Disodium - - 2-Sulfolaurate)

[0876]

[0877] Sodium Methyl Cocoyl Taurate - NT * less than 1-log reduction in CFU / mL;

[0878] +: between 1 and 2-log reduction in CFU / mL;

[0879] ++: between 2 and 3 -log reduction in CFU / mL;

[0880] +++: 3-log or greater reduction in CFU / mL;

[0881] NT: Not tested.

[0882] Example 16. Antimicrobial challenge testing of personal care surfactants treated with preservative cocktail no.2

[0883]

[0235] Surfactants in Table 25 were prepared as 3% w / w solids solutions in deionized water based on the available information of their innate solids content from the suppliers and adjusted to pH 7.0 using citric acid and sodium hydroxide. Each surfactant solution was treated with 1% preservative cocktail no. 2 and re-adjusted to pH 7.0 with citric acid and sodium hydroxide, if necessary, without altering the desired concentration of the treatment. The antimicrobial challenge testing was performed as described in Example 2A. The preservative efficacies of day 7 compared to day 0 are reported in Table 25. In all surfactant solutions, preservative cocktail no. 2 achieved a 3-log or more reduction in CFU / mL at day 7with the exception of Alpha-Step® PC-48 and sodium methyl cocoyl taurate, wherein preservative cocktail no. 2 achieved between a 2 and 3-log reduction in CFU / mL. Attorney Docket No. 15939.0027-01304

[0884] Table 25. Preservative efficacies of preservative cocktail no. 2 in surfactant solutions at pH 7.0 against a bacterial pool

[0885] Surfactant Solution (3% solids) + Preservative Cocktail No. 2 (1%) Day 7*

[0886] Cocamidopropyl Betaine +++ Lauramidopropyl Betaine +++ Cocamidopropyl Hydroxysultaine +++ Sodium Lauroamphoacetate +++ Coco Glucoside +++ Decyl Glucoside +++ Alkyl Polyglucosides +++ Suga®Boost 050 (Functionalized Alkyl Polyglucosides) +++

[0887] Sodium Lauryl Sulfate +++ Sodium Lauryl Ether Sulfate +++ Alpha-Step® PC-48 (Sodium Methyl 2-Sulfolaurate and Disodium 2- ++

[0888] Sulfolaurate)

[0889]

[0890] Sodium Methyl Cocoyl Taurate ++ * less than 1-log reduction in CFU / mL;

[0891] +: between 1 and 2-log reduction in CFU / mL;

[0892] ++: between 2 and 3-log reduction in CFU / mL;

[0893] +++: 3-log reduction or greater in CFU / mL.

[0894] Example 17. Antimicrobial challenge testing of a water-based latex paint treated with a preservative cocktail, an ammonium-containing cationic polymer, or a preservative cocktail combined with sodium benzoate

[0895]

[0236] An unpreserved paint formulation was made as described in Example IE. Different portions of the paint formulation were left untreated or treated with 0.0025% polymer no. 4, 1% preservative cocktail no. 1, 1% preservative cocktail no. 2, or 1% preservative cocktail 2 and 0.7% sodium benzoate. The antimicrobial challenge testing was performed as described in Example 2D. The untreated portion and the portion treated with 0.0025% polymer no. 4 were both heavily contaminated. The contamination prevented the collection of accurate data for those samples. The preservative efficacies are reported in Tables 26A and B as the presence or absence of gramnegative bacteria at the end of the challenge testing. Preservative cocktail no. 1, preservative Attorney Docket No. 15939.0027-01304

[0896] cocktail no. 2, and preservative cocktail no. 2 with sodium benzoate were all effective in eliminating the gram-negative bacteria tested. The unpreserved portion and the portion treated with polymer no. 4 remained contaminated throughout the duration of the testing. Additionally, all three microorganisms tested were present in the contaminated portions at each time point during the testing.

[0897] Tables 26A-B. Preservative efficacy of different preservative cocktails in paint against multiple bacterial strains

[0898] Table 26A, Cycle 1 - Presence or absence of gram-negative bacteria

[0899] Sample Day 1 Day 2 Day 5 Day 7 Unpreserved* Present Present Present Present Polymer No. 4* (0.0025%) Present Present Present Present Preservative Cocktail No. 1 (1%) Absent Absent Absent Absent Preservative Cocktail No. 2 (1%) Absent Absent Absent Absent

[0900]

[0901] Preservative Cocktail No. 2 (1%) + Sodium Benzoate (0.7%) Absent Absent Absent Absent * Contaminated upon arrival at the external testing facility.

[0902] Table 26B, Cycle 2 - Presence or absence of gram-negative bacteria

[0903] Sample Day 8 Day 9 Day 12 Day 14 Unpreserved* Present Present Present Present Polymer No. 4* (0.0025%) Present Present Present Present Preservative Cocktail No. 1 (1%) Present Present Absent Absent Preservative Cocktail No. 2 (1%) Present Present Absent Absent

[0904]

[0905] Preservative Cocktail No. 2 (1%) + Sodium Benzoate (0.7%) Present Present Absent Absent * Contaminated upon arrival at the external testing facility.

[0906] Example 18. Disinfection using a preservative cocktail

[0907]

[0237] Bacteria suspensions were prepared as follows. One vial of P. aeruginosa (ATCC# 9027) stock and one vial of S. aureus stock were rehydrated in 1 m peptone buffer each. The concentration of either bacteria stock was determined based on the Certificates of Analysis Attorney Docket No. 15939.0027-01304

[0908] accompanying each bacteria vial, and the stocks were diluted in BPDB to make several 1-mL aliquots of each microorganism at a concentration of 1 x 106CFU / mL bacteria.

[0909]

[0238] One aliquot of each microorganism was left untreated to serve as a control. Preservative cocktail no. 2 was added to 2 aliquots of each microorganism at concentrations of 1% and 2%, respectively. The treated aliquots were incubated for 10 minutes at ambient conditions and then subjected to 10-fold serial dilutions in BPDB to obtain final diluted aliquots wherein 25-250 colonies were estimated to be yielded from 0.1 mL of each final diluted aliquot. Each final diluted aliquot was plated on a tryptic soy agar petri dish containing polysorbate 80 and lecithin. The inoculated petri dishes were incubated at 31.5 ± 1 °C for 24 to 48 hours, and the colonies in the dishes were counted and multiplied by their corresponding dilution factors to determine the bacteria concentrations (in CFU / mL) of the undiluted aliquots.

[0910]

[0239] The disinfectant efficacies are reported in Table 27 as log reduction in CFU / mL comparing the treated aliquots to the untreated control. A greater than 4-log reduction in CFU / mL was observed in all treated aliquots. A log reduction of almost 6 in CFU / mL was observed in P. aeruginosa treated with 1% preservative cocktail no. 2.

[0911] Table 27. Disinfectant efficacies of preservative cocktail no.2

[0912] Sample 5. aureus* P. aeruginosa* Preservative Cocktail No. 2 (2%) 5.03 4.30

[0913]

[0914] Preservative Cocktail No. 2 (1%) 5.21 5.78 *Log reduction in CFU / mL compared to control cell stock, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0915] Example 19. Sanitization using a preservative cocktail

[0916]

[0240] A bacteria suspension was prepared as follows. One vial of S. aureus stock was rehydrated in 1 mL peptone buffer. The concentration of the stock was determined based on the Attorney Docket No. 15939.0027-01304

[0917] Certificate of Analysis accompanying the bacteria vial, and the stock was diluted in BPDB to yield several 1-mL aliquots of a suspension at a concentration of 1 x 106CFU / mL.

[0918]

[0241] One aliquot was left untreated to serve as a control. Preservative cocktail no. 2 was added to 2 aliquots to concentrations of 1% and 2%, respectively. The treated aliquots were incubated for 5 minutes at ambient conditions and then subjected to 10-fold serial dilutions in BPDB to obtain final diluted aliquots wherein 25-250 colonies were estimated to be yielded from 0.1 mL of each final diluted aliquot. Each diluted aliquot was plated on a tryptic soy agar petri dish containing polysorbate 80 and lecithin. The inoculated petri dishes were incubated at 31.5 ± 1 °C for 24 to 48 hours, and the colonies in the dishes were counted and multiplied by their corresponding dilution factors to determine the bacterial concentrations (in CFU / mL) of the undiluted aliquots.

[0919]

[0242] The sanitizing efficacies are reported in Table 28 as log reduction in CFU / mL comparing treated aliquots to the untreated control. A greater than 4-log reduction in CFU / mL was observed in all treated aliquots.

[0920] Table 28. Sanitizing efficacies of preservative cocktail no.2 at different concentrations Sample S. aureus* Preservative Cocktail No. 2 (2%) 4.60

[0921]

[0922] Preservative Cocktail No. 2 (1%) 4.33

[0923] *Log reduction in CFU / mL compared to control cell stock, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0924] Example 20. Antimicrobial challenge testing of a lotion treated with preservative cocktail no.3

[0925]

[0243] A lotion was prepared as described in Example 1C. Different portions of the lotion were left untreated or treated with 1% preservative cocktail no. 3. The antimicrobial challenge testing was performed as described in Example 2E. The preservative efficacy of day 7 compared Attorney Docket No. 15939.0027-01304

[0926] to day 0 is reported in Table 29. Preservative cocktail no. 3 effectively reduced the microbial growth in the lotion by more than 3-logs at day 7.

[0927] Table 29. Preservative efficacy of preservative cocktail no.3 against a bacterial pool in a lotion

[0928] Sample Day 7*

[0929] Untreated +

[0930]

[0931] Preservative Cocktail No. 3 (1%) +++

[0932] * less than 1-log reduction in CFU / mL;

[0933] +: between 1 and 2-log reduction in CFU / mL;

[0934] ++: between 2 and 3 -log reduction in CFU / mL;

[0935] +++: 3-log or greater reduction in CFU / mL.

[0936] Example 21. Antimicrobial challenge testing of anti-acne lotions containing a preservative cocktail or sodium salicylate

[0937]

[0244] A lotion was prepared as described in Example 1C. Different portions of the lotion were left untreated or treated with either 0.45% sodium salicylate or 1% preservative cocktail no.

[0938] 3. The antimicrobial challenge testing was performed as described in Example 2E except that only C. acnes was used.

[0939]

[0245] The anti-acne bacteria efficacies of untreated at day 7 and day 14 compared to day 0 are reported in Table 30 below. The untreated portion only showed less than 2-log reduction in CFU / mL. The portion treated with 0.45% sodium salicylate resulted in a 3-4 log reduction in CFU / mL at day 7. The portion treated with 1% preservative cocktail no. 3 achieved more than a 4-log reduction in CFU / mL in at day 7 and maintained that level of reduction at day 14.

[0940] Table 30. Anti-acne bacteria efficacies of lotions containing preservative cocktail no.3 or sodium salicylate

[0941] Sample Day 7* Day 14* Untreated - -

[0942]

[0943] Sodium Salicylate (0.45%) ++ +++ Attorney Docket No. 15939.0027-01304

[0944] Sample Day 7* Day 14*

[0945]

[0946] Preservative Cocktail No. 3 (1%) +++ +++

[0947] * less than 2-log reduction in CFU / mL;

[0948] +: between 2 and 3-log reduction in CFU / mL;

[0949] ++: between 3 and 4-log reduction in CFU / mL;

[0950] +++: 4-log or greater reduction in CFU / mL.

[0951] Example 22. Antimicrobial challenge testing of anti-dandruff shampoos containing a preservative cocktail or sodium salicylate with an ammonium-containing cationic polymer

[0246] Shampoos are prepared for dandruff treatment, and the active ingredient is preservative cocktail no. 3 or a combination of sodium salicylate and an ammonium-containing cationic polymer from Table 3 A. Accordingly, shampoos with identical ingredients except for the active ingredient are prepared.

[0952]

[0247] All shampoos are subjected to antimicrobial testing as described in Example 2E. The results of the testing are reported.

[0953] Example 23. Surface disinfection and sanitization using a preservative cocktail

[0954]

[0248] An antimicrobial solution containing 2% preservative cocktail no. 2 in deionized water is prepared aseptically in a spray bottle. The antimicrobial solution is subjected to two tests: a disinfection test according to the AO AC Germicidal Spray Products Test (AO AC 961.02) and a sanitization test according to the EPA Non-Food Contact Sanitizer Test (ASTM E1153).

[0955]

[0249] For the disinfection test (AO AC 961.02), 60 sterile microscope slides (test carriers) are used for each organism (S. aureus, P. aeruginosa (ATCC# 15442), or 5. enierica) wherein the test carriers are inoculated at 106CFU / mL, dried, sprayed with the test solution, and allowed to remain in contact with the active test solution for 10 minutes. Then the test carriers are transferred to individual sterile containers of neutralization growth media so that the test solution is no longer active. The test carriers are incubated in the neutralization media for 48 hours, and then the test Attorney Docket No. 15939.0027-01304

[0956] carriers are visually evaluated for signs of microbial growth. A result is considered a pass if at least 59 of the 60 test carriers demonstrate no detectable growth after incubation.

[0957]

[0250] For the sanitization test (ASTM E1153), 5 test carriers are used for each microorganism (S. aureus and K. pneumoniae), wherein the test carriers are inoculated at 106CFU / mL, dried, sprayed with the test solution, and allowed to remain in contact with the active test solution for 5 minutes. Then small aliquots of the mixture of bacteria, test solution, and a predetermined neutralizer are removed from the test carriers and enumerated using standard techniques. Microbial populations on the test carriers after treatment with the test solution are compared with parallel “initial bacterial concentration controls” to determine percent reduction and log reduction.

[0958] Example 24. Antibacterial challenge testing of a foaming hand soap treated with preservative cocktail no.2 at the presence of chelators

[0959]

[0251] A foaming hand soap (Foaming Hand Soap No. 1) was prepared as described in Example 1A. Different portions of the foaming hand soap were treated with 1% preservative cocktail no. 2 with or without the presence of a chelator and adjusted to pH 7.0 using sodium hydroxide and citric acid. The antimicrobial challenge testing was performed as described in Example 2A. The preservative efficacies are reported in Table 31 as log reduction in CFU / mL at day 2 and day 7 compared to day 0, respectively. While all samples tested achieved a 3 log or more reduction in 7 days, EDDS and EDTA significantly improved the antibacterial activity of preservative cocktail no. 2, achieving a log reduction of 5.98 and 4.59 respectively.

[0960] Table 31. Preservative efficacies of preservative cocktail no.2 against a bacterial pool in a foaming hand soap in the presence of a chelator at pH 7.0

[0961] Sample Day 2* Day 7*

[0962] 1% Preservative Cocktail No. 2 2.95 3.05

[0963]

[0964] 1% Preservative Cocktail No. 2 + 0.025% EDTA 2.82 4.59 Attorney Docket No. 15939.0027-01304

[0965] Sample Day 2* Day 7*

[0966] 1% Preservative Cocktail No. 2 + 0.025% EDDS 4.80 5.98 1% Preservative Cocktail No. 2 + 0.0125% GLDA 3.05 3.34

[0967]

[0968] 1% Preservative Cocktail No. 2 + 0.025% MGDA 3.02 3.25

[0969] *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0970] Example 25. Anti-mold challenge testing of a foaming hand soap treated with preservative cocktail no.2 and D-gluconolactone

[0971]

[0252] A foaming hand soap (Foaming Hand Soap No. 2) was prepared as described in Example IB, and preservative cocktail no. 2 and D-gluconolactone were added to the hand soap and pH adjusted to 7.0. The confirmatory antimicrobial challenge testing was performed with the hand soap containing 2% preservative cocktail no. 2 and 0.3% D-gluconolactone as described in Example 2B against the single mold strain brasiliensis. The preservative efficacy is reported in Table 32 as log reductions in CFU / mL at day 7 and day 14 compared to day 0, respectively. The combination of preservative cocktail no. 2 and D-gluconolactone achieved a log reduction of 3.49 in 7 days and a log reduction of 5.19 in 14 days.

[0972] Table 32. Preservative efficacy of preservative cocktail no.2 with D-gluconolactone against A. brasiliensis in a foaming hand soap at pH 7.0

[0973] Sample Day 7* Day 14*

[0974]

[0975] 2% Preservative Cocktail No. 2 + 0.3% D-Gluconolactone 3.49 5.19 *Log reduction in CFU / mL compared to Day 0, negative number indicates log increase in CFU / mL (i.e., cell growth).

[0976] Example 26. Antimicrobial challenge testing of a foaming hand soap treated with preservative cocktail no.2 and D-gluconolactone or sodium phytate

[0977]

[0253] A foaming hand soap (Foaming Hand Soap No. 1) is prepared as described in Example 1A. Different portions of the foaming hand soap are treated with 1% preservative cocktail no. 2 with or without the presence of 0.5% D-gluconolactone or 0.5% sodium phytate and adjusted to Attorney Docket No. 15939.0027-01304

[0978] pH 7.0 using sodium hydroxide and citric acid. The antimicrobial challenge testing is performed as described in Example 2B. The preservative efficacies of each treatment are calculated as log reductions in CFU / mL at different timepoints (e.g., day 2, day 7, day 14, and day 28) compared to day 0 respectively.

[0979] Example 27. Antimicrobial challenge testing of a foaming hand soap treated with an organic acid chelator alone or in combination with an ammonium-containing cationic polymer

[0980]

[0254] A foaming hand soap (Foaming Hand Soap No. 1) is prepared as described in Example 1A. Different portions of the foaming hand soap are treated with 0.3% sodium phytate, 0.3% gluconolactone, 0.1% MGDA, 0.1% EDDS, or 0.1% GLDA with or without the presence of 0.0025% of an ammonium-containing cationic polymer from Table 20 and then adjusted to pH 7.0 using sodium hydroxide and citric acid. The antimicrobial challenge testing is performed as described in Example 2B. The preservative efficacies of each treatment are calculated as log reductions in CFU / mL at different timepoints (e.g., day 2, day 7, day 14, and day 28) compared to day 0 respectively.

Claims

Attorney Docket No. 15939.0027-01304CLAIMSWhat is claimed:

1. An antimicrobial composition comprising (1) an ammonium-containing cationic polymer and (2) an organic acid chelator, wherein the antimicrobial composition has antimicrobial activity when incorporated into a product to a concentration of about 0.001% to about 1% by weight of the organic acid chelator in the product.

2. The antimicrobial composition of claim 1, wherein the antimicrobial composition has antimicrobial activity from about pH 6.5 to about pH 10.0 when incorporated into the product.

3. The antimicrobial composition of claim 1 or 2, wherein the organic acid chelator is one or more selected from ethylenediamine-Af, Af’-disuccinic acid (EDDS), gluconolactone, dicarboxymethyl alaninate (MGDA), glutamate diacetate (GLDA), and phytic acid.

4. The antimicrobial composition of claim 3, wherein the concentration of EDDS in the product is equivalent to trisodium EDDS at about 0.005% to about 0.2% by weight.

5. The antimicrobial composition of 3 or 4, wherein the concentration of gluconolactone in the product is about 0.05% to about 0.5% by weight.

6. The antimicrobial composition of any of claims 3-5, wherein the concentration of MGDA in the product is equivalent to trisodium MGDA at about 0.005% to about 0.2% by weight.

7. The antimicrobial composition of any of claims 3-6, wherein the concentration of GLDA in the product is equivalent to tetrasodium GLDA at about 0.005% to about 0.2% by weight.

8. The antimicrobial composition of any of claims 3-7, wherein the concentration of phytic acid in the product is about 0.05% to about 0.5% by weight.Attorney Docket No. 15939.0027-013049. The antimicrobial composition of any of claims 1-8, wherein the ammonium-containing cationic polymer has a molecular weight of about 800 g / mol to about 1,000,000 g / mol.

10. The antimicrobial composition of any of claims 1-9, wherein the concentration of the ammonium-containing cationic polymer in the product is about 0.0001% to about 0.2% by weight.

11. The antimicrobial composition of any of claims 1-10, wherein the ammonium-containing cationic polymer is a primary ammonium-containing polymer, a secondary ammonium- containing polymer, a tertiary ammonium-containing polymer, a quaternary ammonium- containing polymer, and / or a copolymer thereof.

12. The antimicrobial composition of any of claims 1-11, wherein the ammonium-containing cationic polymer comprises polymerized monomers, wherein the monomers are selected from ethyleneimine, dimethylamine, epichlorohydrin, aziridine, ethylenediamine, diallyl dimethyl ammonium chloride, acrylamide, hydroxyethyl cellulose, vinylpyrrolidone and dimethylaminoethyl methacrylate, diallyldimethyl ammonium chloride, acrylic acid, and butyl methacrylate-2-methacryloyloxyethylphosphorylcholine copolymer.

13. The antimicrobial composition of any of claims 1-11, wherein the ammonium-containing cationic polymer is selected from a linear polyethylenimine, a branched polyethylenimine, a dimethylamine-epichlorohydrin copolymer, a dimethylamine- epichlorohydrin-ethylenediamine copolymer, polyquaternium-7, polyquaternium- 10, polyquaternium-11, polyquaternium-39, and polyquaternium-51, and the concentration of the ammonium-containing cationic polymer in the product is about 0.00015% to about 0.2% by weight.

14. The antimicrobial composition of any of claims 1-13, further comprising an additional organic acid, wherein the ratio by weight between the ammonium-containing cationic polymer and the organic acid is from about 1:3 to about 1:2,000, and more specifically from about 1: 50 to about 1:200 and the concentration of the additional organic acid in the product is about 0.02% to about 3% by weight.Attorney Docket No. 15939.0027-0130415. The antimicrobial composition of claim 14, wherein the additional organic acid is sodium benzoate and / or sodium salicylate.

16. The antimicrobial composition of claim 15, where in the concentration of sodium benzoate in the product is about 1.0% or lower by weight.

17. The antimicrobial composition of claim 15 or 16, wherein the concentration of sodium salicylate in the product is about 0.5% or lower by weight.

18. The antimicrobial composition of any of claims 1-17, wherein the product is a rinse-off personal care product at about pH 6.5 to about pH 10.0.

19. The antimicrobial composition of claim 18, wherein the concentration of the ammonium- containing cationic polymer in the rinse-off personal care product is about 0.000625% to about 0.2% by weight.

20. The antimicrobial composition of any of claims 17-19, wherein the rinse-off personal care product comprises sodium benzoate wherein the concentration of sodium benzoate in the rinse-off personal product is about 0.1% to about 1.0% by weight.

21. The antimicrobial composition of any of claims 1-17, wherein the product is a leave-on personal care product at about pH 6.5 to about pH 9.0.

22. The antimicrobial composition of claim 21, wherein the concentration of the ammonium- containing cationic polymer in the leave-on personal care product is about 0.000625% to about 0.2% by weight.

23. The antimicrobial composition of claim 21 or 22, wherein the leave-on personal care product comprises sodium benzoate wherein the concentration of sodium benzoate in the leave-on personal care product is about 0.1% to about 1% by weight.

24. The antimicrobial composition of any of claims 1-17, wherein the product is a household product at about pH 6.5 to about pH 10.0.Attorney Docket No. 15939.0027-0130425. The antimicrobial composition of claim 24, wherein the concentration of the ammonium- containing cationic polymer in the household product is about 0.000625% to about 0.2% by weight.

26. The antimicrobial composition of claim 24 or 25, wherein the household product comprises sodium benzoate wherein the concentration of sodium benzoate in the household product is about 0.1% to about 3% by weight.

27. The antimicrobial composition of any of claims 1-17, wherein the product is (1) a paint or related product or (2) a coating, adhesive, or related product wherein the product is at about pH 6.5 to about pH 10.0.

28. The antimicrobial composition of claim 27, wherein the paint or related product comprises sodium benzoate wherein the concentration of sodium benzoate in the paint or related product is about 0.1% to about 1% by weight.

29. The antimicrobial composition of claim 27, wherein the coating, adhesive, or related product comprises sodium benzoate wherein the concentration of sodium benzoate in the coating, adhesive, or related product is about 0.1% to about 7% by weight.

30. The antimicrobial composition of any of claims 27-29, wherein the concentration of the ammonium-containing cationic polymer in the paint or related product or the coating, adhesives, or related product is about 0.000625% to about 0.2% by weight.

31. The antimicrobial composition of any of claims 1-17, wherein the product is an industrial and institutional cleaning, industrial, or recreational water product and is at about pH 6.5 to about pH 9.0.

32. The antimicrobial composition of claim 31, wherein the concentration of the ammonium- containing cationic polymer in the industrial and institutional cleaning, industrial, or recreational water product is about 0.000625% to about 0.2% by weight.

33. A product comprising the antimicrobial composition of any of claims 1-32.Attorney Docket No. 15939.0027-0130434. A method of increasing the shelf life of a product comprising incorporating an antimicrobial composition of any of claims 1-32 into the product in an amount effective to provide antimicrobial activity in comparison to an identical product that does not comprise the antimicrobial composition.

35. A method of preserving a product comprising incorporating an antimicrobial composition of any of claims 1-32 into the product in an amount effective to provide antimicrobial activity in comparison to an identical product that does not comprise the antimicrobial composition.

36. A composition consisting essentially of an ammonium-containing cationic polymer and an organic acid chelator, wherein the composition increases the shelflife of a product when incorporated into the product such that the organic acid chelator is present in the product at a concentration of about 0.001% to about 1% by weight.

37. A composition consisting essentially of the ammonium-containing cationic polymer, an organic acid chelator, and an additional organic acid, wherein the composition increases the shelflife of a product when incorporated into the product such that the organic acid chelator is present in the product at a concentration of about 0.001% to about 1% by weight, and the additional organic acid is sodium benzoate and / or sodium salicylate.

38. The composition of claim 36 or 37, wherein the product is at about pH 6.5 to about pH 10.0.

39. The composition of any of claims 36-38, wherein the organic acid chelator is one or more selected from ethylenediamine- / V, / V’-disuccinic acid (EDDS), gluconolactone, dicarboxymethyl alaninate (MGDA), glutamate diacetate (GLDA), and phytic acid.

40. The composition of claim 39, wherein the concentration of EDDS in the product is equivalent to trisodium EDDS at about 0.005% to about 0.2% by weight.

41. The composition of claim 39 or 40, wherein the concentration of gluconolactone in the product is about 0.05% to about 0.5% by weight.Attorney Docket No. 15939.0027-0130442. The composition of any of claims 39-41, wherein the concentration of MGDA in the product is equivalent to trisodium MGDA at about 0.005% to about 0.2% by weight.

43. The composition of any of claims 39-42, wherein the concentration of GLDAin the product is equivalent to tetrasodium GLDA at about 0.005% to about 0.2% by weight.

44. The composition of any of claims 39-43, wherein the concentration of phytic acid in the product is about 0.05% to about 0.5% by weight.

45. The composition of any of claims 36-44, wherein the concentration of the ammonium - containing cationic polymer in the product is at about 0.0025% by weight.

46. The composition of any of claims 37-44, wherein the ratio by weight between the ammonium-containing cationic polymer and the organic acid is from about 1: 50 to about 1:400, and more specifically from about 1:100 to about 1:200.

47. The composition of claim 46, wherein the concentration of sodium benzoate in the composition is about 30% by weight, and the ratio by weight between the ammonium- containing cationic polymer and sodium benzoate is about 1: 120.

48. The composition of claim 46, wherein the concentration of sodium salicylate in the composition is about 45% by weight, and the ratio by weight between the ammonium- containing cationic polymer and sodium salicylate is about 1:180.

49. The composition of any of claims 36-48, wherein the concentration of the ammonium- containing cationic polymer in the composition is at about 0.25% by weight, and the concentration of the organic acid chelator in the composition is about 0.1% or higher by weight to lower than 50% by weight.

50. The composition of claim 49, wherein the concentration of EDDS in the composition is equivalent to trisodium EDDS at about 0.5% to about 20% by weight.

51. The composition of claim 49, wherein the concentration of gluconolactone in the composition is about 2.5% to about 10% by weight.Attorney Docket No. 15939.0027-0130452. The composition of claim 49, wherein the concentration of MGDA in the composition is equivalent to trisodium MGDA at about 0.5% to about 20% by weight.

53. The composition of any of claims 49, wherein the concentration of GLDA in the composition is equivalent to tetrasodium GLDA at about 0.5% to about 20% by weight.

54. The composition of any of claims 49, wherein the concentration of phytic acid in the composition is about 0.5% to about 50% by weight.

55. The composition of claim 36 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and EDDS equivalent to trisodium EDDS at about 10% by weight.

56. The composition of claim 36 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and gluconolactone at about 10% by weight.

57. The composition of claim 36 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and MGDA equivalent to trisodium MGDA at about 10% by weight.

58. The composition of claim 36 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and GLDA equivalent to tetrasodium GLDA at about 10% by weight.

59. The composition of claim 36 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight and phytic acid at about 30% by weight.

60. The composition of claim 37 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, EDDS equivalent to trisodium EDDS at about 2.5% by weight, and sodium benzoate at about 30% by weight.Attorney Docket No. 15939.0027-0130461. The composition of claim 37 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, gluconolactone at about 10% by weight, and sodium benzoate at about 30% by weight.

62. The composition of claim 37 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, MGDA equivalent to trisodium MGDA at about 2.5% by weight, and sodium benzoate at about 30% by weight.

63. The composition of claim 37 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, GLDA equivalent to tetrasodium GLDA at about 1.25% by weight, and sodium benzoate at about 30% by weight.

64. The composition of claim 37 or 38, wherein the composition consists essentially of the ammonium-containing cationic polymer at about 0.25% by weight, phytic acid at about 50% by weight, and sodium benzoate at about 30% by weight.

Images